Personalized regenerative cells

Abstract

Methods, compositions of matter and protocols for generation of dedifferentiated cells possessing pluripotent or multipotent ability. Methods include extracting cells with proclivity for dedifferentiation from peripheral blood, culturing said cells in a media to provide stable expansion of said cells, and subsequently applying a multistep dedifferentiation protocol to achieve a population of pluripotent and / or multipotent cells. Peripheral blood cells are enriched for cells expressing Vasa and / or Dazl, and / or Stella and expanded under conditions to support proliferation without loss of these markers. Subsequently cells are treated with dedifferentiation cocktails in a multi-step manner in order to generate pluripotent stem cells. Said pluripotent stem cells are capable of generating multi-lineage cells as well as express characteristic markers of pluripotency such as OCT4 and NANOG.

Description

PERSONALIZED REGENERATIVE CELLSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims benefit of United States Provisional Application Serial No. 63 / 591,063, filed on October 17, 2023, entitled “Personalized Regenerative Cells”, the contents of which are incorporated herein by reference in its entirety.FIELD OF THE INVENTION

[0002] The invention herein relates to generation of dedifferentiated cells possessing pluripotent or multipotent ability.BACKGROUND OF THE INVENTION

[0003] New methods of generating pluripotent stem cells are needed. A goal of the invention herein is to use dedifferentiation to generate pluripotent stem cells.SUMMARY OF THE INVENTION

[0004] Preferred embodiments include methods of generating personalized regenerative cells, said method comprising the steps of a) extracting an aliquot of blood; b) separating mononuclear cells from said blood; c) isolating cells with proclivity towards retrodifferentiation; d) optionally expanding in vitro said cells with potential for retrodifferentiation; e) contacting said cells with potential for retrodifferentiation with one or more inducers of retrodifferentiation; f) assessing extent of retrodifferentiation; g) optionally performing another contact with said one or more retrodifferentiating agents; h) assessing pluripotency status of said cells; and i) optionally differentiating said cells into mesenchymal stem cells..

[0005] Preferred methods include embodiments wherein personalized regenerative cells are pluripotent.

[0006] Preferred methods include embodiments wherein said pluripotent stem cells are capable of proliferation for more than 100 passages without exhibiting characteristics of senescence.

[0007] Preferred methods include embodiments wherein said pluripotent stem cells are capable of proliferation for more than 100 passages without exhibiting karyotypic abnormalities.

[0008] Preferred methods include embodiments wherein said pluripotent stem cells are capable of proliferation for more than 100 passages without alteration of rate of proliferation.

[0009] Preferred methods include embodiments wherein said mononuclear cells isolated from blood are purified by use of a density gradient.

[0010] Preferred methods include embodiments wherein said density gradient is ficoll.

[0011] Preferred methods include embodiments wherein said density gradient is percoll.

[0012] Preferred methods include embodiments wherein said mononuclear cell is further purified for expression of CD 105.

[0013] Preferred methods include embodiments wherein said expression of CD 105 is used to magnetically isolate cells from a heterogenous population of cells.

[0014] Preferred methods include embodiments wherein said mononuclear cell is further purified for expression of CD34.

[0015] Preferred methods include embodiments wherein said expression of CD34 is used to magnetically isolate cells from a heterogenous population of cells.

[0016] Preferred methods include embodiments wherein said mononuclear cell is further purified for expression of VASA.

[0017] Preferred methods include embodiments wherein said expression of VASA is used to magnetically isolate cells from a heterogenous population of cells.

[0018] Preferred methods include embodiments wherein said CD 105 expressing cells are expanded in vitro.

[0019] Preferred methods include embodiments wherein said CD 105 expressing cells are placed on mesenchymal stem cell feeder cells.

[0020] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are plastic adherent.

[0021] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells express CD73.

[0022] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells express CD39.

[0023]

[0024] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells express IL- 10 receptor.

[0025] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells express TSGP.

[0026] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells express c-met.

[0027] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are derived from bone marrow.

[0028] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are derived from Whatron’s Jelly.

[0029] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are derived from umbilical cord.

[0030] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are derived from umbilical cord blood.

[0031] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are derived from adipose tissue.

[0032] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are derived from amniotic membrane tissue.

[0033] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are derived from amniotic fluid.

[0034] Preferred methods include embodiments wherein said mesenchymal stem cell feeder cells are treated with a histone deacetylase inhibitor prior to contact with said CD 105 expressing cells.

[0035] Preferred methods include embodiments wherein said histone deacetylase inhibitor is valproic acid.

[0036] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 10 pg of HGF from 1 million mesenchymal stem cells.

[0037] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 20 pg of HGF from 1 million mesenchymal stem cells.

[0038] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of HGF from 1 million mesenchymal stem cells.

[0039] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of VEGF from 1 million mesenchymal stem cells.

[0040] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of VEGF from 1 million mesenchymal stem cells.

[0041] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of VEGF from 1 million mesenchymal stem cells.

[0042] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of IGF from 1 million mesenchymal stem cells.

[0043] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of IGF from 1 million mesenchymal stem cells.

[0044] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of IGF from 1 million mesenchymal stem cells.

[0045] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 1 ng of stem cell factor from 1 million mesenchymal stem cells.

[0046] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 2 ng of stem cell factor from 1 million mesenchymal stem cells.

[0047] Preferred methods include embodiments wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 5 ng of stem cell factor from 1 million mesenchymal stem cells.

[0048] Preferred methods include embodiments wherein said histone deacetylase inhibitor is trichostatin A.

[0049] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 10 pg of HGF from 1 million mesenchymal stem cells.

[0050] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 20 pg of HGF from 1 million mesenchymal stem cells.

[0051] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of HGF from 1 million mesenchymal stem cells.

[0052] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of VEGF from 1 million mesenchymal stem cells.

[0053] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of VEGF from 1 million mesenchymal stem cells.

[0054] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of VEGF from 1 million mesenchymal stem cells.

[0055] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of IGF from 1 million mesenchymal stem cells.

[0056] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of IGF from 1 million mesenchymal stem cells.

[0057] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of IGF from 1 million mesenchymal stem cells.

[0058] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 1 ng of stem cell factor from 1 million mesenchymal stem cells.

[0059] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 2 ng of stem cell factor from 1 million mesenchymal stem cells.

[0060] Preferred methods include embodiments wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 5 ng of stem cell factor from 1 million mesenchymal stem cells.

[0061] Preferred methods include embodiments wherein said histone deacetylase inhibitor is phenylbutyrate.

[0062] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 10 pg of HGF from 1 million mesenchymal stem cells.

[0063] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 20 pg of HGF from 1 million mesenchymal stem cells.

[0064] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of HGF from 1 million mesenchymal stem cells.

[0065] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of VEGF from 1 million mesenchymal stem cells.

[0066] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of VEGF from 1 million mesenchymal stem cells.

[0067] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of VEGF from 1 million mesenchymal stem cells.

[0068] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of IGF from 1 million mesenchymal stem cells.

[0069] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of IGF from 1 million mesenchymal stem cells.

[0070] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of IGF from 1 million mesenchymal stem cells.

[0071] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 1 ng of stem cell factor from 1 million mesenchymal stem cells.

[0072] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 2 ng of stem cell factor from 1 million mesenchymal stem cells.

[0073] Preferred methods include embodiments wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 5 ng of stem cell factor from 1 million mesenchymal stem cells.

[0074] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing CD105.

[0075] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing c-kit.

[0076] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing CD105.

[0077] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing c-met.

[0078] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing leukemia inhibitory factor receptor.

[0079] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing IL-3 receptor.

[0080] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing G- CSF receptor.

[0081] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing GM- CSF receptor.

[0082] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing M- CSF receptor.

[0083] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing erythropoietin receptor.

[0084] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA.

[0085] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and GM-CSF receptor.

[0086] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and stem cell factor receptor.

[0087] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and M-CSF receptor.

[0088] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and oxytocin receptor.

[0089] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and IL-3 receptor.

[0090] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and CD200.

[0091] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and c-kit.

[0092] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and DAZL receptor.

[0093] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and GM-CSF receptor.

[0094] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and IL-3 receptor.

[0095] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and IL-6 receptor.

[0096] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and IL-11 receptor.

[0097] Preferred methods include embodiments wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and NANOG.

[0098] Preferred methods include embodiments wherein cells with proclivity towards retrodifferentiation are treated with cytoplasmic extract from a pluripotent stem cell.

[0099] Preferred methods include embodiments wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing microRNAs.

[0100] Preferred methods include embodiments wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing small molecules.

[0101] Preferred methods include embodiments wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing RNA interference stimulating molecules.

[0102] Preferred methods include embodiments wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing genes.

[0103] Preferred methods include embodiments wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing mRNAs.

[0104] Preferred methods include embodiments wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing proteins.

[0105] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of superoxide dismutase as compared to a non-engineered mesenchymal stem cell.

[0106] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of manganese dependent superoxide dismutase as compared to a non-engineered mesenchymal stem cell.

[0107] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of bone morphogenic protein 2 as compared to a nonengineered mesenchymal stem cell.

[0108] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of bone morphogenic protein 4 as compared to a nonengineered mesenchymal stem cell.

[0109] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of VEGF as compared to a non-engineered mesenchymal stem cell.

[0110] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of VEGF-C as compared to a non-engineered mesenchymal stem cell.[OHl] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of CXCL12 as compared to a non-engineered mesenchymal stem cell.

[0112] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of TIMP-1 as compared to a non-engineered mesenchymal stem cell.

[0113] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of TIMP-3 as compared to a non-engineered mesenchymal stem cell.

[0114] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of TIMP-5 as compared to a non-engineered mesenchymal stem cell.

[0115] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of IL- 10 as compared to a non-engineered mesenchymal stem cell.

[0116] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of Fas ligand as compared to a non-engineered mesenchymal stem cell.

[0117] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of HLA-G as compared to a non-engineered mesenchymal stem cell.

[0118] Preferred methods include embodiments wherein said cell is engineered to possess increased expression of TIMP-5 as compared to a non-engineered mesenchymal stem cell.

[0119] Preferred methods include embodiments wherein said cell is utilized to enhance engraftment of a chondrocytic progenitor.

[0120] Preferred methods include embodiments wherein said chondrocytic progenitor is autologous to the recipient.

[0121] Preferred methods include embodiments wherein said chondrocytic progenitor is allogeneic to the recipient.

[0122] Preferred methods include embodiments wherein said chondrocytic progenitor is xenogeneic to the recipient.

[0123] Preferred methods include embodiments wherein said mesenchymal stem cell is cultured with said chondrocytic progenitor before administration of said chondrocytic progenitor.

[0124] Preferred methods include embodiments wherein said chondrocytic progenitor is utilized to treat a defect of hyalin cartilage.

[0125] Preferred methods include embodiments wherein said chondrocytic progenitor is utilized to treat rheumatoid arthritis.

[0126] Preferred methods include embodiments wherein said chondrocytic progenitor is utilized to treat osteoarthritis.

[0127] Preferred methods include embodiments wherein said chondrocytic progenitor is utilized to treat disc degenerative disease.

[0128] Preferred methods include embodiments wherein said chondrocytic progenitor is administered together with FGF-5.

[0129] Preferred methods include embodiments wherein said cell is utilized to treat a non-union bone fracture.

[0130] Preferred methods include embodiments wherein said mesenchymal stem cell is administered together with an anti-inflammatory agent.

[0131] Preferred methods include embodiments wherein said anti-inflammatory agent is capable of inhibiting activation of NF-kappa B.

[0132] Preferred methods include embodiments wherein said anti-inflammatory agent is capable of inhibiting degradation of i-kappa B.

[0133] Preferred methods include embodiments wherein said anti-inflammatory agent is n-acetylcysteine.

[0134] Preferred methods include embodiments wherein said n-acetylcysteine is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

[0135] Preferred methods include embodiments wherein said n-acetylcysteine is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

[0136] Preferred methods include embodiments wherein said n-acetylcysteine is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

[0137] Preferred methods include embodiments wherein said anti-inflammatory agent is quercetin.

[0138] Preferred methods include embodiments wherein said quercetin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

[0139] Preferred methods include embodiments wherein said quercetin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

[0140] Preferred methods include embodiments wherein said quercetin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

[0141] Preferred methods include embodiments wherein said anti-inflammatory agent is indomethacin.

[0142] Preferred methods include embodiments wherein said indomethacin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

[0143] Preferred methods include embodiments wherein said indomethacin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

[0144] Preferred methods include embodiments wherein said indomethacin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

[0145] Preferred methods include embodiments wherein said anti-inflammatory agent is ampiroxicam

[0146]

[0147] Preferred methods include embodiments wherein said ampiroxicam is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

[0148] Preferred methods include embodiments wherein said ampiroxicam is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

[0149] Preferred methods include embodiments wherein said ampiroxicam is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

[0150] Preferred methods include embodiments wherein said cell is maintained in an undifferentiated state.

[0151] Preferred methods include embodiments wherein said maintenance in said undifferentiated state is accomplished by culture in a media conditioned by dedifferentiated fibroblasts.

[0152] Preferred methods include embodiments wherein said dedifferentiated fibroblasts are fibroblasts transfected with OCT4.

[0153] Preferred methods include embodiments wherein said dedifferentiated fibroblasts are fibroblasts transfected with NANOG.

[0154] Preferred methods include embodiments wherein said dedifferentiated fibroblasts are fibroblasts transfected with lin28.

[0155] Preferred methods include embodiments wherein said dedifferentiated fibroblasts are fibroblasts transfected with one or more proteins selected from a group comprising of: a) PIM1; b) c-myc; c) k-ras; d) bcr-abl; e) KLF4; f) c-met; g) OCT4; h) NANOG; and i) AIRE.

[0156] Preferred methods include embodiments wherein said dedifferentiated fibroblasts are obtained from a tissue possessing immature properties.

[0157] Preferred methods include embodiments wherein said fibroblasts are obtained from testicular tissue.

[0158] Preferred methods include embodiments wherein said fibroblasts are obtained from ovarian tissue.

[0159] Preferred methods include embodiments wherein said fibroblasts are obtained from placental tissue.

[0160] Preferred methods include embodiments wherein said fibroblasts are obtained from amniotic membrane tissue.

[0161] Preferred methods include embodiments wherein said fibroblasts are obtained from amniotic fluid.

[0162] Preferred methods include embodiments wherein said fibroblasts are obtained from bone marrow.

[0163] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood.

[0164] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with G-CSF.

[0165] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with GM-CSF.

[0166] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with M-CSF.

[0167] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with an agonist of CXCR4.

[0168] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with mozibil.

[0169] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with flt3 ligand.

[0170] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with beta glucan.

[0171] Preferred methods include embodiments wherein said fibroblasts are obtained from peripheral blood of a patient treated with Poly IC.

[0172] Preferred methods include embodiments wherein said fibroblasts are obtained from fallopian tube tissue.

[0173] Preferred methods include embodiments wherein said fibroblasts are obtained from adipose tissue.

[0174] Preferred methods include embodiments wherein said fibroblasts are obtained from deciduous tooth tissue.

[0175] Preferred methods include embodiments wherein said fibroblasts are obtained from Wharton’s Jelly.

[0176] Preferred methods include embodiments wherein said fibroblasts are obtained from omental tissue.

[0177] Preferred methods include embodiments wherein said fibroblasts are obtained from adherent pluripotent stem cells.

[0178] Preferred methods include embodiments wherein said pluripotent stem cells are induced pluripotent stem cells.

[0179] Preferred methods include embodiments wherein said pluripotent stem cells are parthenogenic derived pluripotent stem cells.

[0180] Preferred methods include embodiments wherein said pluripotent stem cells are stress derived pluripotent stem cells.

[0181] Preferred methods include embodiments wherein said pluripotent stem cells are somatic nuclear transfer derived pluripotent stem cells.

[0182] Preferred methods include embodiments wherein said fibroblasts are dedifferentiated by treatment with a “dedifferentiating agent”.

[0183] Preferred methods include embodiments wherein said dedifferentiating agent is a histone deacetylase inhibitor.

[0184] Preferred methods include embodiments wherein said histone deacetylase inhibitor is valproic acid.

[0185] Preferred methods include embodiments wherein said valproic acid is added together with lithium chloride.

[0186] Preferred methods include embodiments wherein said valproic acid is added together with a ROCK inhibitor.

[0187] Preferred methods include embodiments wherein said valproic acid is added together with GDF -15.

[0188] Preferred methods include embodiments wherein said valproic acid is added together with a cyclooxygenase 2 inhibitor.

[0189] Preferred methods include embodiments wherein said histone deacetylase inhibitor is trichostatin A.

[0190] Preferred methods include embodiments wherein said trichostatin A is added together with lithium chloride.

[0191] Preferred methods include embodiments wherein said trichostatin A is added together with a ROCK inhibitor.

[0192] Preferred methods include embodiments wherein said trichostatin A is added together with GDF -15.

[0193] Preferred methods include embodiments wherein said trichostatin A is added together with a cyclooxygenase 2 inhibitor.

[0194] Preferred methods include embodiments wherein said histone deacetylase inhibitor is phenylbutyrate.

[0195] Preferred methods include embodiments wherein said phenylbutyrate is added together with lithium chloride.

[0196] Preferred methods include embodiments wherein said phenylbutyrate is added together with a ROCK inhibitor.

[0197] Preferred methods include embodiments wherein said phenylbutyrate is added together with GDF-15.

[0198] Preferred methods include embodiments wherein said phenylbutyrate is added together with a cyclooxygenase 2 inhibitor.

[0199] Preferred methods include embodiments wherein said histone deacetylase inhibitor is vorinostat.

[0200] Preferred methods include embodiments wherein said vorinostat is added together with lithium chloride.

[0201] Preferred methods include embodiments wherein said vorinostat is added together with a ROCK inhibitor.

[0202] Preferred methods include embodiments wherein said vorinostat is added together with GDF -15.

[0203] Preferred methods include embodiments wherein said vorinostat is added together with a cyclooxygenase 2 inhibitor.

[0204] A method of creating an autologous pluripotent stem cell derived from peripheral blood sources, said method comprising of: a) selecting a population of blood mononuclear cell; b) isolating from said blood mononuclear cells a population of cells expressing the marker DAZL; c) expanding said DAZL expressing cell population in vitro; and d) contacting said DAZL expressing cells with a dedifferentiation means.

[0205] Preferred methods include embodiments wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing multipotency.

[0206] Preferred methods include embodiments wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing pluripotency.

[0207] Preferred methods include embodiments wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing ability to form a teratoma when said cells are administered into an immunodeficient animal.

[0208] Preferred methods include embodiments wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing immortality in treated cells.

[0209] Preferred methods include embodiments wherein said dedifferentiation means involves transfer of cytoplasm from an immature cell into a cell which is meant to be dedifferentiated.

[0210] Preferred methods include embodiments wherein said cytoplasm transfer is facilitated by the use of cell fusion.

[0211] Preferred methods include embodiments wherein said fusion is catalyzed by treatment with a membrane fusogenic agent.

[0212] Preferred methods include embodiments wherein said fusogenic agent is polyethylene glycol.

[0213] Preferred methods include embodiments wherein said dedifferentiation means is transfection with one or more genes selected from a group comprising of: a) OCT4; b) NANOG; c) SOX-2; d) KLF4; and e) PIM1.

[0214] The method of generating a pluripotent stem cell, wherein said cell-free means is extracted or obtained from a regenerative cell, wherein said regenerative cell has been treated with a “promoting agent”, wherein said promoting agent inhibits cellular differentiation while maintaining pluripotency.

[0215] Preferred methods include embodiments wherein said promoting agent is GDF-11.

[0216] Preferred methods include embodiments wherein said promoting agent is GDF-15.

[0217] Preferred methods include embodiments wherein said promoting agent is amniotic fluid.

[0218] Preferred methods include embodiments wherein said promoting agent is umbilical cord blood plasma.

[0219] Preferred methods include embodiments wherein said promoting agent is BMP2.

[0220] Preferred methods include embodiments wherein said promoting agent suppresses NF-kappa B activation.

[0221] Preferred methods include embodiments wherein said promoting agent increases NRF2 activation.

[0222] Preferred methods include embodiments wherein said promoting agent increases heme-oxygenase-1 activation.

[0223] Preferred methods include embodiments wherein said promoting agent increases bcl-2 activation.

[0224] Preferred methods include embodiments wherein said promoting agent increases bcl-2XL activation.

[0225] Preferred methods include embodiments wherein said promoting agent increases survivin activation.

[0226] Preferred methods include embodiments wherein said promoting agent increases livin activation.

[0227] Preferred methods include embodiments wherein said promoting agent is an HD AC inhibitor.

[0228] Preferred methods include embodiments wherein said HD AC inhibitor is valproic acid.

[0229] Preferred methods include embodiments wherein said HD AC inhibitor is trichostatin A.

[0230] Preferred methods include embodiments wherein said HD AC inhibitor is sodium phenylbutyrate.

[0231] Preferred methods include embodiments wherein said HD AC inhibitor is butyrate.

[0232] Preferred methods include embodiments wherein said promoting agent is a GSK-3 inhibitor.

[0233] Preferred methods include embodiments wherein said GSK-3 inhibitor is lithium.

[0234] Preferred methods include embodiments wherein said promoting agent causes a change in the genotype of the cell population.

[0235] Preferred methods include embodiments wherein at least one promoting agent comprises or consists of an immortalizing oncogene.

[0236] Preferred methods include embodiments wherein said promoting agent is PIM I .

[0237] Preferred methods include embodiments wherein said promoting agent is SV40 large T antigen.

[0238] Preferred methods include embodiments wherein said promoting agent is abll.

[0239] Preferred methods include embodiments wherein said promoting agent is AFF4.

[0240] Preferred methods include embodiments wherein said promoting agent is AKT2.

[0241] Preferred methods include embodiments wherein said promoting agent is AKL.

[0242] Preferred methods include embodiments wherein said promoting agent is AML I .

[0243] Preferred methods include embodiments wherein said promoting agent is MTG8.

[0244] Preferred methods include embodiments wherein said promoting agent is BCL6.

[0245] Preferred methods include embodiments wherein said promoting agent is MCF2.

[0246] Preferred methods include embodiments wherein said promoting agent is DCF3.

[0247] Preferred methods include embodiments wherein said promoting agent is EGFR.

[0248] Preferred methods include embodiments wherein said promoting agent is MLLT11.

[0249] Preferred methods include embodiments wherein said promoting agent is ERBB2.

[0250] Preferred methods include embodiments wherein said promoting agent is ETS1.

[0251] Preferred methods include embodiments wherein said promoting agent is CSF1R.

[0252] Preferred methods include embodiments wherein said promoting agent is FOS.

[0253] Preferred methods include embodiments wherein said promoting agent is FES.

[0254] Preferred methods include embodiments wherein said promoting agent is GNAS.

[0255] Preferred methods include embodiments wherein said promoting agent is HER2.

[0256] Preferred methods include embodiments wherein said promoting agent is FGF3.

[0257] Preferred methods include embodiments wherein said promoting agent is FGF4.

[0258] Preferred methods include embodiments wherein said promoting agent is JUN.

[0259] Preferred methods include embodiments wherein said promoting agent is c- kit.

[0260] Preferred methods include embodiments wherein said promoting agent is K- SAM.

[0261] Preferred methods include embodiments wherein said promoting agent is AKAP13.

[0262] Preferred methods include embodiments wherein said promoting agent is LCK.

[0263] Preferred methods include embodiments wherein said promoting agent is LM01.

[0264] Preferred methods include embodiments wherein said promoting agent is LYL I .

[0265] Preferred methods include embodiments wherein said promoting agent is MASI.

[0266] Preferred methods include embodiments wherein said promoting agent is MDM2.

[0267] Preferred methods include embodiments wherein said promoting agent is MOS.

[0268] Preferred methods include embodiments wherein said promoting agent is MYH11.

[0269] Preferred methods include embodiments wherein said promoting agent is MYB.

[0270] Preferred methods include embodiments wherein said promoting agent is MYCN.

[0271] Preferred methods include embodiments wherein said promoting agent is PAX5.

[0272] Preferred methods include embodiments wherein said promoting agent is RAF.

[0273] Preferred methods include embodiments wherein said promoting agent is RAS.

[0274] Preferred methods include embodiments wherein said promoting agent is REL.

[0275] Preferred methods include embodiments wherein said promoting agent is ROS1.

[0276] Preferred methods include embodiments wherein said promoting agent is SKI (PDGF-BB).

[0277] Preferred methods include embodiments wherein said promoting agent is SET.

[0278] Preferred methods include embodiments wherein said promoting agent is SRC.

[0279] Preferred methods include embodiments wherein said promoting agent is TALI.

[0280] Preferred methods include embodiments wherein said promoting agent is TAN1.

[0281] Preferred methods include embodiments wherein said promoting agent is TIAN.

[0282] Preferred methods include embodiments wherein said promoting agent is TSC2.

[0283] Preferred methods include embodiments wherein said promoting agent is TRK.

[0284] Preferred methods include embodiments wherein said promoting agent can be conditionally inactivated.

[0285] Preferred methods include embodiments wherein said tissue specific progenitors are immortalized.

[0286] Preferred methods include embodiments wherein said immortalization is performed by transfection with an immortalizing factor.

[0287] 278. Preferred methods include embodiments wherein said immortalizing factor is one or more oncogenes selected from a group comprising of: ABCB1, ABCG2, ABI1, ABL1, ABL2, ACKR3, ACSL3, ACSL6, ACVR1B, ACVR2A, AFF1, AFF3, AFF4, AKAP9, AKT1, AKT2, AKT3, ALDH1A1, ALDH2, ALK, AMER1, ANGPT1, ANGPT2, ANKRD23, APC, AR, ARAF, AREG, ARFRP1, ARHGAP26, ARHGEF12, ARID1A, ARID1B, ARID2, ARNT, ASPSCR1, ASXL1, ATF1, ATIC, ATM, ATP1A1, ATP2B3, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BBC3, BCL10, BCL11 A, BCL1 IB, BCL2, BCL2L1, BCL2L11, BCL2L2, BCL3, BCL6, BCL7A, BCL9, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD3, BRIM, BRINP3, BRIP1, BTG1, BTG2, BTK, BUB1B, Cl lorf30, C15orf65, C2orf44, CA6, CACNA1D, CALR, CAMTAI, CANT1, CARD11, CARS, CASC5, CASP8, CBFA2T3, CBFB, CBL, CBLB, CBLC, CCDC6, CCNB1IP1, CCND1,CCND2, CCND3, CCNE1, CD19, CD22, CD274, CD38, CD4, CD70, CD74, CD79A, CD79B, CD83, CDC73, CDH1, CDH11, CDK12, CDK4, CDK6, CDK7, CDK8, CDK9, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDX2, CEBPA, CHCHD7, CHD2, CHD4, CHEK1, CHEK2, CHIC2, CHN1, CHORDCI, CIC, CIITA, CLP1, CLTC, CLTCL1, CNBP, CNOT3, CNTRL, COL1A1, COPB1, COX6C, CRBN, CREB1, CREB3L1, CREB3L2, CREBBP, CRKL, CRLF2, CRTC1, CRTC3, CSF1R, CSF3R, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3, CXCR4, CYLD, CYP17A1, CYP2D6, DAXX, DDB2, DDIT3, DDR1, DDR2, DDX10, DDX3X, DDX5, DDX6, DEK, DICER1, DIS3, DLL4, DNM2, DNMT1, DNMT3A, DOT1L, DPYD, DUSP4, DUSP6, EBF1, ECT2L, EDNRB, EED, EGFR, EIF4A2, ELF4, ELK4, ELL, ELN, EML4, EP300, EPHA3, EPHA5, EPHA7, EPHA8, EPHB1, EPHB2, EPHB4, EPS15, ERBB2, ERBB3, ERBB4, ERC1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EREG, ERG, ERN1, ERRFI1, ESRI, ETV1, ETV4, ETV5, ETV6, EWSR1, EXT1, EXT2, EZH2, EZR, FAF1, FAIM3, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS, FAT1, FBXO11, FBXW7, FCRL4, FEV, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR1OP, FGFR2, FGFR3, FGFR4, FH, FHIT, FIP1L1, FKBP1A, FLCN, FLU, FLT1, FLT3, FLT4, FNBP1, FOXA1, FOXL2, FOXO1, FOXO3, FOXO4, FOXP1, FRS2, FSTL3, FUBP1, FUS, GABRA6, GAS7, GATA1, GATA2, GATA3, GATA4, GATA6, GID4, GLI1, GMPS, GNA11, GNA12, GNA13, GNAQ, GNAS, GNRH1, GOLGA5, GOPC, GPC3, GPHN, GPR124, GRIN2A, GRM3, GSK3B, GUCY2C, H3F3A, H3F3B, HCK, HDAC1, HERPUD1, HEY1, HGF, HIP1, HIST1H1E, HIST1H3B, HIST1H4I, HLF, HMGA1, HMGA2, HMGN2P46, HNF1A, HNMT, HNRNPA2B1, HNRNPK, H00K3, H0XA11, H0XA13, H0XA9, HOXC11, HOXC13, H0XD11, H0XD13, HRAS, HSD3B1, HSP90AA1, HSP90AB1, IAPP, ID3, IDH1, IDH2, IGF1R, IGF2, IKBKE, IKZF1, IL2, IL21R, IL3RA, IL6, IL6ST, IL7R, INHBA, INPP4B, IRF2, IRF4, IRS2, ITGAV, ITGB1, ITK, ITPKB, JAK1, JAK2, JAK3, JAZF1, JUN, KAT6A, KAT6B, KCNJ5, KDM1A, KDM5A, KDM5C, KDM6A, KDR, KDSR, KEAP1, KEL, KIAA1549, KIF5B, KIR3DL1, KIT, KLF4, KLHL6, KLK2, KMT2A, KMT2C, KMT2D, KRAS, KTN1, LASPI, LCK, LCP1, LGALS3, LGR5, LHFP, LIFR, LM01, LM02, LOXL2, LPP, LRIG3, LRP1B, LUC7L2, LYL1, LYN, LZTR1, MAF, MAFB, MAGED1, MAGI2, MALT1, MAML2, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAPK1, MAPK11, MAX, MCL1, MDM2, MDM4, MDS2, MECOM, MED12, MEF2B, MEN1, MET, MITF, MKI67, MKL1, MLF1, MLH1, MLLT1, MLLT10, MLLT11, MLLT3, MLLT4, MLLT6, MMP9, MN1, MNX1, MPL,MRE1 1 A, MS4A1, MSH2, MSH6, MSI2, MSN, MST1R, MTCP1, MTF2, MTOR, MUC1, MUC16, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, MYH11, MYH9, NACA, NAE1, NBN, NCKIPSD, NCOA1, NCOA2, NCOA4, NDRG1, NF1, NF2, NFE2L2, NFIB, NFKB2, NFKBIA, NIN, NKX2-1, NONO, NOTCH1, NOTCH2, NOTCH3, NPM1, NR4A3, NRAS, NSD1, NT5C2, NTRK1, NTRK2, NTRK3, NUMA1, NUP214, NUP93, NUP98, NUTM1, NUTM2B, OLIG2, OMD, P2RY8, PAFAH1B2, PAK3, PALB2, PARK2, PARP1, PATZ1, PAX3, PAX5, PAX7, PAX8, PBRM1, PBX1, PCM1, PCSK7, PDCD1, PDCD1LG2, PDE4DIP, PDGFB, PDGFRA, PDGFRB, PDK1, PEC AMI, PERI, PHF6, PHOX2B, PICALM, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIM1, PLAG1, PLCG2, PML, PMS1, PMS2, POLDI, POLE, POTI, POU2AF1, POU5F1, PPARG, PPP2R1A, PRCC, PRDM1, PRDM16, PREX2, PRF1, PRKAR1A, PRKCI, PRKDC, PRLR, PRPF40B, PRRT2, PRRX1, PRSS8, PSIP1, PSMD4, PTBP1, PTCHI, PTEN, PTK2, PTPN11, PTPRC, PTPRD, QKI, RABEP1, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAFI, RALGDS, RANBP17, RANBP2, RAP1GDS1, RARA, R131, RBM10, RBM15, RCOR1, RECQL4, REL, RELN, RET, RHOA, RHOH, RICTOR, RIPK1, RMI2, RNF213, RNF43, ROS1, RPL10, RPL22, RPL5, RPN1, RPS6KB1, RPTOR, RUNX1, RUNX1T1, S1PR2, SAMHD1, SBDS, SDC4, SDHA, SDHAF2, SDHB, SDHC, SDHD, SEPT5, SEPT6, SEPT9, SET, SETBP1, SETD2, SF1, SF3A1, SF3B1, SF3B2, SFPQ, SGK1, SH2B3, SH3GL1, SLAMF7, SLC34A2, SLC45A3, SLIT2, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCE1, SMC1A, SMC3, SMO, SNCAIP, SNX29, SOCS1, SOXIO, SOX11, SOX2, SOX9, SPECC1, SPEN, SPOP, SPTA1, SRC, SRGAP3, SRSF2, SRSF3, SS18, SS18L1, SSX1, STAG2, STAT3, STAT4, STAT5B, STEAP1, STIL, STK11, SUFU, SUZ12, SYK, TAF1, TAF15, TALI, TAL2, TBL1XR1, TBX3, TCEA1, TCF12, TCF3, TCF7L2, TCL1A, TEK, TERC, TERT, TET1, TET2, TFE3, TFEB, TFG, TFPT, TFRC, TGFB1, TGFBR2, THRAP3, TIMP1, TJP1, TLX1, TLX3, TM7SF2, TMPRSS2, TNFAIP3, TNFRSF14, TNFRSF17, TNFRSF18, TNFRSF9, TNFSF11, TOPI, TOP2A, TP53, TP63, TPBG, TPM3, TPM4, TPR, TRAF2, TRAF3, TRAF3IP3, TRAF7, TRIM26, TRIM27, TRIM33, TRIP11, TRRAP, TSC1, TSC2, TSHR, TTK, TTL, TYMS, U2AF1, U2AF2, UBA1, UBR5, USP6, VEGFA, VEGFB, VHL, VPS51, VTI1A, WAS, WEE1, WHSCI, WHSC1L1, WIFI, WISP3, WNT11, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT6, WNT7B, WRN, WT1, WWTR1, XBP1, XPA, XPC, XPO1, YWHAE, YWHAZ, ZAK, ZBTB16, ZBTB2, ZMYM2, ZMYM3, ZNF217, ZNF331, ZNF384, ZNF521, ZNF703 and ZRSR2

[0288] A method for treated age associated degeneration and / or stimulation of regeneration in an organism comprising administration of one or more regenerative cells, together with one or more senolytic agents, while concurrently inducing dedifferentiation, wherein said dedifferentiation is induced by using retroviral expression means of dedifferentiation factors.

[0289] Preferred methods include embodiments wherein said retroviral expression vector is a pMXs vector.

[0290] Preferred methods include embodiments wherein said retroviral expression vector is a lentiviral vector.

[0291] Preferred methods include embodiments wherein said retroviral expression vector is an adenoviral vector.

[0292] Preferred methods include embodiments wherein said retroviral expression vector is a pMXs adeno-associated vector.

[0293] Preferred methods include embodiments wherein said retroviral expression vector is a herpesvirus vector.

[0294] Preferred methods include embodiments wherein said dedifferentiation genes are delivered by means of a plasmid based vector.

[0295] Preferred methods include embodiments wherein said dedifferentiation genes are delivered by means of an RNA based vector.

[0296] Preferred methods include embodiments wherein said dedifferentiation genes are delivered by means of an mRNA based vector.

[0297] Preferred methods include embodiments wherein said dedifferentiation genes are delivered by means of an microRNA based vector.

[0298] Preferred methods include embodiments wherein said dedifferentiation factors are administered together with ascorbic acid.

[0299] Preferred methods include embodiments wherein said dedifferentiation factors are administered together with ascorbic acid.

[0300] Preferred methods include embodiments wherein said dedifferentiation factors are administered together with a stimulator of the RAS pathway.

[0301] Preferred methods include embodiments wherein said dedifferentiation factors are administered together with a stimulator of the myc pathway.

[0302] Preferred methods include embodiments wherein said dedifferentiation factors are administered together with a stimulator of the PIM-1 pathway.

[0303] Preferred methods include embodiments wherein said dedifferentiation factors are administered together with a stimulator of the j anus activated kinase pathway.

[0304] A method of reducing age associated fibrosis in a patient comprising administration of T regulatory cells, and / or T regulatory cell derived cell-free means together with one or more senolytic agents.

[0305] Preferred methods include embodiments wherein said T regulatory cells generated subsequent to administration of mesenchymal stem cells or cell free mesenchymal stem cell derived means.

[0306] Preferred methods include embodiments wherein said mesenchymal stem cells are selected for release of brain derived neurotrophic factor upon stimulation with molecular signals associated with tissue injury.

[0307] Preferred methods include embodiments wherein mesenchymal stem cells are selected for expression of CD56.

[0308] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 10 pg of brain derived neurotrophic factor per milliliter subsequent to stimulation with Poly IC.

[0309] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 25 pg of brain derived neurotrophic factor per milliliter subsequent to stimulation with Poly IC.

[0310] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 100 pg of brain derived neurotrophic factor per milliliter subsequent to stimulation with Poly IC.

[0311] Preferred methods include embodiments wherein said mesenchymal stem cells are selected for release of ciliary neurotrophic growth factor upon stimulation with molecular signals associated with tissue injury.

[0312] Preferred methods include embodiments wherein mesenchymal stem cells are selected for expression of CD73.

[0313] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 4 pg of ciliary neurotrophic growth factor per milliliter subsequent to stimulation with Poly IC.

[0314] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 8 pg of ciliary neurotrophic growth factor per milliliter subsequent to stimulation with Poly IC.

[0315] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 12 pg of ciliary neurotrophic growth factor per milliliter subsequent to stimulation with Poly IC.

[0316] Preferred methods include embodiments wherein said mesenchymal stem cells are selected for release of basic fibroblast growth factor upon stimulation with molecular signals associated with tissue injury.

[0317] Preferred methods include embodiments wherein mesenchymal stem cells are selected for expression of CD 105.

[0318] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 50 pg of basic fibroblast growth factor per milliliter subsequent to stimulation with Poly IC.

[0319] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 100 pg of basic fibroblast growth factor per milliliter subsequent to stimulation with Poly IC.

[0320] Preferred methods include embodiments wherein mesenchymal stem cells produce at least 100 pg of basic fibroblast growth factor per milliliter subsequent to stimulation with Poly IC.

[0321] Preferred methods include embodiments wherein said T regulatory cells and / or cell free means secreted by said T regulatory cells are administered subsequent to administration of a fibrinolytic enzyme.

[0322] Preferred methods include embodiments wherein said enzyme is a matrix metalloprotease.

[0323] Preferred methods include embodiments wherein said matrix metalloprotease is MMP-3.

[0324] Preferred methods include embodiments wherein said matrix metalloprotease is MMP-5.

[0325] Preferred methods include embodiments wherein said matrix metalloprotease is MMP-6.

[0326] Preferred methods include embodiments wherein said matrix metalloprotease is MMP-9.

[0327] Preferred methods include embodiments wherein said matrix metalloprotease is MMP-12.

[0328] Preferred methods include embodiments wherein said T regulatory cells and / or cell free means generated by said T regulatory cells are administered subsequent to administration of an inhibitor of NOGO.

[0329] Preferred methods include embodiments wherein said inhibitor of NOGO is an antisense oligonucleotide.

[0330] Preferred methods include embodiments wherein said inhibitor of NOGO is a one or more molecules capable of inducing RNA interference.

[0331] Preferred methods include embodiments wherein said molecule capable of inducing RNA interference is a short interfering RNA.

[0332] Preferred methods include embodiments wherein said molecule capable of inducing RNA interference is a short hairpin RNA.

[0333] Preferred methods include embodiments wherein said inhibitor of NOGO is a small molecule inhibitor.

[0334] Preferred methods include embodiments wherein said inhibitor of NOGO is an antibody.

[0335] Preferred methods include embodiments wherein said inhibitor of NOGO is an aptamer.

[0336] Preferred methods include embodiments wherein said inhibitor of NOGO is a somamer.

[0337] Preferred methods include embodiments wherein said inhibitor of NOGO is bispecific antibody.

[0338] Preferred methods include embodiments wherein said inhibitor of NOGO is a ribozyme.

[0339] Preferred methods include embodiments wherein said inhibitor of NOGO is an antibody.

[0340] Preferred methods include embodiments wherein said inhibitor of NOGO is a microantibody.

[0341] Preferred methods include embodiments wherein said inhibitor of NOGO is a hammerhead ribozyme.

[0342] Preferred methods include embodiments wherein said inhibitor of NOGO is a soluble receptor.

[0343] Preferred methods include embodiments wherein said T regulatory cells are administered subsequent to administration of a myeloid lineage cell. 1

[0344] Preferred methods include embodiments wherein said myeloid lineage cell is a myeloid derived dendritic cell.

[0345] Preferred methods include embodiments wherein said myeloid dendritic cell is immature.

[0346] Preferred methods include embodiments wherein said myeloid dendritic cell generated from a monocytic progenitor.

[0347] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood.

[0348] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with G-CSF.

[0349] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with GM-CSF.

[0350] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with M-CSF.

[0351] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with interleukin-3.

[0352] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with interleukin-10.

[0353] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with beta glucan.

[0354] Preferred methods include embodiments wherein said monocyte is isolated from peripheral blood that is mobilized by treatm6ent with interferon gamma.

[0355] Preferred methods include embodiments wherein said monocyte is isolated from menstrual blood.

[0356] Preferred methods include embodiments wherein said monocyte is isolated from umbilical cord blood.

[0357] Preferred methods include embodiments wherein said monocyte is isolated from Wharton’s Jelly.

[0358] Preferred methods include embodiments wherein said monocyte is isolated from bone marrow.

[0359] Preferred methods include embodiments wherein said monocyte is isolated from adipose tissue.

[0360] Preferred methods include embodiments wherein said monocyte is isolated from omental tissue.

[0361] Preferred methods include embodiments wherein said monocyte is pretreated with one or more agents to induce a tolerogenic phenotype prior to differentiation into a myeloid dendritic cells with immature phenotype and exosomes are derived from said myeloid dendritic cells.

[0362] Preferred methods include embodiments wherein said monocyte is pretreated with PGE2 at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0363] Preferred methods include embodiments wherein said monocyte is pretreated with PGE2 at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0364] Preferred methods include embodiments wherein said monocyte is pretreated with PGE2 at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0365] Preferred methods include embodiments wherein said monocyte is pretreated with genistein at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0366] Preferred methods include embodiments wherein said monocyte is pretreated with genistein at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0367] Preferred methods include embodiments wherein said monocyte is pretreated with genistein at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0368] Preferred methods include embodiments wherein said monocyte is pretreated with quercetin at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0369] Preferred methods include embodiments wherein said monocyte is pretreated with quercetin at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0370] Preferred methods include embodiments wherein said monocyte is pretreated with quercetin at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0371] Preferred methods include embodiments wherein said monocyte is pretreated with hypertonic saline at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0372] Preferred methods include embodiments wherein said monocyte is pretreated with hypertonic saline at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0373] Preferred methods include embodiments wherein said monocyte is pretreated with hypertonic saline at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0374] Preferred methods include embodiments wherein said monocyte is pretreated with VEGF at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0375] Preferred methods include embodiments wherein said monocyte is pretreated with VEGF at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0376] Preferred methods include embodiments wherein said monocyte is pretreated with VEGF at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0377] Preferred methods include embodiments wherein said monocyte is pretreated with PDGF-BB at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0378] Preferred methods include embodiments wherein said monocyte is pretreated with PDGF-BB at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0379] Preferred methods include embodiments wherein said monocyte is pretreated with PDGF-BB at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0380] Preferred methods include embodiments wherein said monocyte is pretreated with IGF-1 at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0381] Preferred methods include embodiments wherein said monocyte is pretreated with IGF-1 at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0382] Preferred methods include embodiments wherein said monocyte is pretreated with IGF-1 at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0383] Preferred methods include embodiments wherein said monocyte is pretreated with salinomycin at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0384] Preferred methods include embodiments wherein said monocyte is pretreated with salinomycin at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0385] Preferred methods include embodiments wherein said monocyte is pretreated with salinomycin at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0386] Preferred methods include embodiments wherein said monocyte is pretreated with erythropoietin at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0387] Preferred methods include embodiments wherein said monocyte is pretreated with erythropoietin at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0388] Preferred methods include embodiments wherein said monocyte is pretreated with erythropoietin at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0389] Preferred methods include embodiments wherein said monocyte is pretreated with NF-kappa B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0390] Preferred methods include embodiments wherein said monocyte is pretreated with NF-kappa B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0391] Preferred methods include embodiments wherein said monocyte is pretreated with NF-kappa B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0392] Preferred methods include embodiments wherein said monocyte is pretreated with Ikk-B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0393] Preferred methods include embodiments wherein said monocyte is pretreated with Ikk-B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0394] Preferred methods include embodiments wherein said monocyte is pretreated with Ikk-B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0395] Preferred methods include embodiments wherein said monocyte is pretreated with interleukin-35 at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0396] Preferred methods include embodiments wherein said monocyte is pretreated with interleukin-35 at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0397] Preferred methods include embodiments wherein said monocyte is pretreated with interleukin-35 at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0398] 386. Preferred methods include embodiments wherein said monocyte is pretreated with TGF-beta at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0399] 387. Preferred methods include embodiments wherein said monocyte is pretreated with TGF-beta at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0400] Preferred methods include embodiments wherein said monocyte is pretreated with TGF-beta at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0401] Preferred methods include embodiments wherein said monocyte is pretreated with ascorbic acid at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0402] Preferred methods include embodiments wherein said monocyte is pretreated with ascorbic acid at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0403] Preferred methods include embodiments wherein said monocyte is pretreated with ascorbic acid at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0404] Preferred methods include embodiments wherein said monocyte is pretreated with n-acetylcysteine at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0405] Preferred methods include embodiments wherein said monocyte is pretreated with n-acetylcysteine at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0406] Preferred methods include embodiments wherein said monocyte is pretreated with n-acetylcysteine at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0407] 392. Preferred methods include embodiments wherein said monocyte is pretreated with alpha lipoic acid at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0408] 393. Preferred methods include embodiments wherein said monocyte is pretreated with alpha lipoic acid at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0409] 394. Preferred methods include embodiments wherein said monocyte is pretreated with alpha lipoic acid at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0410] Preferred methods include embodiments wherein said monocyte is pretreated with methylene blue at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0411] Preferred methods include embodiments wherein said monocyte is pretreated with methylene blue at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0412] Preferred methods include embodiments wherein said monocyte is pretreated with methylene blue at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0413] Preferred methods include embodiments wherein said monocyte is pretreated with valproic acid at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0414] Preferred methods include embodiments wherein said monocyte is pretreated with valproic acid at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0415] Preferred methods include embodiments wherein said monocyte is pretreated with valproic acid at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

[0416] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-10.

[0417] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-4.

[0418] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-13.

[0419] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-20.

[0420] Preferred methods include embodiments wherein said immature dendritic cell expresses TGF-beta.

[0421] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-20.

[0422] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-22.

[0423] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-35.

[0424] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-37.

[0425] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin-38.

[0426] Preferred methods include embodiments wherein said immature dendritic cell expresses TGF-beta.

[0427] Preferred methods include embodiments wherein said immature dendritic cell expresses endoglin.

[0428] Preferred methods include embodiments wherein said immature dendritic cell expresses VEGF.

[0429] Preferred methods include embodiments wherein said immature dendritic cell expresses HLA-G.

[0430] Preferred methods include embodiments wherein said immature dendritic cell expresses interleukin- 12 p40 homodimer.

[0431] Preferred methods include embodiments wherein said immature dendritic cell possesses increased phagocytic activity as compared to a mature dendritic cell.

[0432] Preferred methods include embodiments wherein said immature dendritic cell possesses increased migratory activity towards chemotactic gradients as compared to a mature dendritic cell.

[0433] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine IL-8.

[0434] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine MIP-1 alpha.

[0435] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine MIP-1 beta.

[0436] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine CXCL12.

[0437] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine MCP-1.

[0438] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine TNF-alpha.

[0439] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine lymphotoxin.

[0440] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine hyaluronic acid degradation products.

[0441] Preferred methods include embodiments wherein said chemotactic gradient is comprised of the chemokine HMGB1.

[0442] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased HL A II compared to a mature dendritic cell.

[0443] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased HL A I compared to a mature dendritic cell.

[0444] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased CD la compared to a mature dendritic cell.

[0445] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased CD40 compared to a mature dendritic cell.

[0446] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased CD80 compared to a mature dendritic cell.

[0447] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased CD86 compared to a mature dendritic cell.

[0448] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased interleukin- 15 receptor compared to a mature dendritic cell.

[0449] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased interferon gamma compared to a mature dendritic cell.

[0450] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased interleukin- 18 receptor compared to a mature dendritic cell.

[0451] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased progesterone receptor compared to a mature dendritic cell.

[0452] Preferred methods include embodiments wherein said immature dendritic cell possesses decreased c-kit compared to a mature dendritic cell.

[0453] Preferred methods include embodiments wherein said immature dendritic cell is capable of inducing generation of T regulatory cells upon culture with allogeneic naive T cells.

[0454] Preferred methods include embodiments wherein said immature dendritic cells upregulate expression of AIRE upon contact with said allogeneic naive T cells.

[0455] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in an interleukin- 10 dependent manner.

[0456] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in a TGF-beta dependent manner.

[0457] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in a soluble HLA-G dependent manner.

[0458] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in an endoglin dependent manner.

[0459] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in an FGF-1 dependent manner.

[0460] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in an FGF-2 dependent manner.

[0461] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in an FGF-5 dependent manner.

[0462] Preferred methods include embodiments wherein said dendritic cells upregulate expression of AIRE in a NOTCH dependent manner.

[0463] Preferred methods include embodiments wherein said myeloid lineage cell is an immature neutrophil.

[0464] Preferred methods include embodiments wherein said immature neutrophil is a neutrophil progenitor.

[0465] Preferred methods include embodiments wherein said immature neutrophil is capable of differentiating along the neutrophilic lineage or the monocytic lineage.

[0466] Preferred methods include embodiments wherein said immature neutrophil expresses PU1.1.

[0467] Preferred methods include embodiments wherein said immature neutrophil expresses G-CSF receptor.

[0468] Preferred methods include embodiments wherein said immature neutrophil expresses stem cell factor receptor.

[0469] Preferred methods include embodiments wherein said immature neutrophil expresses c-met.

[0470] Preferred methods include embodiments wherein said immature neutrophil expresses M-CSF receptor.

[0471] Preferred methods include embodiments wherein said immature neutrophil expresses GM-CSF receptor.

[0472] Preferred methods include embodiments wherein said immature neutrophil produces interleukin- 10 upon stimulation with a TLR-4 agonist.

[0473] Preferred methods include embodiments wherein said TLR-4 agonist is beta glucan.

[0474] Preferred methods include embodiments wherein said TLR-4 agonist is hyaluronic acid degradation products.

[0475] Preferred methods include embodiments wherein said TLR-4 agonist is HMGB1.

[0476] Preferred methods include embodiments wherein said TLR-4 agonist is histones.

[0477] Preferred methods include embodiments wherein said myeloid lineage cell is a myeloid suppressor cell.

[0478] Preferred methods include embodiments wherein said myeloid suppressor cell is capable of producing Reptimed.

[0479] Preferred methods include embodiments wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with All Trans Retinoic Acid.

[0480] Preferred methods include embodiments wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with vitamin D3.

[0481] Preferred methods include embodiments wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with M-CSF.

[0482] Preferred methods include embodiments wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with GM-CSF.

[0483] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of nitric oxide.

[0484] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of reactive oxygen species.

[0485] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of superoxide.

[0486] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of hydrogen peroxide.

[0487] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of arginase.

[0488] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of interleukin- 10.

[0489] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of soluble PD-L1.

[0490] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of soluble VISTA.

[0491] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of LAG-3.

[0492] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of TIM3.

[0493] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of PGE2.

[0494] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of secreted vimentin.

[0495] Preferred methods include embodiments wherein said myeloid suppressor cell inhibit T cell proliferation by production of secreted calreticulin.

[0496] Preferred methods include embodiments wherein said T regulatory cell is administered together with a mesenchymal cell differentiated to the oligodendrocyte linage.

[0497] Preferred methods include embodiments wherein said T regulatory cell is administered together with a pluripotent stem cell differentiated to the oligodendrocyte linage.

[0498] Preferred methods include embodiments wherein said pluripotent stem cell is generated by transfecting a somatic cell with cytoplasm from an oocyte.

[0499] Preferred methods include embodiments wherein said cytoplasm is transfected by use of electroporation.

[0500] Preferred methods include embodiments wherein said cytoplasm is transfected by use of cell fusion.

[0501] Preferred methods include embodiments wherein said cytoplasm is transfected by use of streptolysin O to generate transient holes in the cytoplasm of said recipient cell.

[0502] Preferred methods include embodiments wherein said cytoplasm is transfected by use of cell penetrating peptides to generate transient holes in the cytoplasm of said recipient cell.

[0503] Preferred methods include embodiments wherein said pluripotent stem cell is an induced pluripotent stem cell.

[0504] Preferred methods include embodiments wherein said induced pluripotent stem cell is created by transfection of cells with pluripotency inducing factors.

[0505] Preferred methods include embodiments wherein said pluripotency inducing factor is OCT4.

[0506] Preferred methods include embodiments wherein said pluripotency inducing factor is PIM-1.

[0507] Preferred methods include embodiments wherein said pluripotency inducing factor is NANOG.

[0508] Preferred methods include embodiments wherein said pluripotency inducing factor is c-met.

[0509] Preferred methods include embodiments wherein said pluripotency inducing factor is hTERT.

[0510] Preferred methods include embodiments wherein said pluripotency inducing factor is OCT4.

[0511] Preferred methods include embodiments wherein said pluripotency inducing factor is KLF4.

[0512] Preferred methods include embodiments wherein said pluripotency inducing factor is RAS.

[0513] Preferred methods include embodiments wherein said pluripotency inducing factor is NOTCH.

[0514] Preferred methods include embodiments wherein said pluripotency inducing factor is BMP2.

[0515] Preferred methods include embodiments wherein said pluripotency inducing factor is BMP4.

[0516] Preferred methods include embodiments wherein said pluripotency inducing factor is AIRE.

[0517] A method of regenerating aged tissue comprising administration of T regulatory cell derived cell-free means, wherein said T regulatory cells are optionally treated with one or more histone deactylase inhibitors.

[0518] Preferred methods include embodiments wherein said cell free means are exosomes.

[0519] Preferred methods include embodiments wherein said cell free means are exosomes expressing CD8.

[0520] Preferred methods include embodiments wherein said cell free means are exosomes expressing phosphatidylserine.

[0521] Preferred methods include embodiments wherein said cell free means are apoptotic bodies

[0522] Preferred methods include embodiments wherein said cell free means are ferroptotic bodies.

[0523] Preferred methods include embodiments wherein said cell free means is conditioned media.

[0524] Preferred methods include embodiments wherein said cell free means is conditioned media from stressed cells.

[0525] Preferred methods include embodiments wherein said cellular stress is exposure to inflammatory stimuli.

[0526] Preferred methods include embodiments wherein said inflammatory stimuli is activation of one or more danger associated receptors.

[0527] Preferred methods include embodiments wherein said danger associated receptor is a toll like receptor.

[0528] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with beta glucan.

[0529] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with poly IC.

[0530] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with poly LC.

[0531] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with CpG DNA.

[0532] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with BCG.

[0533] The methods of claim 512, wherein said toll like receptor is activated by treatment with flaggelin.

[0534] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with lipopolysaccharide.

[0535] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with low molecular weight hyaluronic acid.

[0536] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with free histone.

[0537] The methods of claim 512, wherein said toll like receptor is activated by treatment with a Isoxazolo[5,4 -d]pyrimidine.

[0538] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with imiquimod.

[0539] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with Poly A:U.

[0540] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with MPL.

[0541] The methods of claim 512, wherein said toll like receptor is activated by treatment with Poly G3.

[0542] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with Poly GIO.

[0543] Preferred methods include embodiments wherein said toll like receptor is activated by treatment with hyperthermia exposed cells.

[0544] Preferred methods include embodiments wherein said hyperthermia exposed cells possess an upregulation of hsp90 of more than 50% as compared to untreated cells of the same type.

[0545] Preferred methods include embodiments wherein a histone deacetylase inhibitor is administered locally and / or systemically to enhance reparative activity of said T regulatory cell.

[0546] Preferred methods include embodiments wherein said histone deacetylase inhibitor i s CXD 101.

[0547] Preferred methods include embodiments wherein said histone deacetylase inhibitor i s HD AC 10-IN - 1.

[0548] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Tubastatin A TFA.

[0549] Preferred methods include embodiments wherein said histone deacetylase inhibitor is ACY-775.

[0550] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Panobinostat.

[0551] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Trichostatin A.

[0552] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Vorinostat.

[0553] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Entinostat.

[0554] Preferred methods include embodiments wherein said histone deacetylase inhibitor is BML-210.

[0555] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Abexinostat.

[0556] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Dacinostat.

[0557] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Quisinostat.

[0558] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Mocetinostat.

[0559] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Valproic Acid.

[0560] Preferred methods include embodiments wherein said histone deacetylase inhibitor is CUDC-101

[0561] Preferred methods include embodiments wherein said histone deacetylase inhibitor is GSK3117391.

[0562] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Droxinostat.

[0563] Preferred methods include embodiments wherein said histone deacetylase inhibitor is MCI 568.

[0564] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Pracinostat.

[0565] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Divalproex Sodium.

[0566] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Diferuloylmethane.

[0567] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Sodium butyrate.

[0568] Preferred methods include embodiments wherein said histone deacetylase inhibitor is PCI-34051.

[0569] Preferred methods include embodiments wherein said histone deacetylase inhibitor is SR-4370.

[0570] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Givinostat.

[0571] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Tubacin.

[0572] Preferred methods include embodiments wherein said histone deacetylase inhibitor is AR-42.

[0573] Preferred methods include embodiments wherein said histone deacetylase inhibitor is (-)-Parthenolide.

[0574] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Tubastatin A HC1.

[0575] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Resminostat.

[0576] Preferred methods include embodiments wherein said histone deacetylase inhibitor is CUDC-907.

[0577] Preferred methods include embodiments wherein said histone deacetylase inhibitor is M344.

[0578] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Tacedinaline.

[0579] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Romidepsin.

[0580] Preferred methods include embodiments wherein said histone deacetylase inhibitor is 4-Phenylbutyric acid.

[0581] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Sinapinic acid.

[0582] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Sulforaphane.

[0583] Preferred methods include embodiments wherein said histone deacetylase inhibitor is UFO 10.

[0584] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Suberohydroxamic acid.

[0585] Preferred methods include embodiments wherein said histone deacetylase inhibitor is NKL 22.

[0586] Preferred methods include embodiments wherein said histone deacetylase inhibitor is ITSA-1.

[0587] Preferred methods include embodiments wherein said histone deacetylase inhibitor is KA2507.

[0588] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Isoguanosine.

[0589] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Raddeanin A.

[0590] Preferred methods include embodiments wherein said histone deacetylase inhibitor is BRD3308.

[0591] Preferred methods include embodiments wherein said histone deacetylase inhibitor is TH34.

[0592] Preferred methods include embodiments wherein said histone deacetylase inhibitor is Tinostamustine.

[0593] Preferred methods include embodiments wherein exosomes from a pluripotent stem cell derived mesenchymal stem cell population are administered systemically from either a culture vessel or through the use of a bioreactor.

[0594] Preferred methods include embodiments wherein said mesenchymal stem cell is transfected with a growth factor.

[0595] Preferred methods include embodiments wherein said growth factor is HGF- 1.

[0596] Preferred methods include embodiments wherein said growth factor is FGF- 1.

[0597] Preferred methods include embodiments wherein said growth factor is EGF- 1.

[0598] Preferred methods include embodiments wherein said growth factor is angiopoietin.

[0599] Preferred methods include embodiments wherein said growth factor is placental growth factor.

[0600] Preferred methods include embodiments wherein said growth factor is adiponectin.

[0601] Preferred methods include embodiments wherein said growth factor is vasoactive intestinal peptide precursor.

[0602] Preferred methods include embodiments wherein said growth factor is endoglin.

[0603] Preferred methods include embodiments wherein said growth factor is myostatin.

[0604] Preferred methods include embodiments wherein said growth factor is TGF- beta.

[0605] Preferred methods include embodiments wherein said growth factor is vascular endothelial growth factor.

[0606] Preferred methods include embodiments wherein said growth factor is GDF- 11.

[0607] Preferred methods include embodiments wherein said growth factor is GDF- 15.

[0608] Preferred methods include embodiments wherein said growth factor is hyaluronic acid synthease.

[0609] Preferred methods include embodiments wherein said growth factor is interleukin-33.

[0610] Preferred methods include embodiments wherein said growth factor is osteosarcoma-derived growth factor.

[0611] Preferred methods include embodiments wherein said growth factor is midkine.

[0612] Preferred methods include embodiments wherein said growth factor is PDGF-BB.

[0613] Preferred methods include embodiments wherein said growth factor is IGF- 1.

[0614] Preferred methods include embodiments wherein said growth factor is nerve growth factor.BRIEF DESCRIPTION OF DRAWINGS

[0615] Figure l is a bar graph showing the results of generating pluripotent stem cells from VASA expressing peripheral blood cells.

[0616] Figure 2A is a bar graph showing the results of generating pluripotent stem cells from VASA expressing peripheral blood mononuclear cells.

[0617] Figure 2B is a bar graph showing the results of generating pluripotent stem cells from VASA expressing peripheral blood mononuclear cells.

[0618] Figure 3 A is a bar graph showing the results of generating pluripotent stem cells from peripheral blood mononuclear cell derived T cells.

[0619] Figure 3B is a bar graph showing the results of generating pluripotent stem cells from peripheral blood mononuclear cell derived T cells.

[0620] Figure 4 is a bar graph showing the results of generating pluripotent stem cells from monocytes using cytoplasmic extract.

[0621] Figure 5 is a bar graph showing the superior activity of combined senolytic immunotherapy with mesenchymal stem cells and hepatic progenitor cells.DETAILED DESCRIPTION OF THE INVENTION

[0622] “Peripheral blood derived germline stem cells” are any multipotent cells obtained from peripheral blood that include a population of male or female germline stem cells.

[0623] “Expansion” refers to the propagation of a cell or cells without terminal differentiation. “Isolation phenotype” refers to the structural and functional characteristics of the peripheral blood derived germline stem cells upon isolation. “Expansion phenotype” refers to the structural and functional characteristics of the peripheral blood derived germline stem cells during expansion. The expansion phenotype can be identical to the isolation phenotype, or alternatively, the expansion phenotype can be more differentiated than the isolation phenotype.

[0624] “Differentiation” refers to the developmental process of lineage commitment. A “lineage” refers to a pathway of cellular development, in which precursor or “progenitor” cells undergo progressive physiological changes to become a specified cell type having a characteristic function (e.g., nerve cell, muscle cell or endothelial cell). Differentiation occurs in stages, whereby cells gradually become more specified until they reach full maturity, which is also referred to as “terminal differentiation.” A “terminally differentiated cell” is a cell that has committed to a specific lineage, and has reached the end stage of differentiation (i.e., a cell that has fully matured). Oocytes are an example of a terminally differentiated cell type.

[0625] The term “isolated” as used herein refers to a peripheral blood derived germline stem cell or its progenitor cell, in a non-naturally occurring state (e.g., isolated from the body or a biological sample, such as peripheral blood, from the body).

[0626] “Progenitor cells” as used herein are germ lineage cells that are 1) derived from germline stem cells of the invention as the progeny thereof which contain a set of common marker genes; 2) are in an early stage of differentiation; and 3) retain mitotic capacity.

[0627] “Progeny” as used herein are all cells derived from peripheral blood derived germline stem cells of the invention, including progenitor cells, differentiated cells, and terminally differentiated cells.

[0628] “Derived from” as used herein refers to the process of obtaining a daughter cell.

[0629] “Engraft” refers to the process of cellular contact and incorporation into an existing tissue of interest (e.g., ovary) in vivo.

[0630] “Agents” refer to cellular (e.g., biologic) and pharmaceutical factors, preferably growth factors, cytokines, hormones or small molecules, or to genetically- encoded products that modulate cell function (e.g., induce lineage commitment, increase expansion, inhibit or promote cell growth and survival). For example, “expansion agents” are agents that increase proliferation and / or survival of peripheral blood derived germline stem cells. “Differentiation agents” are agents that induce peripheral blood derived germline stem cells to differentiate into committed cell lineages, such as oocytes or sperm cells.

[0631] A “follicle” refers to an ovarian structure consisting of a single oocyte surrounded by somatic (granulosa without or with theca-interstitial) cells. Somatic cells of the gonad enclose individual oocytes to form follicles. Each fully formed follicle is enveloped in a complete basement membrane. Although some of these newly formed follicles start to grow almost immediately, most of them remain in the resting stage until they either degenerate or some signal(s) activate(s) them to enter the growth phase. For reviews on ovarian structure, function and physiology, see Gougeon, A., (1996) Endocr Rev. 17: 121-55; Anderson, L. D., and Hirshfield, A. N. (1992) Md Med J. 41 : 614-20; and Hirshfield, A. N. (1991) hit Rev Cytol. 124: 43-101.

[0632] A “sperm cell” refers to a male germ cell, in either a pre-meiotic (i.e., mitotically competent) or post-meiotic state of development, including a fully mature spermatozoan. “Spermatogenesis” is the developmental process by which a sperm cell is formed.

[0633] “Mitotically competent” refers to a cell that is capable of mitosis, the process by which a cell divides and produces two daughter cells from a single parent cell.

[0634] A “non-embryonic” cell refers to a cell that is obtained from a post-natal source (e.g., infant, child or adult tissue).

[0635] A “subject” is a vertebrate, preferably a mammal, more preferably a primate and still more preferably a human. Mammals include, but are not limited to, primates, humans, farm animals, sport animals, and pets.

[0636] The term “obtaining” as in “obtaining the agent” is intended to include purchasing, synthesizing or otherwise acquiring the agent (or indicated substance or material).

[0637] The terms “comprises”, “comprising”, and are intended to have the broad meaning ascribed to them in U.S. Patent Law and can mean “includes”, “including” and the like.

[0638] In one embodiment, proteins and derivative proteins are used to induce the formation of pluripotent stem cell can include any combination of AIRE polypeptides, PIM-1 polypeptides, Oct3 / 4 polypeptides, Sox family polypeptides (e.g., Sox2 polypeptides), Klf family of polypeptides (e.g., Klf4 polypeptides), Myc family polypeptides (e.g., c-Myc), Nanog polypeptides, and Lin28 polypeptides. These polypeptides are administered, in one embodiment of the invention, to cells which already possess a dedifferentiated phenotype. In some embodiments stem cells are utilized to generated pluripotent stem cells. Said stem cells may be mesenchymal stem cells, or in some embodiments hematopoietic stem cells.

[0639] The iPSCs can be cultured using suitable culturing conditions. For example, iPSCs can be maintained using protocols such as those disclosed in Gao Y, Guo X, Santostefano K et al. Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy. Mol Ther. 2016; 24: 1378-1387; Xia G, Gao Y, Jin S et al. Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells. Stem Cells. 2015; 33:1829-1838; Xia G, Santostefano K, Hamazaki T et al. Generation of human- induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. J Mol Neurosci. 2013; 51 :237-248; and Xia G, Santostefano K E, Goodwin M et al. Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis. Cell Reprogram. 2013; 15: 166-177, each of which is incorporated by reference. According to some embodiments, these protocols may be modified to meet the criteria of clinically-clean iPSCs, including the use of feeder-free, xeno-free culture and coating media. While common cultures call for the use of an extracellular matrix such as, for example, the Coming Matrigel matrix (Corning, New York, N. Y.), it should be noted that the Corning Matrigel matrix contains a mixture of matrix proteins and growth factors of non-human origin. Accordingly, for applications wherein the cells are ultimately to be implanted in a human subject, it may be desirable to use cultures conditions that do not utilize non-human origin additives. According to a specific example, cultured cells may be coated with laminin and collagen IV from human cell culture (for example, Sigma-Aldrich C6745, Sigma-Aldrich Co.) and adapted to Laminin 521 coating culture conditions. Laminin 521 (LaminStem™ 521,05-753-lF, Biological Industries) is a chemically defined, animal component-free, xeno-free matrix. Those of skill in the art will be familiar with other suitable culturing conditions as well asthe adaptation of those conditions for the specific uses of the presently described genome corrected cells.

[0640] The genetically altered iPSC colonies can then be cultured for harvest as needed to obtain the genetically altered cells. As a specific example, iPSC colonies are detached and resuspended in embryoid body (EB) culture medium containing BMP -4 (50 ng / ml), VEGF (50ng / ml), FGF (10 ng / ml) and Y-27632 (10 pM) at a concentration of 1.2x 105. 100 pl is then seeded to into 96-well ultra-low adherence plate for EB formation. After four days of EB differentiation, EBs are transferred into six-well tissueculture plate (8 EBs per well) and cultured in differentiation medium (containing IL-3 (25-50 ng / ml) and M-CSF (50-100 ng / ml)). After four days, 4 ml of the differentiation medium will be added, and cells can be harvested at day 8. Differentiation of the genetically altered iPSCs into monocyte cells can also be achieved using methods described in, for example: Lachmann N., et al., Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies. Stem Cell Reports. 2015; 4:282-296; Yanagimachi M D., et al. Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS One. 2013;8:e59243; van Wilgenburg B., et al., Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS One. 2013; 8:e71098; Karlsson K R., et al. Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp Hematol. 2008; 36: 1167-1175.

[0641] Cells to be dedifferentiated are subsequently made to express proteins / polypeptides associated with dedifferentiation. This can be accomplished through the administration of nucleic acid vectors designed to express AIRE, Pim-1, Oct3 / 4, Sox2, Klf4, and c-Myc.

[0642] In some embodiments AIRE, Pim-1, Oct3 / 4, Sox2, Klf4, and c-Myc polypeptides can be directly delivered into target cells to obtain induced pluripotent stem cells using a polypeptide transfection method (e.g., liposome or electroporation). In one embodiment, nucleic acid vectors designed to express Oct3 / 4, Sox2, and Klf4 polypeptides, and not a c-Myc polypeptide, can be used to obtain induced pluripotent stem cells. In some cases, Oct3 / 4, Sox2, and Klf4 polypeptides can be directly delivered into target cells to obtain induced pluripotent stem cells using a polypeptide transfection method. Any appropriate cell type can be used to obtain induced pluripotent stem cells.For example, skin, lung, heart, liver, blood, kidney, or muscle cells can be used to obtain induced pluripotent stem cells. Such cells can be obtained from any type of mammal including, without limitation, humans, mice, rats, dogs, cats, cows, pigs, or monkeys. In addition, any stage of the mammal can be used, including mammals at the embryo, neonate, newborn, or adult stage. For example, fibroblasts obtained from an adult human patient can be used to obtain induced pluripotent stem cells. Such induced pluripotent stem cells can be used to treat that same human patient (or to treat a different human) or can be used to create differentiated cells that can be used to treat that same human patient (or a different human). For example, somatic cells from a human patient can be treated as described herein to obtain induced pluripotent stem cells. The obtained induced pluripotent stem cells can be differentiated into cardiomyocytes that can be implanted into that same human patient. In some cases, the obtained induced pluripotent stem cells can be directly administered to that same human patient. Any appropriate method can be used to introduce nucleic acid (e.g., nucleic acid encoding polypeptides designed to induce pluripotent stem cells from cells) into a cell. For example, nucleic acid encoding polypeptides (e.g., Oct3 / 4, Sox2, Klf4, and c-Myc polypeptides) designed to induce pluripotent stem cells from other cells (e.g., non-embryonic stem cells) can be transferred to the cells using recombinant viruses that can infect cells, or liposomes or other non-viral methods such as electroporation, microinjection, transposons, phage integrases, or calcium phosphate precipitation, that are capable of delivering nucleic acids to cells. The exogenous nucleic acid that is delivered typically is part of a vector in which a regulatory element such as a promoter is operably linked to the nucleic acid of interest. The promoter can be constitutive or inducible. Non-limiting examples of constitutive promoters include cytomegalovirus (CMV) promoter and the Rous sarcoma virus promoter. As used herein, “inducible” refers to both up-regulation and down regulation. An inducible promoter is a promoter that is capable of directly or indirectly activating transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer, the DNA sequences or genes will not be transcribed. The inducer can be a chemical agent such as a protein, metabolite, growth regulator, phenolic compound, or a physiological stress imposed directly by, for example heat, or indirectly through the action of a pathogen or disease agent such as a virus. Additional regulatory elements that may be useful in vectors, include, but are not limited to, polyadenylation sequences, translation control sequences (e.g., an internal ribosome entry segment, IRES), enhancers, or introns. Such elements may not be necessary, although they can increaseexpression by affecting transcription, stability of the mRNA, translational efficiency, or the like. Such elements can be included in a nucleic acid construct as desired to obtain optimal expression of the nucleic acids in the cells. Sufficient expression, however, can sometimes be obtained without such additional elements. Vectors also can include other elements. For example, a vector can include a nucleic acid that encodes a signal peptide such that the encoded polypeptide is directed to a particular cellular location (e.g., the cell surface) or a nucleic acid that encodes a selectable marker. Non-limiting examples of selectable markers include puromycin, adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate reductase (DHFR), hygromycin-B- phosphtransferase, thymidine kinase (TK), and xanthin-guanine phosphoribosyltransferase (XGPRT). Such markers are useful for selecting stable transformants in culture.

[0643] The invention provides numerous means of achieving dedifferentiation for the generation of pluripotent stem cells. In some embodiments, viral vectors can be used to introduce sternness-related factors, such as Oct3 / 4, Klf4, Sox2 and c-Myc. Examples of viral vectors include, without limitation, vectors based on DNA or RNA viruses, such as adenovirus, adeno-associated virus (AAV), retroviruses, lentiviruses, vaccinia virus, measles viruses, herpes viruses, baculoviruses, and papilloma virus vectors. See, Kay et al., Proc. Natl. Acad. Sci. USA, 94: 12744-12746 (1997) for a review of viral and non- viral vectors. Viral vectors can be modified so the native tropism and pathogenicity of the virus has been altered or removed. The genome of a virus also can be modified to increase its infectivity and to accommodate packaging of the nucleic acid encoding the polypeptide of interest. In some cases, the induced pluripotent stem cells provided herein can be obtained using viral vectors that do not integrate into the genome of the cells. Such viral vectors include, without limitation, adenoviral vectors, AAV vectors, baculovirus vectors, and herpesvirus vectors. For example, cells obtained from a human can be provided nucleic acid encoding human Oct3 / 4, Sox2, Klf4, and c-Myc polypeptides using viral vectors that do not integrate the exogenous nucleic acid into the cells. Once the polypeptides are expressed and induced pluripotent stem cells are obtained, the induced pluripotent stem cells can be maintained in culture such that the induced pluripotent stem cells are devoid of the exogenous nucleic acid. Any appropriate non-viral vectors can be used to introduce sternness-related factors, such as Oct3 / 4, Klf4, Sox2, and c-Myc. Examples of non-viral vectors include, without limitation, vectors based on plasmid DNA or RNA, retroelement, transposon, and episomal vectors. Non-viral vectors can bedelivered to cells via liposomes, which are artificial membrane vesicles. The composition of the liposome is usually a combination of phospholipids, particularly high-phase- transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations. Transduction efficiency of liposomes can be increased by using dioleoylphosphatidylethanolamine during transduction. See, Feigner et al., J. Biol. Chem., 269:2550-2561 (1994). High efficiency liposomes are commercially available. See, for example, SuperFect® from Qiagen (Valencia, Calif.). In some cases, induced pluripotent stem cells can be obtained using culture conditions that do not involve the use of serum or feeder cells. For example, cells obtained from a human can be provided nucleic acid encoding human Oct3 / 4, Sox2, Klf4, and c-Myc polypeptides and cultured using media lacking serum (e.g., human or non-human serum) and lacking feeder cells (e.g., human or non-human feeder cells).

[0644] Unfortunately, it is recognized that two of the four genes, c-Myc and Klf4, are oncogenic and may cause cancer. The efficiency of generating iPSCs is very low if c- Myc and Klf4 are not used. Cbx7 is downregulated during ESC differentiation and Cbx7 is never used to generate iPS cells generation. In one embodiment of the invention, it was surprisingly found that introduction of a Cbx family gene sequence but not c-Myc family gene sequence and Klf4 family gene sequence to somatic cells can efficiently reprogram differentiated cells into iPSCs that do not have oncogenic properties. Accordingly, the present disclosure provides a population of iPSCs, wherein the genetically modified somatic cells comprise a Cbx family gene sequence and one or more reprogramming factor sequences other than a cMyc family gene sequence and a Klf4 family gene sequence. Furthermore in one embodiment the invention suppression of p53 gene expression is used to increase efficacy of iPSC generation. For the purposes of iPSC generation, the invention teaches the use of dedifferentiated cells such as adult stem cells, however in some embodiments, somatic cells may be used. Somatic cells are cells that have differentiated sufficiently that they will not naturally generate cells of all three germ layers of the body, i.e. ectoderm, mesoderm and endoderm. They may differentiate to the point that they are capable of giving rise to cells of a specific lineage, e.g. adult non- pluripotent multipotent stem cells, e.g. mesenchymal stem cells, neural stem cells, cardiac stem cells, hepatic stem cells, and the like. Examples of somatic cells include the cells from ectodermal (e.g., keratinocytes), mesodermal (e.g., fibroblast), endodermal (e.g.,pancreatic cells), or neural crest lineages (e.g. melanocytes). Certain embodiments include fibroblasts, keratinocytes, pancreatic beta cells, neurons, oligodendrocytes, astrocytes, hepatocytes, hepatic stem cells, cardiomyocytes, skeletal muscle cells, smooth muscle cells, hematopoietic cells, osteoclasts, osteoblasts, pericytes, vascular endothelial cells, Schwann cells, and the like. Somatic cells are reprogrammed using a Cbx family gene sequence and one or more reprogramming factor sequences (other than a cMyc family gene sequence and a Klf4 family gene sequence). Preferably, the Cbx family gene sequence is a nucleic acid sequence having at least 70% identical to the sequence of Cbx7. More preferably, the Cbx family gene sequence is Cbx7. The one or more reprogramming factor sequences are preferably Oct family gene sequence, a Sox family gene sequence, a Nanog family gene sequence, a Lin28 family gene sequence. In a preferred embodiment, the one or more reprogramming factor sequences include Oct family gene sequence and a Sox family gene sequence. Preferably, the Oct family gene sequence is a nucleic acid sequence having at least 70% identical to the amino acid sequence of Oct 3 / 4. Preferably, the Sox family gene sequence is a nucleic acid sequence having at least 70% identical to the amino acid sequence of Sox2. Preferably, the Nanog family gene sequence is a nucleic acid sequence having at least 70% identical to the amino acid sequence of Nanog. Preferably, the Lin28 family gene sequence is a nucleic acid sequence having at least 70% identical to the amino acid sequence of Lin28. The iPSC cells of the present disclosure are generated by a method comprising a step of (a) introducing somatic cells with a vector expressing a Cbx family gene and one or more vectors expressing one or more reprogramming factor genes rather than a cMyc family gene and a Klf4 family gene; and (b) culturing the resulting somatic cells of (a) under conditions which reprogram the resulting somatic cells of (a) to produce the iPSCs. Any appropriate vector expressing the reprogramming factors described herein may be used to introduce transgenes into somatic cells. Suitable vectors notably include plasmid vectors and viral vectors. Viral vectors can be replication-competent or -selective (e.g. engineered to replicate better or selectively in specific host cells), or can be genetically disabled so as to be replication-defective or replication-impaired. Typically, such vectors are commercially available (e.g. in Invitrogen, Stratagene, Amersham Biosciences, Promega, etc.) or available from depository institutions such as the American Type Culture Collection (ATCC, Rockville, Md.) or have been the subject of numerous publications describing their sequence, organization and methods of production, allowing the artisan to apply them. Representative examples of suitable viral vectors are generated from avariety of different viruses (e.g. retrovirus, adenovirus, adenovirus-associated virus (AAV), poxvirus, herpes virus, measles virus, foamy virus, alphavirus, vesicular stomatitis virus, lentivirus, etc). As described above, the term “viral vector” encompasses vector DNA, genomic DNA as well as viral particles generated therefrom, and especially infectious viral particles. In a preferred embodiment, a retrovirus vector or lentivirus vector. In a preferred embodiment of the present disclosure, a lentivirus is used to introduce transgenes into differentiated cells. Representative examples of suitable plasmid vectors include, without limitation, pREP4, pCEP4 (Invitrogen), pCI (Promega), pVAX (Invitrogen) and pGWiz (Gene Therapy System Inc.).

[0645] Vectors used for providing reprogramming factors to the subject cells as nucleic acids will typically comprise suitable promoters for driving the expression, that is, transcriptional activation, of the reprogramming factor nucleic acids. This may include ubiquitously acting promoters, for example, the CMV-b-actin promoter, or inducible promoters, such as promoters that are active in particular cell populations or that respond to the presence of drugs such as tetracycline. Subsequently, the genetically modified somatic cells harboring the Cbx family gene sequence and reprogramming factor sequences as described herein can transform to iPSCs by culturing and expanding the resulting somatic cells of under conditions which reprogram the resulting somatic cells to produce the iPSCs in the presence of feeder cells. The iPSCs are substantially isolated if it is mixed with carriers or diluents, such as culture medium, which will not interfere with its intended use. Alternatively, the iPSC of the invention may be present in a growth matrix or immobilized on a surface. For increasing efficacy of iPSC generation, in some embodiments the invention calls for generation of iPSC form peripheral blood or mobilized peripheral blood. Stem cell mobilization is a common procedure and usually involves administration of a mobilizing agent such as G-CSF. In one particular embodiment the invention generates iPSC by reprogramming blood cells (BCs) including peripheral mononuclear blood cells (PBMCs) into iPSCs (BC-iPSCs) and show that these iPSC lines are superior in terms of cytogenetic stability in comparison to their fibroblast- derived iPSC (Fib-iPSCs) lines obtained from public repositories or local clinics. In contrast to mature T or B cells, the alternative source of blood progenitors contain an intact genome. In addition, they can be expanded in culture conditions that favor the proliferation of myeloid cells or erythroid cells. Blood stem / progenitor cells express surface marker CD34 and reside in the stem cell niche. However, only about 1% stem / progenitor cells enter circulation each day and as a result, only 0.01-0.1% cells inPB are CD34+ cells. This population can be enriched by magnetic-activated cell sorting (MACS) or culture of MNCs for several days can be relied upon to expand CD34+ cells to a 5-20% purity, which can be used for reprogramming without further purification.

[0646] Other nucleated peripheral blood cells include granulocytes (mostly neutrophils), monocytes, T lymphocytes, B lymphocytes and a few progenitor cells. Focusing on these constitutes of blood can be achieved by depleting red blood cells and platelet using lysis buffer followed by multiple centrifugations. Ficoll gradient centrifugation can also be utilized to deplete both red blood cells and granulocytes, leading to the enrichment of mononuclear cells (MNCs). Against this backdrop, reprogramming with exogenously expressed factors is notoriously inefficient and requires multiple cell cycles to achieve pluripotency. As such, primary granulocytes, monocytes and B lymphocytes are among the most difficult cells to be reprogrammed due to the lack of reliable protocols to expand these cells. Primary success in this area includes Epstein- Barr virus immortalized lymphoblastoid B cells can be readily expanded in ex vivo culture and thus be reprogrammed to pluripotency. In view of the above, of great interest is reprogramming of the non-T cell component of blood. Existing techniques are largely unable to reprogram this population from isolated peripheral blood mononuclear cells (PBMCs). More specifically, PBMCs are any peripheral blood cell having a round nucleus. This includes lymphocytes (T cells, B cells, NK cells), monocytes, dendritic cells. Lymphocytes are Small (5-10 pm) and Medium (10-18 pm) and constitute 70-90% of PBMCs. Of these cells, 70-85% CD3+ T cells (40-70% of PBMCs), CD4 Helper T cells (25-60% of PBMCs), typically with CD4 to CD8 ratio of 2: 1, CD8 “Cytotoxic” compartment T cells (5-30% of PBMCs). The remaining compartment includes 5-20% B Cells (up to 15% of PBMCs) and 5-20% NK Cells (up to 15% of PBMCs). Monocytes are 16-25 pm and 10-30% of PBMCs (macrophages). Dendritic cells: 1-2% of PBMCs. These described approaches allow for use of peripheral blood as a readily accessible resource for cellular reprogramming with superior properties in genomic and karyotype stability avoiding environmental insults for which mutations or other forms of structural alteration would otherwise be therapeutic materials derived therein. As described, the Inventors have established improved techniques for highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from blood cells, including whole blood and peripheral blood, the resulting reprogrammed pluripotent cells described herein as “BC-iPSCs”. Generally, different approaches for non-integrative reprogramming span at least categories: 1) integration-defective viral delivery, 2) episomal delivery, 3) direct RNA delivery, 4) direct protein delivery and 5) chemical induction. As described further herein, the adoption of episomal vectors allows for generation of iPSCs substantially free of the vectors used in their production, as episomal or similar vectors do not encode sufficient viral genome sufficient to give rise to infection or a replication-competent virus. At the same time, these vectors do possess a limited degree of self-replication capacity in the beginning somatic host cells. This self-replication capacity provides a degree of persistent expression understood to be beneficial in allowing the dedifferentiation process to initiate take hold in a target host cell.

[0647] One example of a plasmid vector satisfying these criteria includes the Epstein Barr oriP / Nuclear Antigen-1 (“EBNA1”) combination, which is capable of limited self-replication and known to function in mammalian cells. As containing two elements from Epstein-Barr virus, oriP and EBNA1, binding of the EBNA1 protein to the virus replicon region oriP maintains a relatively long-term episomal presence of plasmids in mammalian cells. This particular feature of the oriP / EBNAl vector makes it ideal for generation of integration-free iPSCs. More specifically, persistent expression of reprogramming factor encoded in an oriP / EBNAl vector occurs across multiple cell divisional cycles. Sufficiently high levels of reprogramming factors across several cell divisions allows for successful reprogramming even after only one infection. While sustained expression of reprogramming factors is understood to be beneficial during initial programming stages, otherwise unlimited constitutive expression would hamper subsequent stages of the reprogramming process. For example, unabated expression of reprogramming factors would interfere with subsequent growth, development, and fate specification of the host cells.

[0648] At the same time, a further benefit is the eventual removal of the reprogramming factor transgenes, as a small portion of episomes is lost per cell cycle. This is due to the asymmetric replication capacity of the host cell genome and episomal self-replication and it is estimated that approximately 0.5% of vector is lost per generation. Gradual depletion of plasmids during each cell division is inevitable following propagation leading to a population of integration-free iPSCs. The persistent, yet eventual abrogation of reprogramming factor expression on oriP / EBNAl is highly coincident with the needs for different stages of the reprogramming process and eliminates the need for further manipulation steps for excision of the reprogramming factors, as has been attempted through use of transposons and excisable polycistroniclentiviral vector elements. Although oriP / EBNAl has been applied by others in reprogramming studies, the reported efficiencies are extremely low (as few as 3 to 6 colonies per million cells nucleofected), which may be due, in-part, to reliance on large plasmids encoding multiple reprogramming factors (e.g., more than 12 kb), negatively impacting transfection efficiency.

[0649] In addition to these choices in vector designs, the specific combinations of reprogramming factors implemented in the literature have varied. As mentioned, reprogramming factors that have been used include pluripotency-related genes Oct-4, Sox-2, Lin-28, Nanog, Sal 14, Fbx-15 and Utf-1. These factors, traditionally are understood be normally expressed early during development and are involved in the maintenance of the pluripotent potential of a subset of cells that will constituting the inner cell mass of the pre-implantation embryo and post-implantation embryo proper. Their ectopic expression of is believed to allow the establishment of an embryonic-like transcriptional cascade that initiates and propagates an otherwise dormant endogenous core pluripotency program within a host cell. Certain other reprogramming determinants, such as Tert, Klf-4, c-Myc, SV40 Large T Antigen (“SV40LT”) and short hairpin RNAs targeting p53 (“shRNA-p53”) have been applied. There determinants may not be potencydetermining factors in and of themselves, but have been reported to provide advantages in reprogramming. For example, TERT and SV40LT are understood to enhance cell proliferation to promote survival during reprogramming, while others such as short hairpin targeting of p53 inhibit or eliminate reprogramming barriers, such as senescence and apoptosis mechanisms. In each case, an increase in both the speed and efficiency of reprogramming is observed. In addition, microRNAs (“miRNAs”) are also known to influence pluripotency and reprogramming, and some miRNAs from the miR-290 cluster have been applied in reprogramming studies. For example, the introduction of miR-291- 3p, miR-294 or miR-295 into fibroblasts, along with pluripotency-related genes, has also been reported to increase reprogramming efficiency.

[0650] While various vectors and reprogramming factors in the art appear to present multiple ingredients capable of establishing reprogramming in cells, a high degree of complexity occurs when taking into account the stoichiometric expression levels necessary for successful reprogramming to take hold. For example, somatic cell reprogramming efficiency is reportedly fourfold higher when Oct-4 and Sox2 are encoded in a single transcript on a single vector in a 1 : 1 ratio, in contrast to delivering the two factors on separate vectors. The latter case results in a less controlled uptake ratio of thetwo factors, providing a negative impact on reprogramming efficiency. One approach towards addressing these obstacles is the use of polycistronic vectors, such as inclusion of an internal ribosome entry site (“IRES”), provided upstream of transgene(s) that is distal from the transcriptional promoter. This organization allows one or more transgenes to be provided in a single reprogramming vector, and various inducible or constitutive promoters can be combined together as an expression cassette to impart a more granular level of transcriptional control for the plurality of transgenes. These more specific levels of control can benefit the reprogramming process considerably, and separate expression cassettes on a vector can be designed accordingly as under the control of separate promoters.

[0651] Although there are advantages to providing such factors via a single, or small number of vectors, upper size limitations on eventual vector size do exist, which can stymie attempts to promote their delivery in a host target cell. For example, early reports on the use of polycistronic vectors were notable for extremely poor efficiency of reprogramming, sometimes occurring in less than 1% of cells, more typically less than 0.1%. These obstacles are due, in-part, to certain target host cells possessing poor tolerance for large constructs (e.g., fibroblasts), or inefficient processing of IRES sites by the host cells. Moreover, positioning of a factor in a vector expression cassette affects both its stoichiometric and temporal expression, providing an additional variable impacting reprogramming efficiency. Thus, some improved techniques can rely on multiple vectors each encoding one or more reprogramming factors in various expression cassettes. Under these designs, alteration of the amount of a particular vector for delivery provides a coarse, but relatively straightforward route for adjusting expression levels in a target cell.

[0652] A further advantage of the techniques described herein is the use of defined media conditions for the reprogramming process, including the use of ESC media and / or E7 media. While certain additives may be present to spur the reprogramming process (e.g., L-Ascorbic Acid, Transferrin, Sodium Bicarbonate, Insulin, Sodium Selenite and / or bFGF), no serum or animal components are used. In some instances, there may be further benefits in altering the chemical and / or atmospheric conditions under which reprogramming will take place. For example, as the pre-implantation embryo is not vascularized and hypoxic (similar to bone marrow stem-cell niches) reprogramming under hypoxic conditions of 5% 02, instead of the atmospheric 21% 02, may further provide an opportunity to increase the reprogramming efficiency. Similarly, chemicalinduction techniques have been used in combination with reprogramming, particularly histone deacetylase (HD AC) inhibitor molecule, valproic acid (VP A), which has been found wide use in different reprogramming studies. At the same time, other small molecules such as MAPK kinase (MEK)-ERK (“MEK”) inhibitor PD0325901, transforming growth factor beta (“TGF- ”) type I receptor ALK4, ALK5 and ALK7 inhibitor SB431542 and the glycogen synthase kinase-3 (“GSK3”) inhibitor CHIR99021 have been applied for activation of differentiation-inducing pathways (e.g. BMP signaling), coupled with the modulation of other pathways (e.g. inhibition of the MAPK kinase (MEK)-ERK pathway) in order to sustain self-renewal. Other small molecules, such as Rho-associated coiled-coil-containing protein kinase (“ROCK”) inhibitors, such as Y-27632 and thiazovivin (“Tzv”) have been applied in order to promote survival and reduce vulnerability of pSCs to cell death, particularly upon single-cell dissociation.

[0653] In addition to the choice of delivery vectors, reprogramming factor combinations, and conditions for reprogramming, further variations must consider the nature of the host target cell for reprogramming. To date, a wide variety of cells have served as sources for reprogramming including fibroblasts, stomach and liver cell cultures, human keratinocytes, adipose cells, and frozen human monocyte. Clearly, there is a wide and robust potential for dedifferentiation across many tissues sources. Nevertheless, it is widely understood that depending on the donor cell type, reprogramming is achieved with different efficiencies and kinetics. For example, although fibroblasts remain the most popular donor cell type for reprogramming studies, other types of cells such as human primary keratinocytes transduced with Oct-4, Sox-2, Klf-4 and c-Myc have been reported to reprogram 100 times more efficiently and two-fold faster. Additionally, some other cell types, such as cord blood cells, may only require a subset of reprogramming factors, such as Oct-4 and Sox-2 for dedifferentiation to take hold, while neural progenitor cells may only require Oct-4. Without being bound to any particular theory, it is believed that differences in reprogramming efficiency and / or reprogramming factor requirements of specific host cells result from high endogenous levels of certain reprogramming factors and / or intrinsic epigenetic states that are more amenable to reprogramming. Although these many other sources have been used across studies for the generation of iPSCs, mononuclear cells (MNCs) from peripheral blood (PB) are a highly attractive host cell candidate due to convenience and features as an almost unlimited resource for cell reprogramming. PB cells in particular are relatively easy to isolate (e.g., blood draw) compared to isolation from other sources such asfibroblasts (e.g., skin biopsy). These cells do not require laborious culturing and propagation prior to reprogramming, thereby reducing the overall time from which reprogramming iPSCs can be obtained.

[0654] Following successful reprogramming, clonal selection allows for generation of pluripotent stem cell lines. Ideally, such cells possess requisite morphology (i.e., compact colony, high nucleus to cytoplasm ratio and prominent nucleolus), self-renewal capacity for unlimited propagation in culture (i.e., immortal), and with the capability to differentiate into all three germ layers (e.g., endoderm, mesoderm and ectoderm). Further techniques to characterize the pluripotency of a given population of cells include injection into an immunocompromised animal, such as a severe combined immunodeficient (“SCID”) mouse, for formation of teratomas containing cells or tissues characteristic of all three germ layers.

[0655] Described herein is a composition of blood cell derived induced pluripotent stem cells (“BC-iPSCs”). In certain embodiments, the composition of blood cell derived induced pluripotent stem cells includes cells generated by providing a quantity of blood cells, delivering a quantity of reprogramming factors into the blood cells, culturing the blood cells in a reprogramming media for at least 4 days, wherein delivering the reprogramming factors, and culturing generates the blood cells derived induced pluripotent stem cells. In certain embodiments, the blood cells are T-cells. In other embodiments, the blood cells are non-T-cells. In other embodiments, the blood cells are mononuclear cells (MNCs), including for example peripheral blood mononuclear cells (PBMCs). In other embodiments, the cells are primary granulocytes, monocytes and B lymphocytes. In certain embodiments, the reprogramming factors are Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40 Large T Antigen (“SV40LT”), and short hairpin RNAs targeting p53 (“shRNA-p53”). In other embodiments, these reprogramming factors are encoded in a combination of vectors including pEP4 E02S ET2K, pCXLE-hOCT3 / 4-shp53-F, pCXLE-hSK, pCXLE-hUL and pCXWB-EBNAl. This includes, for example, using about 0.5-1.0 ug pCXLE-hOCT3 / 4-shp53, 0.5-1.0 ug pCXLE-hSK, 0.5-1.0 ug pCXLE- UL, about 0.25-0.75 ug pCXWB-EBNAl and 0.5-1.0 ug pEP4 E02S ET2K. This includes, for example, using 0.83 ug pCXLE-hOCT3 / 4-shp53, 0.83 ug pCXLE-hSK, 0.83 ug pCXLE-UL, 0.5 ug pCXWB-EBNAl and 0.83 ug pEP4 E02S ET2K, wherein the stoichiometric ratio of SV40LT (encoded in pEP4 E02S ET2K) and EBNA-1 (encoded in pCXWB-EBNAl) supports the reprogramming of non-T cell component of blood, including peripheral blood mononuclear cells. In certain other embodiments, thereprogramming media includes PD0325901, CHIR99021, HA-100, and A-83-01. In other embodiments, the culturing the blood cells in a reprogramming media is for 4-30 days. In various embodiments, the blood cells are plated on a treated cell culture surface after delivering a quantity of reprogramming factors. In various embodiments, treatment includes plating of feeder cells, such as mouse embryonic fibroblasts. In other embodiments, treatment includes coating with extracellular matrix proteins. In various embodiment, extracellular matrix proteins include laminin.

[0656] In various embodiments, the BC-iPSCs are capable of serial passaging as a cell line. In various embodiments, the BC-iPSCs possess genomic stability. Genomic stability can be ascertained by various techniques known in the art. For example, G-band karyotyping can identify abnormal cells lacking genomic stability, wherein abnormal cells possess about 10% or more mosaicism, or one or more balanced translocations of greater than about 5, 6, 7, 8, 9, 10 or more Mb. Alternatively, genomic stability can be measured using comparative genomic hybridization (aCGH) microarray, comparing for example, BC-iPSCs against iPSCs from a non-blood cell source such as fibroblasts. Genomic stability can include copy number variants (CNVs), duplications / deletions, and unbalanced translocations. In various embodiments, BC-iPSCs exhibit no more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, or 20 Mb average size of amplification and deletion. In various embodiments, BC-iPSCs exhibit no more than about 20-30 Mb average size of amplification and deletion. In various embodiments, BC- iPSCs exhibit no more than about 30-40 Mb average size of amplification and deletion. In various embodiments, BC-iPSCs exhibit no more than about 40-50 Mb average size of amplification and deletion. In various embodiments, the average number of acquired de novo amplification and deletions in BC-iPSCs is less than about 5, 4, 3, 2, or 1. For example, de novo amplification and deletions in fib-iPSCs are at least two-fold greater than in PBMC-iPSCs.

[0657] In different embodiments, reprogramming factors can also include one or more of following: Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40LT, shRNA-p53, nanog, Sal 14, Fbx-15, Utf-1, Tert, or a Mir-290 cluster microRNA such as miR-291-3p, miR- 294 or miR-295. In different embodiments, the reprogramming factors are encoded by a vector. In different embodiments, the vector can be, for example, a non-integrating episomal vector, minicircle vector, plasmid, retrovirus (integrating and non-integrating) and / or other genetic elements known to one of ordinary skill. In different embodiments, the reprogramming factors are encoded by one or more oriP / EBNAl derived vectors. Indifferent embodiments, the vector encodes one or more reprogramming factors, and combinations of vectors can be used together to deliver one or more of Oct-4, Sox-2, Klf- 4, c-Myc, Lin-28, SV40LT, shRNA-p53, nanog, Sal 14, Fbx-15, Utf-1, Tert, or a Mir-290 cluster microRNA such as miR-291-3p, miR-294 or miR-295. For example, oriP / EBNAl is an episomal vector that can encode a vector combination of multiple reprogramming factors, such as pCXLE-hUL, pCXLE-hSK, pCXLE-hOCT3 / 4-shp53-F, pEP4 EO2S T2K and pCXWB-EBNAl. In other embodiments, the reprogramming factors are delivered by techniques known in the art, such as nuclefection, transfection, transduction, electrofusion, electroporation, microinjection, cell fusion, among others. In other embodiments, the reprogramming factors are provided as RNA, linear DNA, peptides or proteins, or a cellular extract of a pluripotent stem cell. In various embodiments, the reprogramming media is embryonic stem cell (ESC) media. In various embodiments, the reprogramming media includes bFGF. In various embodiments, the reprogramming media is E7 media. In various embodiments, the reprogramming E7 media includes L- Ascorbic Acid, Transferrin, Sodium Bicarbonate, Insulin, Sodium Selenite and / or bFGF In different embodiments, the reprogramming media comprises at least one small chemical induction molecule. In different embodiments, the at least one small chemical induction molecule comprises PD0325901, CHIR99021, HA-100, A-83-01, valproic acid (VP A), SB431542, Y-27632 or thiazovivin (“Tzv”). In different embodiments, culturing the BCs in a reprogramming media is for at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days. In certain embodiments, the BC-iPSCs are derived from blood cells previously isolated from a subject, by for, example, drawing a blood sample from the subject. In other embodiments, the blood cells are isolated from a subject possessing a disease mutation. For example, subjects possessing any number of mutations, such as autosomal dominant, recessive, sex-linked, can serve as a source of blood cells to generate BC-iPSCs possessing said mutation. In other embodiments, the disease mutation is associated with a neurodegenerative disease, disorder and / or condition. In other embodiments, the disease mutation is associated with an inflammatory bowel disease, disorder, and / or condition. In various embodiments, the BC-iPSCs possess features of pluripotent stem cells. Some exemplary features of pluripotent stem cells including differentiation into cells of all three germ layers (ectoderm, endoderm, mesoderm), either in vitro or in vivo when injected into an immunodeficient animal, expression of pluripotency markers such as Oct-4, Sox-2, nanog, TRA-1-60, TRA-1-81, SSEA4, high levels of alkaline phosphatase (“AP”)expression, indefinite propagation in culture, among other features recognized and appreciated by one of ordinary skill. Also described herein is an efficient method for generating induced pluripotent stem cells, including providing a quantity of cells, delivering a quantity of reprogramming factors into the cells, culturing the cells in a reprogramming media for at least 4 days, wherein delivering the reprogramming factors, and culturing generates induced pluripotent stem cells. In certain embodiments, the cells are primary culture cells. In other embodiments, the cells are blood cells (BCs). In certain embodiments, the blood cells are T-cells. In other embodiments, the blood cells are non- T-cells. In other embodiments, the cells are mononuclear cells (MNCs), including for example peripheral blood mononuclear cells (PBMCs). In other embodiments, the cells are primary granulocytes, monocytes and B lymphocytes. In certain embodiments, the reprogramming factors are Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40 Large T Antigen (“SV40LT”), and short hairpin RNAs targeting p53 (“shRNA-p53”). In other embodiments, these reprogramming factors are encoded in a combination of vectors including pEP4 E02S ET2K, pCXLE-hOCT3 / 4-shp53-F, pCXLE-hSK, pCXLE-hUL and pCXWB-EBNAl. This includes, for example, using about 0.5- 1.0 ug pCXLE-hOCT3 / 4- shp53, 0.5-1.0 ug pCXLE-hSK, 0.5-1.0 ug pCXLE-UL, about 0.25-0.75 ug pCXWB- EBNA1 and 0.5-1.0 ug pEP4 E02S ET2K. This includes, for example, using 0.83 ug pCXLE-hOCT3 / 4-shp53, 0.83 ug pCXLE-hSK, 0.83 ug pCXLE-UL, 0.5 ug pCXWB- EBNA1 and 0.83 ug pEP4 E02S ET2K, wherein the stoichiometric ratio of SV40LT (encoded in pEP4 E02S ET2K) and EBNA-1 (encoded in pCXWB-EBNAl) supports the reprogramming of non-T cell component of blood, including peripheral blood mononuclear cells. In various embodiments, the reprogramming media is embryonic stem cell (ESC) media. In various embodiments, the reprogramming media includes bFGF. In various embodiments, the reprogramming media is E7 media. In various embodiments, the reprogramming E7 media includes L-Ascorbic Acid, Transferrin, Sodium Bicarbonate, Insulin, Sodium Selenite and / or bFGF. In different embodiments, the reprogramming media comprises at least one small chemical induction molecule. In certain other embodiments, the reprogramming media includes PD0325901, CHIR99021, HA-100, and A-83-01. In other embodiments, the culturing the blood cells in a reprogramming media is for 4-30 days. In various embodiments, the BC-iPSCs are capable of serial passaging as a cell line. In various embodiments, the BC-iPSCs possess genomic stability. Genomic stability can be ascertained by various techniques known in the art. For example, G-band karyotyping can identify abnormal cells lacking genomicstability, wherein abnormal cells possess about 10% or more mosaicism, or one or more balanced translocations of greater than about 5, 6, 7, 8, 9, 10 or more Mb. Alternatively, genomic stability can be measured using comparative genomic hybridization (aCGH) microarray, comparing for example, BC-iPSCs against iPSCs from a non-blood cell source such as fibroblasts. Genomic stability can include copy number variants (CNVs), duplications / deletions, and unbalanced translocations. In various embodiments, BC-iPSCs exhibit no more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, or 20 Mb average size of amplification and deletion. In various embodiments, BC-iPSCs exhibit no more than about 20-30 Mb average size of amplification and deletion. In various embodiments, BC-iPSCs exhibit no more than about 30-40 Mb average size of amplification and deletion. In various embodiments, BC-iPSCs exhibit no more than about 40-50 Mb average size of amplification and deletion. In various embodiments, the average number of acquired de novo amplification and deletions in BC-iPSCs is less than about 5, 4, 3, 2, or 1. For example, de novo amplification and deletions in fib-iPSCs are at least two-fold greater than in PBMC-iPSCs. In various embodiments, the methods produces iPSC cell lines collectively exhibiting about 20%, 15%, 10%, 5% or less abnormal karyotypes over 4-8, 9-13, 13-17, 17-21, 21-25, or 29 or more passages when serially passaged as a cell line. In different embodiments, reprogramming factors can also include one or more of following: Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40LT, shRNA-p53, nanog, Sal 14, Fbx-15, Utf-1, Tert, or a Mir-290 cluster microRNA such as miR-291-3p, miR-294 or miR-295. In different embodiments, the reprogramming factors are encoded by a vector. In different embodiments, the vector can be, for example, a nonintegrating episomal vector, minicircle vector, plasmid, retrovirus (integrating and nonintegrating) and / or other genetic elements known to one of ordinary skill. In different embodiments, the reprogramming factors are encoded by one or more oriP / EBNAl derived vectors. In different embodiments, the vector encodes one or more reprogramming factors, and combinations of vectors can be used together to deliver one or more of Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40LT, shRNA-p53, nanog, Sal 14, Fbx-15, Utf-1, Tert, or a Mir-290 cluster microRNA such as miR-291-3p, miR-294 or miR-295. For example, oriP / EBNAl is an episomal vector that can encode a vector combination of multiple reprogramming factors, such as pCXLE-hUL, pCXLE-hSK, pCXLE-hOCT3 / 4-shp53-F, pEP4 EO2S T2K and pCXWB-EBNAl. In other embodiments, the reprogramming factors are delivered by techniques known in the art, such as nuclefection, transfection, transduction, electrofusion, electroporation,microinjection, cell fusion, among others. In other embodiments, the reprogramming factors are provided as RNA, linear DNA, peptides or proteins, or a cellular extract of a pluripotent stem cell. In certain embodiments, the cells are treated with sodium butyrate prior to delivery of the reprogramming factors. In other embodiments, the cells are incubated or 1, 2, 3, 4, or more days on a tissue culture surface before further culturing. This can include, for example, incubation on a Matrigel coated tissue culture surface. In other embodiments, the reprogramming conditions include application of norm-oxygen conditions, such as 5% 02, which is less than atmospheric 21% 02. In various embodiments, the reprogramming media is embryonic stem cell (ESC) media. In various embodiments, the reprogramming media includes bFGF. In various embodiments, the reprogramming media is E7 media. In various embodiments, the reprogramming E7 media includes L-Ascorbic Acid, Transferrin, Sodium Bicarbonate, Insulin, Sodium Selenite and / or bFGF. In different embodiments, the reprogramming media comprises at least one small chemical induction molecule. In different embodiments, the at least one small chemical induction molecule comprises PD0325901, CHIR99021, HA-100, A-83- 01, valproic acid (VP A), SB431542, Y-27632 or thiazovivin (“Tzv”). In different embodiments, culturing the BCs in a reprogramming media is for at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days. Efficiency of reprogramming is readily ascertained by one of many techniques readily understood by one of ordinary skill. For example, efficiency can be described by the ratio between the number of donor cells receiving the full set of reprogramming factors and the number of reprogrammed colonies generated. Measuring the number donor cells receiving reprogramming factors can be measured directly, when a reporter gene such as GFP is included in a vector encoding a reprogramming factor. Alternatively, indirect measurement of delivery efficiency can be provided by transfecting a vector encoding a reporter gene as a proxy to gauge delivery efficiency in paired samples delivering reprogramming factor vectors. Further, the number of reprogrammed colonies generated can be measured by, for example, observing the appearance of one or more embryonic stem cell-like pluripotency characteristics such as alkaline phosphatase (AP)-positive clones, colonies with endogenous expression of transcription factors Oct or Nanog, or antibody staining of surface markers such as Tra-1-60. In another example, efficiency can be described by the kinetics of induced pluripotent stem cell generation. For example, efficiency can include producing cell lines of normal karyotype, including the method producing iPSC cell lines collectively exhibiting about 20%, 15%, 10%, 5% or lessabnormal karyotypes over 4-8, 9-13, 13-17, 17-21, 21-25, or 29 or more passages when serially passaged as a cell line.

[0658] In some embodiments of this invention, the pluripotency of a cell is tested in vivo by examining its capability of growing into teratoma containing all three germ cells. In another embodiment, the pluripotency is tested by the expression of certain markers in cultured cells ex vivo. In yet another embodiment, the pluripotency of a cell is tested by its contribution to the development of an embryo into a living organism. The pluripotent stem cells are injected into the inner cell mass (ICM) of an embryonic blastocyst, which is then implanted into the uterus of a female organism and developing into a fetus. The term “chimerism” refers to the contribution of the stem cells and their progenies to all three germ layers that give rise to various tissues in a living organism.

[0659] There are numerous methods of differentiating the induced cells into a more specialized cell type. Methods of differentiating induced cells may be similar to those used to differentiate stem cells, particularly ES cells, MSCs, MAPCs, MIAMI, hematopoietic stem cells (HSCs). In some cases, the differentiation occurs ex vivo; in some cases the differentiation occurs in vivo. In one embodiment, neural stem cells may be generated by culturing the induced cells as floating aggregates in the presence of noggin, or other bone morphogenetic protein antagonist According to some embodiments, the composition of the present invention may be formulated with an excipient, carrier or vehicle including, but not limited to, a solvent. The pharmaceutically acceptable carrier must be of sufficiently high purity and of sufficiently low toxicity to render it suitable for administration to the mammal being treated. It further should maintain the stability and bioavailability of an active agent. The pharmaceutically acceptable carrier can be liquid or solid and is selected, with the planned manner of administration in mind, to provide the desired bulk, consistency, etc., when combined with an active agent and other components of a given composition. Suitable pharmaceutically acceptable carriers for the compositions of the present invention include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatins, amyloses, magnesium stearates, talcs, silicic acids, viscous paraffins, hydroxymethylcelluloses, polyvinylpyrrolidones and the like. Such carrier solutions also can contain buffers, diluents and other suitable additives. The term “buffer” as used herein refers to a solution or liquid whose chemical makeup neutralizes acids or bases without a significant change in pH. Examples of buffers envisioned by the present invention include, but are not limited to, Dulbecco's phosphate buffered saline (PBS),Ringer's solution, 5% dextrose in water (D5W), normal / physiologic saline (0.9% NaCl). According to some embodiments, the infusion solution is isotonic to subject tissues. According to some embodiments, the infusion solution is hypertonic to subject tissues. Compositions of the present invention that are for parenteral administration can include pharmaceutically acceptable carriers such as sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions in a liquid oil base. The compositions of the present invention may be administered parenterally in the form of a sterile injectable aqueous or oleaginous suspension. The term “parenteral” or “parenterally” as used herein refers to introduction into the body by way of an injection (i.e., administration by injection), including, but not limited to, infusion techniques. According to some embodiments, parenteral administration includes but is not limited to intravascular delivery (meaning into a blood vessel), intravenous delivery (meaning into a vein), intra-arterial delivery (meaning into an artery), intraosseous delivery (meaning into the bone marrow), intramuscular delivery (meaning into a muscle), subcutaneous delivery (meaning under the skin), cardiac delivery (meaning into the heart, myocardium), etc. The delivery route may vary and depend on the origin of degenerative diseases. In a preferred embodiment, the delivery route for treating degenerative conditions in central nervous system is intracranial injection.

[0660] In one embodiment of the invention, the generation of pluripotent stem cells is provided in a manner which is scalable to production of commercial-grade cellular products. Although several methodologies have been reported for generation of pluripotent stem cells, these are characterized by low level of cellular dedifferentiation, as well as problems with large-scale expansion. In one embodiment the invention provides conditions for enhancing the generation of pluripotent stem cells in part by creating environments that resemble embryonic stem cell development. Accordingly target cells to be dedifferentiated are grown in conditions that possess the multiple cells associated with the three dimensional embryonic environment. Specifically, in some embodiments amniotic membrane stem cells are utilized as feeder layers or as a cellular composite to support the cells which are to be dedifferentiated. Cells included in culture to support dedifferentiation include mesenchymal stem cells, monocytes, B cells and NKT cells. In some embodiments bone marrow endothelial cells are utilized to expand various cells to be dedifferentiated. It is occasionally desired to utilized defined liquid media in order to avoid reproducibility issues associated with fetal calf serum lot to lot variability.Accordingly, the invention provides the utilization of liquid media containing varioushistone deacetylase inhibitors to allow for expansion of stem cells without differentiation. Useful histone deacetylase inhibitors include valproic acid, trichostatin A, sodium phenylbutyrate and sulforaphane. The invention discloses culture medium being serum- free and devoid of non-human contaminants comprising ascorbic acid at a concentration range of about 200-6000 pg / ml, basic fibroblast growth factor (bFGF) at a concentration range of about 5-2000 ng / ml, serum replacement and a lipid mixture, wherein the culture medium is capable of maintaining pluripotent stem cells in an undifferentiated state and with a stable karyotype for at least 40 passages in the absence of feeder cell support. In some embodiments the invention provides for feeder layers as well. The expansion of stem cells may be performed utilizing various types of liquid culture media as a base. For example, the GIBCO™ KNOCKOUT™ Serum Replacement (Gibco-Invitrogen Corporation, Grand Island, N.Y. USA, Catalogue No. 10828028) is a defined serum-free formulation optimized to grow and maintain undifferentiated ES cells in culture. It should be noted that the formulation of GIBCO™ Knockout™ Serum Replacement includes Albumax (Bovine serum albumin enriched with lipids) which is from an animal source (International Patent Publication No. WO 98 / 30679 to Price, P. J. et al According to some embodiments of the invention, the concentration of GIBCO™ KNOCKOUT™ Serum Replacement in the culture medium is in the range of from about 1% [volume / volume (v / v)] to about 50% (v / v), e.g., from about 5% (v / v) to about 40% (v / v), e.g., from about 5% (v / v) to about 30% (v / v), e.g., from about 10% (v / v) to about 30% (v / v), e.g., from about 10% (v / v) to about 25% (v / v), e.g., from about 10% (v / v) to about 20% (v / v), e.g., about 10% (v / v), e.g., about 15% (v / v), e.g., about 20% (v / v), e.g., about 30% (v / v). For expansion of iPSC there may be various cytokines added to said media. One such cytokine is leukemia inhibitory factor, which may be added at concentrations of 1 pg / ml to 500 ng / ml, more preferably 10 pg / ml to 200 ng / ml, more preferably 100 pg / ml to 100 ng / ml. There exist other commercially available serum replacement is the B27 supplement without vitamin A which is available from Gibco-Invitrogen, Corporation, Grand Island, N.Y. USA, Catalogue No. 12587-010. The B27 supplement is a serum-free formulation which includes d-biotin, fatty acid free fraction V bovine serum albumin (BSA), catalase, L-camitine HC1, corticosterone, ethanolamine HC1, D-galactose (Anhyd.), glutathione (reduced), recombinant human insulin, linoleic acid, linolenic acid, progesterone, putrescine-2-HCl, sodium selenite, superoxide dismutase, T-3 / albumin complex, DL alpha-tocopherol and DL alpha tocopherol acetate. However, the use of B27 supplement is limited since it includes albumin from an animal source. In oneembodiment leukemia inhibitory factor is added to said B27 supplement. In conditions in which animal-free media are desirable, such as in cases in which generation of autoantibodies, alloantibodies or xenoantibodies are to be avoided, it may be preferably to utilizing animal free media, which is sometimes referred to as “xeno-free”. Non-limiting examples of commercially available xeno-free serum replacement compositions include the premix of ITS (Insulin, Transferrin and Selenium) available from Invitrogen corporation (ITS, Invitrogen, Catalogue No. 51500-056); Serum replacement 3 (Sigma, Catalogue No. S2640) which includes human serum albumin, human transferring and human recombinant insulin and does not contain growth factors, steroid hormones, glucocorticoids, cell adhesion factors, detectable Ig and mitogens. According to some embodiments of the invention, the xeno-free serum replacement formulations ITS (Invitrogen corporation) and SR3 (Sigma) are diluted in a 1 to 100 ratio in order to reach a xl working concentration. According to some embodiments of the invention the culture medium is capable of maintaining pluripotent stem cell in a proliferative, pluripotent and undifferentiated state for at least about 5 passages, at least about 10 passages, at least about 15 passages, at least about 20 passages, at least about 22 passages, at least about 25 passages, at least about 30 passages, at least about 35 passages, at least about 40 passages, at least about 45 passages, at least about 50 passages and more. According to some embodiments of the invention the culture medium is capable of expanding the pluripotent stem cells in an undifferentiated state. One of the important aspects of the current invention is the proliferation or expansion of pluripotent stem cells without their differentiation. The number of pluripotent stem cells over the culturing period (by at least about 5%, 10%, 15%, 20%, 30%, 50%, 100%, 200%, 500%, 1000%, and more). It will be appreciated that the number of pluripotent stem cells which can be obtained from a single pluripotent stem cell depends on the proliferation capacity of the pluripotent stem cell. The proliferation capacity of a pluripotent stem cell can be calculated by the doubling time of the cell (i.e., the time needed for a cell to undergo a mitotic division in the culture) and the period the pluripotent stem cell culture can be maintained in the undifferentiated state (which is equivalent to the number of passages multiplied by the days between each passage). According to some embodiments of the invention, the culture medium of some embodiments of the invention is capable of supporting expansion of a single pluripotent stem cell (e.g., hESC or human iPS cell) or a population of pluripotent stem cells by at least 223 (i.e., 8^ 106) within about one month, e.g., at least 224 (i.e., 16.7x 106) within about one month. According to some embodiments of theinvention the serum-free and xeno-free culture medium comprises basic fibroblast growth factor (bFGF), transforming growth factor beta-3 (TGFP3) and ascorbic acid, wherein a concentration of the ascorbic acid in the culture medium is at least 50 pg / ml and wherein the culture medium is capable of maintaining pluripotent stem cells in an undifferentiated state in the absence of feeder cell support. Ascorbic acid (also known as vitamin C) is a sugar acid (C6H8O6; molecular weight 176.12 grams / mole) with antioxidant properties. The ascorbic acid used by the culture medium of some embodiments of the invention can be a natural ascorbic acid, a synthetic ascorbic acid, an ascorbic acid salt (e.g., sodium ascorbate, calcium ascorbate, potassium ascorbate), an ester form of ascorbic acid (e.g., ascorbyl palmitate, ascorbyl stearate), a functional derivative thereof (a molecule derived from ascorbic acid which exhibits the same activity / function when used in the culture medium of the invention), or an analogue thereof (e.g., a functional equivalent of ascorbic acid which exhibits an activity analogous to that observed for ascorbic acid when used in the culture medium of the invention). Non-limiting examples of ascorbic acid formulations which can be used in the culture medium of some embodiments of the invention include L-ascorbic acid and ascorbic acid 3 -phosphate. Ascorbic acid can be obtained from various manufacturers such as Sigma, St Louis, Mo., USA (e.g., Catalogue numbers: A2218, A5960, A7506, A0278, A4403, A4544, A2174, A2343, 95209, 33034, 05878, 95210, 95212, 47863, 01-6730, 01-6739, 255564, A92902, W210901). As mentioned, the concentration of ascorbic acid in the culture medium is at least about 50 pg / ml. According to some embodiments of the invention, the ascorbic acid can be used in a range of concentrations such as from about 50 pg / ml to about 50 mg / ml, e.g., from about 50 pg / ml to about 5 mg / ml, e.g., from about 50 pg / ml to about 1 mg / ml, e.g., from about 100 pg / ml to about 800 pg / ml, e.g., from about 200 pg / ml to about 800 pg / ml, e.g., from about 300 pg / ml to about 700 pg / ml, e.g., from about 400 pg / ml to about 600 pg / ml, e.g., from about 450 pg / ml to about 550 pg / ml. According to some embodiments of the invention the concentration of ascorbic acid in the culture medium is at least about 75 pg / ml, e.g., at least about 100 pg / ml, e.g., at least about 150 pg / ml, e.g., at least about 200 pg / ml, e.g., at least about 250 pg / ml, e.g., at least about 300 pg / ml, e.g., at least about 350 pg / ml, e.g., at least about 400 pg / ml, e.g., at least about 450 pg / ml, e.g., about 500 pg / ml.Basic fibroblast growth factor (also known as bFGF, FGF2 or FGF-P) is a member of the fibroblast growth factor family. The bFGF used in the culture medium of some embodiments of the invention can be a purified, a synthetic or a recominantly expressed bFGF protein [(e.g., human bFGF polypeptide GenBank Accession No. NP — 001997.5(SEQ ID N0:31); human bFGF polynucleotide GenBank Accession No. NM — 002006.4 (SEQ ID NO:32). It should be noted that for the preparation of a xeno-free culture medium the bFGF is preferably purified from a human source or is recombinantly expressed as is further described hereinbelow. bFGF can be obtained from various commercial sources such as Cell Sciences®, Canton, Mass., USA (e.g., Catalogue numbers CRF001 A and CRF001B), Invitrogen Corporation products, Grand Island N.Y., USA (e.g., Catalogue numbers: PHG0261, PHG0263, PHG0266 and PHG0264), ProSpec-Tany TechnoGene Ltd. Rehovot, Israel (e.g., Catalogue number: CYT-218), and Sigma, St Louis, Mo., USA (e.g., catalogue number: F0291). According to some embodiments the concentration of bFGF in culture medium is in the range from about 1 ng / ml to about 10 pg / ml, e.g., from about 2 ng / ml to about 1 pg / ml, e.g., from about 1 ng / ml to about 500 ng / ml, e.g., from about 2 ng / ml to about 500 ng / ml, e.g., from about 5 ng / ml to about 250 ng / ml, e.g., from about 5 ng / ml to about 200 ng / ml, e.g., from about 5 ng / ml to about 150 ng / ml, e.g., about 10 ng / ml, e.g., about 20 ng / ml, e.g., about 30 ng / ml, e.g., about 40 ng / ml, e.g., about 50 ng / ml, e.g., about 60 ng / ml, e.g., about 70 ng / ml, e.g., about 80 ng / ml, e.g., about 90 ng / ml, e.g., about 100 ng / ml, e.g., about 110 ng / ml, e.g., about 120 ng / ml, e.g., about 130 ng / ml, e.g., about 140 ng / ml, e.g., about 150 ng / ml. According to some embodiments of the invention the concentration of bFGF in the culture medium is at least about 1 ng / ml, at least about 2 ng / ml, at least about 3 ng, at least about 4 ng / ml, at least about 5 ng / ml, at least about 6 ng / ml, at least about 7 ng, at least about 8 ng / ml, at least about 9 ng / ml, at least about 10 ng / ml, at least about 15 ng / ml, at least about 20 ng / ml, at least about 25 ng / ml, at least about 30 ng / ml, at least about 35 ng / ml, at least about 40 ng / ml, at least about 45 ng / ml, at least about 50 ng / ml, at least about 55 ng / ml, at least about 60 ng / ml, at least about 70 ng / ml, at least about 80 ng / ml, at least about 90 ng / ml, at least about 95 ng / ml, e.g., about 100 ng / ml. Transforming growth factor beta-3 (TGFP3) is involved in the control of proliferation, differentiation, and other functions in many cell types, acts in inducing transformation and as a negative autocrine growth factor. TGFP3 can be obtained from various commercial sources such as R&D Systems Minneapolis Minn., USA. According to some embodiments of the invention, the concentration of TGFP3 in the culture medium is in the range of about 0.05 ng / ml to about 1 pg / ml, e.g., from 0.1 ng / ml to about 1 pg / ml, e.g., from about of about 0.5 ng / ml to about 100 ng / ml. According to some embodiments of the invention, the concentration of TGFP3 in the culture medium is at least about 0.5 ng / ml, e.g., at least about 0.6 ng / ml, e.g., at least about 0.8 ng / ml, e.g., at least about 0.9ng / ml, e.g., at least about 1 ng / ml, e.g., at least about 1.2 ng / ml, e.g., at least about 1.4 ng / ml, e.g., at least about 1.6 ng / ml, e.g., at least about 1.8 ng / ml, e.g., about 2 ng / ml.

[0661] According to some embodiments of the invention, the culture medium comprises bFGF at a concentration range of about 0.1 ng / ml to about 500 ng / ml, TGFP3 at a concentration range of about 0.1 ng / ml to about 20 ng / ml, and ascorbic acid at a concentration range of about 50 pg / ml to about 5000 pg / ml. According to some embodiments of the invention, the culture medium of some embodiments of the invention comprises bFGF at a concentration range of about 5 ng / ml to about 150 ng / ml, TGFP3 at a concentration range of about 0.5 ng / ml to about 5 ng / ml, and ascorbic acid at a concentration range of about 400 pg / ml to about 600 pg / ml. According to some embodiments of the invention, the concentration of the lipid mixture in the culture medium is from about 0.5% [volume / volume (v / v)] to about 3% v / v, e.g., from about 0.5% v / v to about 2% v / v, e.g., from about 0.5% v / v to about 1% v / v, e.g., about 1% v / v. According to some embodiments of the invention, the culture medium of some embodiments of the invention comprises bFGF at a concentration range of about 0.1 ng / ml to about 500 ng / ml, TGFP3 at a concentration range of about 0.1 ng / ml to about 20 ng / ml, ascorbic acid at a concentration range of about 50 pg / ml to about 5000 pg / ml, xeno-free serum replacement and a lipid mixture. Non-limiting examples of xeno-free and serum-free culture media which comprise TGFP3, bFGF and ascorbic acid at a concentration of at least 50 pg / ml and which can be used to maintain pluripotent stem cells in a proliferative and undifferentiated states include the HA75 and HA78 culture media. According to some embodiments of the invention, the culture medium further comprises sodium bicarbonate. Sodium bicarbonate can be obtained from Biological Industries, Beit HaEmek, Israel. According to some embodiments of the invention, the concentration of sodium bicarbonate in the culture medium is from about 5% to about 10%, e.g., from about 6% to about 9%, e.g., from about 7% to about 8%, e.g., about 7.5%. The present inventors uncovered that pluripotent stem cells can be maintained in a proliferative, pluripotent and undifferentiated state for at least 15 passages when cultured in a serum-free and xeno-free culture medium which comprises bFGF and ascorbic acid but does not comprise a TGFP isoform. According to some embodiments of the invention, the culture medium comprises no more than 1 ng / ml of the TGFP isoform, e.g., no more than 0.5 ng / ml, e.g., no more than 0.1 ng / ml, e.g., no more than 0.05 ng / ml, e.g., no more than 0.01 ng / ml of the TGFP isoform. According to some embodiments of the invention the culture medium comprises ascorbic acid at a concentration range of about 400-600pg / ml and basic fibroblast growth factor (bFGF) at a concentration range of about 50-200 ng / ml. According to some embodiments of the invention the culture medium the culture medium which comprises ascorbic acid at a concentration range of about 400-600 pg / ml and basic fibroblast growth factor (bFGF) at a concentration range of about 50-200 ng / ml is capable of maintaining pluripotent stem cells in an undifferentiated state in the absence of feeder cell support. According to some embodiments of the invention, the concentration of ascorbic acid in the culture medium is between about 410 pg / ml to about 590 pg / ml, between about 420 pg / ml to about 580 pg / ml, between about 450 pg / ml to about 550 pg / ml, between about 460 pg / ml to about 540 pg / ml, between about 470 pg / ml to about 530 pg / ml, between about 490 pg / ml to about 520 pg / ml, e.g., between about 490 pg / ml to about 510 pg / ml, e.g., about 500 pg / ml. According to some embodiments of the invention, the concentration of bFGF in the culture medium is between about 50 ng / ml to about 200 ng / ml, between about 60 ng / ml to about 190 ng / ml, between about 70 ng / ml to about 180 ng / ml, between about 80 ng / ml to about 170 ng / ml, between about 90 ng / ml to about 160 ng / ml, between about 90 ng / ml to about 150 ng / ml, between about 90 ng / ml to about 130 ng / ml, between about 90 ng / ml to about 120 ng / ml, e.g., about 100 ng / ml. According to some embodiments of the invention, the concentration of bFGF in the culture medium is about 50, about 55, about 60, about 65, about 70, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200 ng / ml. According some embodiments of the invention the culture medium which comprises ascorbic acid at a concentration range of about 400-600 pg / ml and basic fibroblast growth factor (bFGF) at a concentration range of about 50-200 ng / ml, further comprises xeno-free serum replacement. According to some embodiments of the invention, the culture medium which comprises ascorbic acid at a concentration range of about 400-600 pg / ml and basic fibroblast growth factor (bFGF) at a concentration range of about 50-200 ng / ml, further comprises a lipid mixture. According to some embodiments of the invention, the culture medium comprises bFGF at a concentration of about 50-200 ng / ml and ascorbic acid at a concentration of about 400-600 pg / ml is devoid of sodium-bicarbonate. According to some embodiments of the invention, the culture medium comprises bFGF at a concentration of about 50-200 ng / ml and ascorbic acid at a concentration of about 400- 600 pg / ml, xeno-free serum replacement at a concentration of about 1% and lipid mixture at a concentration of about 1%.

[0662] A non-limiting example of a xeno-free, serum-free, and TGFP isoform-free culture medium which comprises ascorbic acid at a concentration range of about 400-600 pg / ml, bFGF at a concentration range of about 50-200 ng / ml, xeno-free serum replacement and a lipid mixture and which is capable of maintaining pluripotent stem cells such as hESCs and human iPS cells in a proliferative and undifferentiated state for at least 21 passages in the absence of feeder cell support is the HA77 culture medium or a culture medium similar to the HA77 medium but which is devoid of sodium bi-carbonate such as a culture medium which consists of DMEM / F12 (94%) (Biological Industries, Israel, Sigma Israel), L-glutamine 2 mM (Invitrogen corporation, Sigma, Israel), ascorbic acid 500 pg / ml (Sigma, Israel), bFGF — 100 ng (Invitrogen corporation), SR3 — 1% (Sigma, Israel), and defined lipid mixture 1% (Invitrogen corporation, Sigma, Israel). The present inventors have uncovered novel serum-free and highly defined culture media, which can maintain pluripotent stem cells in a proliferative, pluripotent and undifferentiated state in two-dimensional and three-dimensional (i.e., a suspension culture) systems in the absence of feeder cell support.

[0663] As used herein the phrase “suspension culture” refers to a culture in which the pluripotent stem cells are suspended in a medium rather than adhering to a surface.

[0664] According to some embodiments of the invention the serum-free culture medium which can maintain pluripotent stem cells in a proliferative, pluripotent and undifferentiated state in two-dimensional and three-dimensional culture systems in the absence of feeder cell support comprises basic fibroblast growth factor (bFGF) at a concentration range of about 50-200 ng / ml. m According to some embodiments of the invention the culture medium comprises between about 55-190 ng / ml, e.g., between about 60-190 ng / ml, e.g., between about 70-180 ng / ml, e.g., between about 80-160 ng / ml, e.g., between about 90-150 ng / ml, e.g., between about 90-140 ng / ml, e.g., between about 90- 130 ng / ml, e.g., between about 90-120 ng / ml, e.g., between about 90-110 ng / ml, e.g., between about 95-105 ng / ml, e.g., about 100 ng / ml. According to some embodiments of the invention the culture medium which comprises bFGF between about 50-200 ng / ml further comprises serum replacement.

[0665] A non-limiting example of a culture medium which comprises bFGF at a concentration between about 50-200 ng / ml is the YF100 medium which comprises a basic medium (e.g., DMEM / F12, 85%), serum replacement (15%), bFGF (100 ng / ml), L- glutamine (2 mM), P — mercaptoethanol (0.1 mM) and non-essential amino acid stock (1%). According to some embodiments of the invention the serum-free culture mediumwhich can maintain pluripotent stem cells in a proliferative, pluripotent and undifferentiated state in two-dimensional and three-dimensional culture systems in the absence of feeder cell support consists of a basic medium, ascorbic acid at a concentration range of about 50 pg / ml to about 500 pg / ml, bFGF at a concentration range between about 2 ng / ml to about 20 ng / ml, L-glutamine, and serum replacement.

[0666] According to some embodiments of the invention the serum-free culture medium which can maintain pluripotent stem cells in a proliferative, pluripotent and undifferentiated state in two-dimensional and three-dimensional culture systems in the absence of feeder cell support consists of a basic medium, ascorbic acid at a concentration range of about 50 pg / ml to about 500 pg / ml, bFGF at a concentration range between about 2 ng / ml to about 20 ng / ml, L-glutamine, serum replacement and a lipid mixture.

[0667] The serum replacement can be any xeno-free serum replacement (devoid of animal contaminants) at a concentration range from 1-20% depending on the serum replacement used. For example, if the SR3 serum replacement is used then it concentration in the medium is about 1%. Non-limiting examples of such a culture medium include the modified HA13(a) medium [DMEM / F12 (95%), L-glutamine 2 mM, ascorbic acid 500 pg / ml, bFGF — 4 ng, and SR3 — 1%]; the modified HA13(b) medium [DMEM / F12 (95%), L-glutamine 2 mM, ascorbic acid 500 pg / ml, bFGF — 4 ng, SR3 — 1% and a lipid mixture (1%)]; the modified HA13(c) medium [DMEM / F12 (95%), L- glutamine 2 mM, ascorbic acid 50 pg / ml, bFGF — 4 ng, and SR3 — 1%]; and the modified HA13(d) medium [DMEM / F12 (95%), L-glutamine 2 mM, ascorbic acid 50 pg / ml, bFGF — 4 ng, SR3 — 1% and a lipid mixture (1%)]. These culture media were capable of maintaining pluripotent stem cells (e.g., hESCs and hips cells) in a proliferative, pluripotent and undifferentiated state for at least 20 passages when cultured in a two- dimensional (e.g., on a feeder-layer free culture system; data not shown) and for at least 20 passages when cultured on a three-dimensional culture system (e.g., suspension culture without adherence to an external substrate, cell encapsulation or to protein carrier; data not shown). According to some embodiments of the invention the serum-free culture medium which can maintain pluripotent stem cells in a proliferative, pluripotent and undifferentiated state in two-dimensional and three-dimensional culture systems in the absence of feeder cell support comprises an IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg / ml). According to some embodiments of the invention, the concentration of the IL6RIL6 chimera in the culture medium is in the range from about 55 pg / ml to about 195 pg / ml, e.g., from about 60 pg / ml to about 190 pg / ml,e.g., from about 65 pg / ml to about 185 pg / ml, e.g., from about 70 pg / ml to about 180 pg / ml, e.g., from about 75 pg / ml to about 175 pg / ml, e.g., from about 80 pg / ml to about 170 pg / ml, e.g., from about 85 pg / ml to about 165 pg / ml, e.g., from about 90 pg / ml to about 150 pg / ml, e.g., from about 90 pg / ml to about 140 pg / ml, e.g., from about 90 pg / ml to about 130 pg / ml, e.g., from about 90 pg / ml to about 120 pg / ml, e.g., from about 90 pg / ml to about 110 pg / ml, e.g., from about 95 pg / ml to about 105 pg / ml, e.g., from about 98 pg / ml to about 102 pg / ml, e.g., about 100 pg / ml. According to some embodiments of the invention, the IL6RIL6 chimera-containing culture medium further comprises bFGF. According to some embodiments of the invention, concentration of bFGF in the IL6RIL6 chimera-containing culture medium is in the range of from about 1 ng / ml to about 10 pg / ml, e.g., from about 2 ng / ml to about 1 pg / ml, e.g., from about 2 ng / ml to about 500 ng / ml, e.g., from about 5 ng / ml to about 150 ng / ml, e.g., from about 5 ng / ml to about 100 ng / ml, e.g., from about 5 ng / ml to about 80 ng / ml, e.g., from about 5 ng / ml to about 50 ng / ml, e.g., from about 5 ng / ml to about 30 ng / ml, e.g., about 5 ng / ml, e.g., about 10 ng / ml, e.g., about 15 ng / ml, e.g., about 20 ng / ml. According to some embodiments of the invention, the IL6RIL6 chimera-containing culture medium further comprises serum replacement. According to some embodiments of the invention, the concentration of KNOCKOUT™ Serum Replacement in the IL6RIL6 chimera-containing culture medium is in the range from about 1% (v / v) to about 50% (v / v), e.g., from about 5% (v / v) to about 40% (v / v), e.g., from about 5% (v / v) to about 30% (v / v), e.g., from about 10% (v / v) to about 30% (v / v), e.g., from about 10% (v / v) to about 25% (v / v), e.g., from about 10% (v / v) to about 20% (v / v), e.g., about 15% (v / v). According to some embodiments of the invention, the culture medium comprises IL6RIL6 chimera at a concentration range of about 50-200 pg / ml, bFGF at a concentration range of about 5-50 ng / ml and serum replacement at a concentration of about 5-40%. According to some embodiments of the invention, the serum-free culture medium which can maintain pluripotent stem cells in a proliferative, pluripotent and undifferentiated state in two-dimensional and three- dimensional culture systems in the absence of feeder-cells support comprises LIF at a concentration of at least 2000 units / ml. Leukemia inhibitory factor (LIF) is a pleiotropic cytokine which is involved in the induction of hematopoietic differentiation, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. The LIF used in the culture medium of some embodiments of the invention can be a purified, synthetic or recombinantly expressed LIF protein [e.g., human LIFpolypeptide GenBank Accession No. NP — 002300.1. It should be noted that for the preparation of a xeno-free culture medium LIF is preferably purified from a human source or is recombinantly expressed. Recombinant human LIF can be obtained from various sources such as Chemicon, USA (Catalogue No. LIF 10100) and AbD Serotec (MorphoSys US Inc, Raleigh, N.C. 27604, USA). Murine LIF ESGRO® (LIF) can be obtained from Millipore, USA (Catalogue No. ESG1107).

[0668] According to some embodiments of the invention, the concentration of LIF in the culture medium is from about 2000 units / ml to about 10,000 units / ml, e.g., from about 2000 units / ml to about 8,000 units / ml, e.g., from about 2000 units / ml to about 6,000 units / ml, e.g., from about 2000 units / ml to about 5,000 units / ml, e.g., from about 2000 units / ml to about 4,000 units / ml. According to some embodiments of the invention, the concentration of LIF in the culture medium is at least about 2000 units / ml, e.g., at least about 2100 units / ml, e.g., at least about 2200 units / ml, e.g., at least about 2300 units / ml, e.g., at least about 2400 units / ml, e.g., at least about 2500 units / ml, e.g., at least about 2600 units / ml, e.g., at least about 2700 units / ml, e.g., at least about 2800 units / ml, e.g., at least about 2900 units / ml, e.g., at least about 2950 units / ml, e.g., about 3000 units / ml. According to some embodiments of the invention, the LIF-containing culture medium further comprises bFGF. The concentration of bFGF in the LIF-containing culture medium is in the range of about 0.1 ng / ml to about 10 pg / ml, e.g., from about 2 ng / ml to about 1 pg / ml, e.g., from about 2 ng / ml to about 500 ng / ml, e.g., from about 5 ng / ml to about 150 ng / ml, e.g., from about 5 ng / ml to about 100 ng / ml, e.g., from about 5 ng / ml to about 80 ng / ml, e.g., from about 5 ng / ml to about 50 ng / ml, e.g., from about 5 ng / ml to about 30 ng / ml, e.g., about 5 ng / ml, e.g., about 10 ng / ml, e.g., about 15 ng / ml, e.g., about 20 ng / ml. According to some embodiments of the invention, the LIF- containing culture medium further comprises serum replacement. According to some embodiments of the invention, the culture medium comprises LIF at a concentration of about 2000-10,000 units / ml, bFGF at a concentration range from about 0.1 ng / ml to about 10 pg / ml and KNOCKOUT™ Serum Replacement at a concentration range from about 1% (v / v) to about 50% (v / v). According to some embodiments of the invention, the culture medium comprises LIF at a concentration of about 2000-5,000 units / ml, bFGF at a concentration of about 5-50 ng / ml and serum replacement at a concentration of about 5- 30%. According to some embodiments of the invention, the ingredients included in the culture medium of some embodiments of the invention are substantially pure, with a tissue culture and / or a clinical grade. According to an aspect of some embodiments of theinvention there is provided a cell culture which comprises the pluripotent stem cell of some embodiments of the invention and the culture medium of some embodiments of the invention. According to an aspect of some embodiments of the invention cell culture is feeder cells free (e.g., being devoid of feeder cells or feeder cell conditioned medium). According to some embodiments of the invention the pluripotent stem cells which are included in the cell culture of some embodiments of the invention exhibit a stable karyotype (chromosomal stability) during the culturing period, e.g., for at least 2 passages, e.g., at least 4 passages, e.g., at least 8 passages, e.g., at least 15 passages, e.g., at least 20 passages, e.g., at least 25 passages, e.g., at least 30 passages, e.g., at least 35 passages, e.g., at least 40 passages, e.g., at least 45 passages, e.g., at least 50 passages.

[0669] In one embodiment the invention provides the administration of agents capable of acting as senolytic agents together with regenerative cells such as the regenerative cells generated through the current invention. Regenerative cells may be stem cells, progenitor cells, monocytes, T cells, B cells, or other cells capable of directly or indirectly inducing healing of the body, organs, or cells. In one embodiment enhancement of endogenous regenerative activity is enhanced through administration of senolytic agents. Some senolytic agents include least one of tetracycline, chlortetracycline, oxytetracycline, demeclocycline, methacycline, doxycycline, minocycline, tigecycline, pyrvinium, atovaquone, bedaquiline, irinotecan, sorafenib, niclosamide, stirpentol, chloroquine, rapamycin, a mitoriboscin, a mitoketoscin, a mitoflavoscin, 2-butene-l,4-bis-TPP; a derivative of 2-butene-l,4-bis-TPP; 2- chlorobenzyl-TPP; a derivative of 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; a derivative of 3-methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; a derivative of 2,4-dichlorobenzyl-TPP; 1 -naphthylmethyl -TPP; a derivative of 1 -naphthylmethyl -TPP; p-xylylenebis-TPP; a derivative of p-xylylenebis-TPP; Vitamin C, berberine, caffeic acid phenyl ester, silibinin, brutieridin, and melitidin. Examples of endogenous regenerative cells include cells capable of stimulating neurogenesis. Neurogenic regenerative cells have been described in the brain and their dysfunction has been associated with numerous pathological states including depression [1], multiple sclerosis, stroke, drug addiction,

[0670] In one embodiment, senolytic agents are used together with approaches that stimulate neurogenesis for example electroconvulsive therapy [2, 3], transcranial magnetic stimulation [4-31], low intensity transcranial ultrasound stimulation [32-34], transcranial direct current stimulation

[0035] , In another embodiment senolytic agents areused together with approaches that suppress inflammation, including approaches that reduce Macrophage 2

[0036] , astrocyte 2, or neutrophil 2 activity.

[0671] In some embodiments agents that suppress activity of senescent cells are combined with suppressors of interleukin- 17 for treatment of inflammatory diseases

[0037] ,

[0672] It is known that patients with liver failure have elevated systemic levels of IL-17 as well as IL-17 made by T cells [38, 39], IL-17 levels correlate with severity of liver failure [40-44], Levels of Thl7 cells which produce IL-17 correlate with liver failure [45-48], L-17 induces liver failure in animal models [49-52] and patients

[0053] , Suppressing IL-17 reduces liver failure in animal models [54-60],

[0673] In the case of multi-organ failure, production of IL- 17 during ischemia reperfusion injury stimulates organ failure

[0061] , additionally, association between IL-17 and organ failure [62, 63], In the situation of heart failure, it is published that blocking IL-17 reduces autoimmune heart failure [64, 65], IL-17 induces inflammation and pathology in models of heart failure [66-68], IL-17 associated with heart failure in people [69-77], with correlation between IL- 17 and severity of cardiac dysfunction. Agents that increase IL-17 cause heart failure in people

[0078] , Blocking IL-17 reduces animal models of heart failure

[0079] , In the contects of aplastic anemia, Thl7 cells, which are T cells that make IL- 17, cause bone marrow inflammation and aplastic anemia [SO- 82] . Additionally, IL- 17 stimulates monocytes to make inflammatory agents that block hematopoiesis in aplastic anemia

[0083] ,

[0674] In one embodiment of the invention, senolytic agents are utilized to augment efficacy of regenerative stem cell therapies such as adult stem cells, or combinations of cells. Senolytic agents, in some embodiments, may include, BTSA1

[0084] , vilazodone

[0085] , a SGLT2 inhibitor such as ca

[0086] nagliflozin which directly is senolytic but also stimulates immune mediated clearing of senolytic cells

[0087] , a casein kinase 2 inhibitor such as 4,5,6,7-tetrabromo-2-azabenzamidazole

[0088] , LY-D6 / 2

[0088] , PI3K-inhibitors such as wortmannin and its clinical derivative, PX-866

[0089] , USP7 inhibitors such as P5091

[0090] , bcl-2 inhibitors such as the Bh3 mimetic ABT-263 [91-147], ABT-737 [148-151], piperlongumine

[0152] , fisetin [153-170], EF24

[0171] , R406

[0172] , FOXO4-p53 interfering peptide

[0173] , lorlatinib,

[0174] , azithromycin

[0175] ,

[0675] One such combination of cells that are utilized in the context of the current invention is adipose derived regenerative cells. One such population is the stromal vascular fraction (SVF), which is comprised of adipose-derived mononuclear cells, pericytes, EPCs with several cell types, including MSC, hematopoietic stem cells

[0176] ,Treg

[0177] , and alternatively activated monocytes. This mixture conceptually may be a useful source of cells with both immune modulatory, and regenerative properties. Whereas MSC are rare in bone marrow, comprising only 0.01-0.001% of bone marrow cells

[0178] , these cells are found at 100-500 fold higher frequencies in the SVF

[0179] , Cell quantification of SVF harvested from middle-aged humans revealed a range of approximately 400 000 cells / mL of aspirate

[0180] of which approximately 20% of the cells are endothelial and hematopoietic cells

[0179] , Additionally, the cell yield from SVF is highly dependent upon the site of adipose tissue collection and the methods used for enzymatic digestion

[0181] , Since ASC are located in the adipose perivascular niche

[0182] , the extent of vascularization strongly influences the MSC numbers that can be recovered from different subcutaneous body sites

[0183] ,

[0676] In some embodiments of the invention MSC are generated as immature MSC from more immature cellular sources such as the pluripotent stem cells described in the current invention. In other embodiments MSC are dedifferentiated. Generation of dedifferentiated MSC can be found in numerous publications, for example, valproic acid, a histone deacetylase inhibitor has been used previously to endow a “younger” state onto MSC. This has been shown in models of cardiomyocyte differentiation

[0184] , osteogenic differentiation [185-188], neuronal differentiation

[0189] , blood making cell production differentiation

[0190] , neurogenic differentiation [191-200], hematopoietic differentiation [201, 202], pancreatic differentiation [203, 204], MSC proliferation [205-207], hepatic differentiation [208-211], nephrotic differentiation [212, 213],

[0677] The less invasive extraction method for ASC compared to BMSC and the increased numbers of cells available from adipose tissue has led to the widespread application of ASC in regenerative medicine. Notably, SVF also has great therapeutic potential as an autologous stem cell therapy since it also contains endothelial progenitor cells capable of stimulating angiogenesis, as well as monocytes / macrophages and regulatory T cells that inhibit inflammation and immunity

[0214] , After prolonged in vitro culture MSC become senescent, a process that is marked by arrested cell division [215- 217], Human MSC typically undergo senescence after approximately 6 to 16 doublings in vitro

[0218] although parameters such as cell density

[0219] , oxygen concentrations

[0220] , age of the cell donor [221, 222] and tissue source of MSC

[0223] affect the rate of replicative senescence. While this form of growth arrest is considered to serve as a tumor suppressive mechanism, the rare cells that persist beyond senescence and continue to divide can stimulate tumor formation

[0224] , Therefore, protocols for stem cell expansionmust balance the necessity of achieving a therapeutic dose of cells with the risk of potentially tumorigenic cells arising from high number of passages. ASC therefore offer an advantage over BMSC from other sources since their comparatively larger numbers at harvest offer the possibility that in vitro expansion can be minimized or avoided entirely. Indeed, the clinical efficacy of freshly derived ASC has been demonstrated for several indications [214, 225], Hence, a clear understanding of the growth kinetics of MSC populations is critical to the development of safe and effective cell-based therapies. A hallmark of MSC is their ability to counteract inflammatory responses. The immune suppressive and immune modulatory effects of MSC have led to their widespread application in pre-clinical and clinical studies for treating autoimmune disorders

[0226] , MSC are considered to be poorly immunogenic cells, exhibiting low expression levels of HLA class I and negligible expression of HL A class II or costimulatory molecules [227, 228], although expression of HLA molecules is upregulated upon exposure of MSC to pro-inflammatory stimuli such as the cytokine IFN-D [227, 229], MSC possess immune modulatory abilities that are mediated by direct contact with immune cells and / or through secretion of soluble factors such as prostaglandin E2 (PGE2), nitric oxide (NO), transforming growth factor (TGF-D), leukemia inhibitory factor (LIF), and indolamine 2.3 -dioxygenase (IDO) [230-233], BMSCs inhibit the differentiation of dendritic cells from their precursors

[0234] , inhibit B cell maturation

[0235] , and stimulate the release of the immune suppressive cytokine IL-10 from tissue macrophages

[0236] , MSC also demonstrate inhibitory effects against NK cells, which in turn exhibit a reduced ability to kill tumor cells in vitro

[0237] , Notably, MSC are not exclusively immune suppressive, as exemplified by the recent identification of distinct “MSC1” and “MSC2” subtypes to describe pro- and anti-inflammatory cell types

[0238] , The functional plasticity of MSC is dictated by the specific stimulation conditions they experience

[0239] ; therefore, a precise understanding of the activation state of MSC will be essential to their successful use as immune modulators in cell-based therapies. In one embodiment of the invention, senolytic agents are utilized to enhance activity of T regulatory cells. Feuerer et al.

[0177] examined adipose tissue for content of Treg cells based on functionality and expression of the CD4+, CD25+, FoxP3+ phenotype. Increased numbers of these cells were observed in adipose compared to other peripheral tissues. The authors made a case for the role of Treg in controlling inflammation associated with obesity. Interestingly, the adipose Treg’s appeared to have a “primed” phenotype, as witnessed by highly elevated IL- 10 transcript and protein levels in adipose Treg. The invention discloses augmentation of Tregulatory cell activity by senolytic agents regardless if the T regulatory cells are endogenously derived or are exogenous. In some cases T regulatory cells are generated by treatment of the patient with means that expand T regulatory cells in vivo.

[0678] According to some embodiments of the invention, the cell culture of the invention exhibit a doubling time of at least 20 hours, e.g., a doubling time which is between 20 to 40 hours (e.g., about 36 hours), thus representing a non-tumorigenic, genetically stable pluripotent stem cells (e.g., hESCs and iPS cells). According to some embodiments of the invention, the cell culture of the invention is characterized by at least 40%, at least 50%, at least 60%, e.g., at least 70%, e.g., at least 80%, e.g., at least 85%, e.g., at least 90%, e.g., at least 95% of undifferentiated pluripotent stem cells. According to an aspect of some embodiments of the invention, there is provided a method of expanding and maintaining pluripotent stem cells in a pluripotent and undifferentiated state. Furthermore, for generation of iPSC for creating MSC to use in orthopedic conditions, we present multiple culture conditions and media, which permit the indefinite culture and robust proliferation of primate pluripotent stem cells in an undifferentiated state with continued expression of characteristic pluripotency markers. Also, the media described are prepared in the complete absence of both feeder cells and conditioned medium. As described here, the defined culture conditions and media are suitable for use with human pluripotent stem cells. Pluripotent cells express one or more pluripotent cellspecific marker, such as Oct-4, SSEA-3, SSEA-4, Tra 1-60, Tra 1-81. They include, but are not limited to human ES cells (e.g., Hl, H7, H9 and H14), iPS cells (e.g., iPS- Foreskin and iPS-IMR90), and vector-free iPS cells (e.g., iPS-DF19-9, iPS-DF4-3, and iPS-DF6-9), which are all available through WiCell® International Stem Cell (WISC) Bank (Madison, Wis.). iPS cells are described in Yu J. et al. Science, 318(5858), pp. 1917-1920 (2007) and vector-free iPS cells are described in Yu J. et al. Science, 324(5928), pp. 797-801 (2009), both of these references are incorporated by reference here in their entirety. For some primate pluripotent stem cells, including iPS and vector- free iPS cells, certificate of analyses for primate pluripotent stem cells cultured on growth matrix using the fully defined medium disclosed here is available on the WISC website. Additional pluripotent stem cell lines include, but are not limited to, disease model cell lines and genetically modified lines containing marker genes. In many embodiments of the invention, the culture conditions and media are entirely free of non-human animal products and all proteins used are of human origin. The development of these media and culture conditions make possible the derivation and maintenance of human pluripotentstem cell lines in defined and controlled conditions without direct or indirect exposure to non-human animal cells of any kind. Also, the media and culture conditions described here enable the derivation of new lines of human pluripotent stem cells which have never been exposed to non-human cells or a to medium in which animal cells were cultured. In one embodiment, the medium is free of animal products or proteins. This medium has been demonstrated to support undifferentiated pluripotent stem cell proliferation through at least twenty -five passages, which is firm evidence that it will support such cultures indefinitely. A suitable medium is capable of supporting the derivation of new human ES and iPS cell lines, and derived using the media described herein after as “new lines”. These lines have passed through more than ten passages in culture. In the past, use of conditioned medium has sometimes been referred to as creating “feeder-free” culture conditions. This phrase is a misnomer, since feeder cells of some type are still needed to condition the “conditioned medium.” As described here, culture conditions permit the “feeder-independent” culture of human pluripotent stem cells. By “feeder-independent” it is meant that no feeder cells of any kind, human or animal, are needed anywhere in the process and are neither required for culture nor to condition the medium. Feederindependent conditions do not require feeder cells at all for any purpose. A defined and humanized medium for the culture and proliferation of human pluripotent stem cells typically includes salts, vitamins, lipids, an energy source such as glucose, minerals, amino acids, growth factors and other components. As a supplement to support cell growth, stem cell media have included serum from one source or another. Also, previously it has been reported that the addition of FGF plus a serum replacement additive permits the cultivation of human pluripotent stem cells without serum. The serum replacement additive can be a commercially available product sold for that purpose or can be a formulated mixture of proteins, including but not limited to serum albumin, vitamins, minerals, a transferrin or a transferrin substitute, and insulin or an insulin substitute. The albumin, insulin and transferrin may be recombinant proteins. This serum replacement additive may also be supplemented with, but is not limited to, selenium and a mixture of lipids. Preferably, a defined serum replacement mix is used in lieu of serum from any source in culturing human pluripotent stem cells, to avoid variation in serum constituents and to use media that are as defined as possible. Other growth factors which have been found to be advantageous additives to the culture medium include, but are not limited to, gamma-aminobutyric acid (GABA), pipecolic acid (PA), lithium chloride (LiCl) and transforming growth factor beta (TGFP). It has been found that TGFP may notbe needed when increasing levels of FGF are added to the medium. It is envisioned that other lithium salts can substitute for LiCl in the cell culture medium. These may include lithium salts, wherein the anion includes, but is not limited to, chloride, bromide, carbonate, citrate, sulfate, or other biologically compatible monovalent anion (see, for example, US 2004 / 0028656 and WO 2008 / 055224). To avoid the need for a fibroblast feeder layer, previously thought to be necessary to maintain human pluripotent stem cells (ES and iPS cells) in an undifferentiated state, it is reported here that combining the use of higher concentrations of FGF (10 to 1000 ng / ml) together with the use of GABA, PA, Li and TGFp, will enable a medium to support long term (at least three passages, and suitably 170 passages) undifferentiated stem cell growth. The combination of these additives has been found to be sufficient to maintain the culture of human pluripotent stem cells in an undifferentiated state indefinitely without exposure to either feeder cells or conditioned media. These additives are demonstrably sufficient. However, all of them may not be necessary for every medium formulation. By selective deletion of these additives, it may be empirically determined if one or more of them is not required to achieve this result for a given medium. However, it is clear that the combination is sufficient to enable a variety of media that will support the long-term culture and proliferation of undifferentiated human pluripotent stem cells without feeder cells or conditioned medium.

[0679] These additives are subject to some variation. For example, GABA is believed to interact with the GABA receptor and the scientific literature includes the identification of several molecules which are agonists of that same receptor and might be substituted for GABA in the medium as an equivalent. It is also believed that PA also interacts with the GABA receptor. While both PA and GABA were found to be helpful in the medium at the concentrations used here, it is also envisioned that one or the other of these constituents could be increased in concentration to obviate the need for the other. The FGF in higher concentrations (40 to 100 ng / ml) seems to obviate the need for feeder cells. The preferred FGF is bFGF, also referred to as FGF2, but other FGFs, including at least FGF4, FGF9, FGF17, and FGF18, will suffice for this purpose as well. Other FGFs may also work, even if at higher concentrations, which can be empirically determined by researchers. Initial subjective screens performed by the inventors identified several growth factors, chosen based on the receptors expressed by the human pluripotent stem cells, as having positive effects on undifferentiated proliferation. Of these, bFGF, LiCl, GABA, PA, and TGFp were ultimately included in TeSRl. For each of the multiple celllines tested, the proliferation rate and the percentage of cells maintaining expression of characteristic human pluripotent stem cell markers were higher in TeSRl than in control cells cultured in fibroblast-conditioned medium and removal of any one of these five factors decreased culture performance. Some of these data are illustrated in FIG. 6, which shows that cultures grown in media with any one of these constituents omitted exhibited a lesser percentage of cells which remained undifferentiated as compared to cultures with all five of these medium constituents included. Note that Oct-4, SSEA-1, SSEA-4, Tra 1- 60 and Tra 1-81 are all cell surface markers or transcription factors (Oct-4) which are used to track the differentiation status of stem cells. FIG. 4 illustrates similar trials in which it was demonstrated that, over multiple passages, undifferentiated cell proliferation was the highest when all these constituents together were in the culture medium.

[0680] The inventors also found it advantageous to include in the culture vessel of human pluripotent stem cells a biological matrix. One such material that has been used previously is Matrigel™, which is an artificial basement matrix of mouse cell origin, which is supplied as a commercial product free of mouse cells. However, the use of Matrigel introduces into the culture a material which is poorly defined and includes material of murine origin. Accordingly, also described here is how to create a biological matrix of human proteins that can substitute completely for the Matrigel. This matrix is composed of a blend of four human proteins: collagen isolated from human placenta, fibronectin isolated from human plasma, vitronectin isolated from human plasma or from a recombinant source, and laminin isolated from human placenta. Other extracellular matrices may be suitable for use in the present invention, which include, but are not limited to, proteoglycan, entactin, heparan sulfate, and the like, alone or in various combinations. Other suitable extracellular matrices may include, but are not limited to, Geltrex™. The major components of Geltrex™ matrix include laminin, collagen IV, entactin, and heparin sulfate proteoglycan. Also suitable are human plasma fibronectin, recombinant human plasma fibronectin, human cellular fibronectin, recombinant human cellular fibronectin, and synthetic fibronectin in combination with at least one other matrix, such as collagen. Preferred matrices of the present invention include collagen, fibronectin, vitronectin, and laminin derived matrices.Example 1: Generation of Pluripotent Stem Cells from VASA Expressing PeripheralBlood Cells

[0681] Peripheral blood mononuclear cells were isolated by Ficoll from a health volunteer and separated into Vasa positive or Vasa negative cells using magnetic activated cell sorting according to the manufacturers instructions. Cells are subsequently exposed to a “dedifferentiation cocktail” of OCT4, NANOG and KLF4 (R&D Systems) according to the manufacturers instructions. Cells were cultured on feeder cells and were assessed for OCT4 gene expression after 1, 2, and 4 weeks of culture using quantitative RT-PCR and expressed as relative units compared to internal control (GAPDH). As a positive control a standard iPSC cell line was used. Results are shown in FIG. 1.Example 2: Generation of Pluripotent Stem Cells from Peripheral Blood Mononuclear Cell Derived VASA Expressing Monocytes

[0682] Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll and monocytes were isolated by selection for CD14 using magnetic activated cell sorting. Subsequently, VASA expressing monocytes were further purified using MACS based on detection of extracellular VASA. Cells were treated with valproic acid and tricostatin A prior to transfection with cytoplasmic extract from induced pluripotent stem cells. Cells were treated with 1 microMolar of valproic acid and 100 nanoMolar of tricostatin A. Subsequent to transfection cells were assessed for expression of pluripotency markers by flow cytometry at days 7, 14 and 21. Results are shown in FIGs. 2A and 2B, and the tables below.

[0683] Table 1

[0684] Table 2Day 14Control KLF4 TRA-1-60 SSEA41.0 24.0 969.0 5435.0 1523.02.0 33.0 1009.0 5535.0 1221.03.0 35.0 1086.0 5245.0 1432.04.0 32.0 1121.0 5342.0 1454.05.0 36.0 1216.0 5465.0 1343.06.0 34.0 1164.0 5342.0 1365.07.0 33.0 1121.0 5624.0 1332.08.0 36.0 1112.0 5524.0 1435.09.0 34.0 1121.0 5345.0 1325.010.0 33.0 1521.0 5251.0 1325.0 Average 33.0 1144.0 5410.8 1375.5 STDEV 3.4 150.0 126.5 86.1

[0685] Table 3Day 14Control KLF4 TRA-1-60 SSEA41.0 24.0 969.0 5435.0 1523.02.0 33.0 1009.0 5535.0 1221.03.0 35.0 1086.0 5245.0 1432.04.0 32.0 1121.0 5342.0 1454.05.0 36.0 1216.0 5465.0 1343.06.0 34.0 1164.0 5342.0 1365.07.0 33.0 1121.0 5624.0 1332.08.0 36.0 1112.0 5524.0 1435.09.0 34.0 1121.0 5345.0 1325.010.0 33.0 1521.0 5251.0 1325.0 Average 33.0 1144.0 5410.8 1375.5 STDEV 3.4 150.0 126.5 86.1

[0686] Table 4Day 21Control KLF4 TRA-1-60 SSEA41.0 32.0 898.0 8755.0 7677.02.0 33.0 896.0 7787.0 7765.03.0 32.0 874.0 8846.0 7787.04.0 43.0 789.0 8764.0 7675.05.0 23.0 847.0 8768.0 7756.06.0 25.0 878.0 8746.0 7643.07.0 26.0 775.0 8745.0 7684.08.0 24.0 789.0 8875.0 7746.09.0 22.0 868.0 8734.0 7647.010.0 25.0 857.0 8674.0 7567.0 Average 28.5 847.1 8669.4 7694.7 STDEV 6.5 46.1 315.1 68.2

[0687] Table 5

[0688] Table 6Day 14Control NANOG CD9 CD241.0 19.0 886.0 546.0 1121.0 2.0 12.0 986.0 554.0 1142.0 3.0 15.0 965.0 575.0 1214.0 4.0 12.0 895.0 534.0 1215.0 5.0 12.0 895.0 654.0 1125.0 6.0 15.0 986.0 573.0 1142.0 7.0 13.0 894.0 583.0 1041.0 8.0 12.0 896.0 576.0 1251.0 9.0 13.0 893.0 536.0 1124.0 10.0 15.0 954.0 536.0 1214.0 Average 13.8 925.0 566.7 1158.9 STDEV 2.3 42.2 35.9 63.2

[0689] Table 7Day 21Control NANOG CD9 CD241.0 11.0 1124.0 746.0 1324.0 2.0 13.0 1215.0 774.0 1524.0 3.0 12.0 1312.0 745.0 1325.0 4.0 14.0 1152.0 743.0 1326.0 5.0 15.0 1215.0 785.0 1215.0 6.0 12.0 1212.0 743.0 1327.0 7.0 14.0 1121.0 764.0 1332.0 8.0 12.0 1131.0 734.0 1216.0 9.0 15.0 1214.0 754.0 1126.0 10.0 12.0 1214.0 755.0 1216.0 Average 13.0 1191.0 754.3 1293.1 STDEV 1.4 59.4 15.8 108.0Example 3: Generation of Pluripotent Stem Cells from Peripheral Blood Mononuclear Cell Derived T Cells

[0690] Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll. T cells were isolated using magnetic activated cell sorting for CD3 positive selection. Cultured T cells were treated with valproic acid and tricostatin A prior to transfection with OCT4, KLF4, SOX2 and c-Myc. Cells were treated with 1 microMolar of valproic acid and 100 nanoMolar of tricostatin A. Subsequent to transfection cells were assessed for expression of pluripotency markers by flow cytometry at days 7, 14 and 21. Results are shown in FIGs. 3 A and 3B and the tables below.

[0691] Table 8

[0692] Table 9Day 14

[0693] Table 10Day 21Control KLF4 TRA-1-60 SSEA41.0 22.0 7746.0 10311.0 23235.02.0 21.0 7458.0 11112.0 22315.03.0 24.0 7463.0 12152.0 23132.04.0 28.0 7847.0 12152.0 22316.05.0 27.0 7635.0 12162.0 29522.06.0 38.0 8756.0 11215.0 29523.07.0 26.0 7569.0 12152.0 30236.08.0 24.0 8764.0 11215.0 29525.09.0 24.0 7873.0 12152.0 23125.010.0 27.0 7858.0 12152.0 21523.0 Average 26.1 7896.9 11677.5 25445.2 STDEV 4.7 480.1 664.6 3703.4

[0694] Table 11

[0695] Table 12Day 14Control NANOG CD9 CD241.0 19.0 2334.0 1004.0 885.02.0 12.0 2315.0 1214.0 864.03.0 15.0 2313.0 1121.0 894.04.0 12.0 2674.0 1041.0 956.05.0 12.0 2768.0 1036.0 864.06.0 15.0 2453.0 1215.0 884.07.0 13.0 2765.0 1043.0 894.08.0 12.0 2657.0 1053.0 863.09.0 13.0 2747.0 1217.0 768.010.0 15.0 2426.0 1121.0 658.0 Average 13.8 2545.2 1106.5 853.0 STDEV 2.3 194.9 83.4 82.7

[0696] Table 13Day 21Control NANOG CD9 CD24 1.0 21.0 5458.0 5545.0 4544.0 2.0 22.0 5546.0 4347.0 3453.0 3.0 24.0 5535.0 4347.0 4585.0 4.0 21.0 5866.0 4432.0 3247.0 5.0 21.0 4573.0 5735.0 4573.0 6.0 27.0 5753.0 4348.0 4434.0 7.0 26.0 5638.0 4352.0 4234.0 8.0 27.0 5325.0 4573.0 3263.0 9.0 23.0 6548.0 4537.0 3238.0 10.0 23.0 6547.0 4853.0 3246.0Average 23.5 5678.9 4706.9 3881.7 STDEV 2.4 576.1 518.2 634.9Example 4: Generation of Pluripotent Stem Cells from Monocytes using Cytoplasmic Extract

[0697] Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll and monocytes were isolated by selection for CD14 using magnetic activated cell sorting. Cells were treated with valproic acid and tricostatin and transfected with iPSC cytoplasm. Prior to transfection cells were treated with 1 microMolar of valproic acid and 100 nanoMolar of tricostatin A. Subsequent to transfection cells were assessed for expression of pluripotency markers by flow cytometry at days 7, 14 and 21. Results are shown in FIG. 4 and the tables below.

[0698] Table 14

[0699] Table 15Day 14Control CD11 b CD13 CD341.0 22.0 293.0 23.0 1052.0 2.0 24.0 232.0 23.0 1215.0 3.0 23.0 105.0 26.0 1252.0 4.0 26.0 212.0 23.0 1215.0 5.0 23.0 219.0 26.0 1321.0 6.0 26.0 221.0 23.0 1123.0 7.0 23.0 295.0 26.0 1215.0 8.0 23.0 235.0 34.0 1383.0 9.0 21.0 215.0 34.0 1285.0 10.0 24.0 215.0 32.0 1251.0 Average 23.5 224.2 27.0 1231.2 STDEV 1.6 52.2 4.6 93.9

[0700] Table 16Day 21Control CD11b CD13 CD341.0 34.0 75.0 24.0 2363.02.0 33.0 75.0 26.0 2332.03.0 23.0 78.0 23.0 2483.04.0 32.0 95.0 26.0 2328.05.0 32.0 85.0 23.0 2368.06.0 53.0 74.0 26.0 2396.07.0 12.0 54.0 26.0 2182.08.0 14.0 85.0 34.0 2216.09.0 24.0 65.0 23.0 2168.010.0 32.0 45.0 26.0 2175.0Average 28.9 73.1 25.7 2301.1STDEV 11.6 15.0 3.2 109.1Example 5: Superior Activity of Combined Senolytic Immunotherapy with Mesenchymal Stem Cells and Hepatic Progenitor Cells

[0701] Non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice on BALB / c background were divided into the following groups, with each group consisting of 12 mice per group (based on previous experience immune deficient mice have a high rate of contamination, we are adding 2 mice per group to account for this). For the SenoVax group, NOD-SCID mice received purified IgG antibodies from wildtype BALB / c mice adoptively transferred Based on previous studies a concentration of 2 micrograms of antibody protein per mouse was injected. The following groups were used:

[0702] 1. Control saline

[0703] 2. CCL4

[0704] 3. CCL4 + PPC

[0705] 4. CCL4 + pMSC

[0706] 5. CCL4 + SenoVax

[0707] 6. CCL4 + PPC + pMSC

[0708] 7. CCL4 + PPC + SenoVax

[0709] 8. CCL4 + pMSC + SenoVax

[0710] 9. CCL4 + pMSC + PPC + SenoVax

[0711] Carbon tetrachloride was purchased from Sigma Aldrich (ThermoFisher) and dissolved in vegetable oil at 10% concentration and administered to animals by gavage at a dose of 0.28 mL / kg. Animals received treatment interventions listed above 24 hours after CCL4 administration. Cells were administered at a concentration of 500,000 cells per mouse. After the cellular transplantation, blood samples were collected at 24, 48 and 72 hours and assessed for liver function by AST quantification. Results are shown in FIG. 5.References:

[0712] 1. Jacobs, B.L., H. van Praag, and F.H. Gage, Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry, 2000. 5(3): p. 262-9.

[0713] 2. Hellsten, J., et al., Electroconvulsive seizures increase hippocampal neurogenesis after chronic corticosterone treatment. Eur J Neurosci, 2002. 16(2): p. 283- 90.

[0714] 3. Sauvaget, A., et al., ECT: An essential therapy in psychiatry. Encephale,2023. 49(1): p. 103-106.

[0715] 4. Qin, T., et al., Repetitive transcranial magnetic stimulation ameliorates cognitive deficits in mice with radiation-induced brain injury by attenuating microglial pyroptosis and promoting neurogenesis via BDNF pathway. Cell Commun Signal, 2024. 22(1): p. 216.

[0716] 5. Luo, J., et al., High-frequency repetitive transcranial magnetic stimulation promotes neural stem cell proliferation after ischemic stroke. Neural Regen Res, 2024. 19(8): p. 1772-1780.

[0717] 6. Zhou, L., et al., Current evidence, clinical applications, and future directions of transcranial magnetic stimulation as a treatment for ischemic stroke. Front Neurosci, 2023. 17: p. 1177283.

[0718] 7. Ramirez-Rodriguez, G.B., et al., Repetitive transcranial magnetic stimulation and fluoxetine reverse depressive-like behavior but with differential effects on Olig2-positive cells in chronically stressed mice. Neuropharmacology, 2023. 236: p. 109567.

[0719] 8. Badoiu, A., et al., From Molecule to Patient Rehabilitation: The Impact ofTranscranial Direct Current Stimulation and Magnetic Stimulation on Stroke-A Narrative Review. Neural Plast, 2023. 2023: p. 5044065.

[0720] 9. Zhang, T.R., et al., Intermittent theta burst transcranial magnetic stimulation induces hippocampal mossy fibre plasticity in male but not female mice. Eur J Neurosci, 2023. 57(2): p. 310-323.

[0721] 10. Zong, X., et al., Continuous theta-burst stimulation enhances and sustains neurogenesis following ischemic stroke. Theranostics, 2022. 12(13): p. 5710- 5726.

[0722] 11. El emery, M., et al., Change of Circulating Vascular EndothelialGrowth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation. Front Psychiatry, 2022. 13: p. 806731.

[0723] 12. Ramirez-Rodriguez, G.B., D.M. Juan, and J.J. Gonzalez-Olvera,5 Hz of repetitive transcranial magnetic stimulation improves cognition and induces modifications in hippocampal neurogenesis in adult female Swiss Webster mice. Brain Res Bull, 2022. 186: p. 91-105.

[0724] 13. Wang, L., et al., Long-term iTBS promotes neural structural and functional recovery by enhancing neurogenesis and migration via miR-551b- 5p / BDNF / TrkB pathway in a rat model of cerebral ischemia-reperfusion injury. Brain Res Bull, 2022. 184: p. 46-55.

[0725] 14. Cambiaghi, M., et al., The Effects of 1-Hz rTMS on EmotionalBehavior and Dendritic Complexity of Mature and Newly Generated Dentate Gyrus Neurons in Male Mice. Int J Environ Res Public Health, 2020. 17(11).

[0726] 15. Baeken, C., G. Wu, and H.A. Sackeim, Accelerated iTBS treatment applied to the left DLPFC in depressed patients results in a rapid volume increase in the left hippocampal dentate gyrus, not driven by brain perfusion. Brain Stimul, 2020. 13(5): p. 1211-1217.

[0727] 16. Zuo, C., et al., Neuroprotective efficacy of different levels of high- frequency repetitive transcranial magnetic stimulation in mice with CUMS-induced depression: Involvement of the pl 1 / BDNF / Homer la signaling pathway. J Psychiatr Res, 2020. 125: p. 152-163.

[0728] 17. Caglayan, A.B., et al., Acute and Post-acute NeuromodulationInduces Stroke Recovery by Promoting Survival Signaling, Neurogenesis, and Pyramidal Tract Plasticity. Front Cell Neurosci, 2019. 13: p. 144.

[0729] 18. Cullen, C.L., et al., Low-intensity transcranial magnetic stimulation promotes the survival and maturation of newborn oligodendrocytes in the adult mouse brain. Glia, 2019. 67(8): p. 1462-1477.

[0730] 19. Cui, M., et al., Repetitive Transcranial Magnetic StimulationPromotes Neural Stem Cell Proliferation and Differentiation after Intracerebral Hemorrhage in Mice. Cell Transplant, 2019. 28(5): p. 568-584.

[0731] 20. Peng, J. J., et al., Repetitive transcranial magnetic stimulation promotes functional recovery and differentiation of human neural stem cells in rats after ischemic stroke. Exp Neurol, 2019. 313: p. 1-9.

[0732] 21. Boonzaier, J., et al., Noninvasive Brain Stimulation to EnhanceFunctional Recovery After Stroke: Studies in Animal Models. Neurorehabil Neural Repair, 2018. 32(11): p. 927-940.

[0733] 22. Heath, A., et al., Medium- and high-intensity rTMS reduces psychomotor agitation with distinct neurobiologic mechanisms. Transl Psychiatry, 2018. 8(1): p. 126.

[0734] 23. Peng, Z., et al., Mechanism of Repetitive Transcranial MagneticStimulation for Depression. Shanghai Arch Psychiatry, 2018. 30(2): p. 84-92.

[0735] 24. Guo, F., et al., Repetitive Transcranial Magnetic StimulationAmeliorates Cognitive Impairment by Enhancing Neurogenesis and Suppressing Apoptosis in the Hippocampus in Rats with Ischemic Stroke. Front Physiol, 2017. 8: p. 559.

[0736] 25. Luo, J., et al., High-Frequency Repetitive Transcranial MagneticStimulation (rTMS) Improves Functional Recovery by Enhancing Neurogenesis and Activating BDNF / TrkB Signaling in Ischemic Rats. Int J Mol Sci, 2017. 18(2).

[0737] 26. Braun, R., et al., Transcranial direct current stimulation accelerates recovery of function, induces neurogenesis and recruits oligodendrocyte precursors in a rat model of stroke. Exp Neurol, 2016. 279: p. 127-136.

[0738] 27. Tang, A., G. Thickbroom, and J. Rodger, Repetitive TranscranialMagnetic Stimulation of the Brain: Mechanisms from Animal and Experimental Models. Neuroscientist, 2017. 23(1): p. 82-94.

[0739] 28. Wobrock, T., A. Hasan, and P. Falkai, Innovative treatment approaches in schizophrenia enhancing neuroplasticity: aerobic exercise, erythropoetin and repetitive transcranial magnetic stimulation. Curr Pharm Biotechnol, 2012. 13(8): p. 1595-605.

[0740] 29. Ueyama, E., et al., Chronic repetitive transcranial magnetic stimulation increases hippocampal neurogenesis in rats. Psychiatry Clin Neurosci, 2011. 65(1): p. 77-81.

[0741] 30. Arias-Carrion, O., et al., Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions. J Neurosci Res, 2004. 78(1): p. 16-28.

[0742] 31. Czeh, B., et al., Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biol Psychiatry, 2002. 52(11): p. 1057-65.

[0743] 32. Qin, P.P., et al., The effectiveness and safety of low-intensity transcranial ultrasound stimulation: A systematic review of human and animal studies. Neurosci Biobehav Rev, 2024. 156: p. 105501.

[0744] 33. Tsai, S.J., Transcranial focused ultrasound as a possible treatment for major depression. Med Hypotheses, 2015. 84(4): p. 381-3.

[0745] 34. Zhang, Y., et al., Deep-brain magnetic stimulation promotes adult hippocampal neurogenesis and alleviates stress-related behaviors in mouse models for neuropsychiatric disorders. Mol Brain, 2014. 7: p. 11.

[0746] 35. Walter, H.L., et al., Transcranial-Direct-Current-StimulationAccelerates Motor Recovery After Cortical Infarction in Mice: The Interplay of Structural Cellular Responses and Functional Recovery. Neurorehabil Neural Repair, 2022. 36(10- 11): p. 701-714.

[0747] 36. Luo, J., et al., Repetitive Transcranial Magnetic StimulationImproves Neurological Function and Promotes the Anti-inflammatory Polarization of Microglia in Ischemic Rats. Front Cell Neurosci, 2022. 16: p. 878345.

[0748] 37. Liu, H., et al., Repetitive magnetic stimulation promotes the proliferation of neural progenitor cells via modulating the expression of miR-106b. Int J Mol Med, 2018. 42(6): p. 3631-3639.

[0749] 38. Zhang, J.Y., et al., Interleukin- 17 -producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology, 2010. 51(1): p. 81-91.

[0750] 39. Ye, Y., et al., Involvement of Th 17 and Thl effector responses in patients with Hepatitis B. J Clin Immunol, 2010. 30(4): p. 546-55.

[0751] 40. Yasumi, Y., et al., Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol Res, 2007. 37(4): p. 248-54.

[0752] 41. Du, W.J., et al., Expression of interleukin- 17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol, 2013. 8: p. 40.

[0753] 42. Zhang, G.L., et al., High level of IL-27 positively correlated withThl7 cells may indicate liver injury in patients infected with HBV. Liver Int, 2014. 34(2): p. 266-73.

[0754] 43. Kim, H.Y., et al., Interleukin-6 upregulates Thl7 response via mTOR / STAT3 pathway in acute-on-chronic hepatitis B liver failure. J Gastroenterol, 2014. 49(8): p. 1264-73.

[0755] 44. Xie, H., et al., Clinical Significance and Properties oflFN- gamma+IL-17+ Thl 7 Cells in Liver Injury Associated with Chronic Hepatitis B Virus Infection. Digestion, 2022. 103(6): p. 438-450.

[0756] 45. Niu, Y., et al., The balance between intrahepatic IL-17(+) T cells and Foxp3(+) regulatory T cells plays an important role in HBV-r elated end-stage liver disease. BMC Immunol, 2011. 12: p. 47.

[0757] 46. Wang, L.Y., et al., Increased frequency of circulating Thl7 cells in acute-on-chronic hepatitis B liver failure. Dig Dis Sci, 2012. 57(3): p. 667-74.

[0758] 47. Yang, B., et al., Increased Th 17 cells and interleukin- 17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett, 2013. 149(1-2): p. 41-9.

[0759] 48. Liang, X.S., et al., Changes in circulating Foxp 3 (+) regulatory T cells and interleukin- 17 -producing T helper cells during HBV-r elated acute-on-chronic liver failure. World J Gastroenterol, 2014. 20(26): p. 8558-71.

[0760] 49. Lafdil, F., et al., Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin- 17 production. Gastroenterology, 2009. 137(6): p. 2125-35 el-2.

[0761] 50. Zhu, L., et al., Contribution of IL- 17 to mouse hepatitis virus strain3-induced acute liver failure. J Huazhong Univ Sci Technolog Med Sci, 2012. 32(4): p. 552-556.

[0762] 51. Furuya, S., et al., Interleukin 17 A plays a role in lipopolysaccharide / D-galactosamine-induced fulminant hepatic injury in mice. J Surg Res, 2015. 199(2): p. 487-93.

[0763] 52. Tedesco, D., et al., Alterations in Intestinal Microbiota Lead toProduction of Interleukin 17 by Intrahepatic gammadelta T-Cell Receptor-Positive Cellsand Pathogenesis of Cholestatic Liver Disease. Gastroenterology, 2018. 154(8): p. 2178- 2193.

[0764] 53. Zhang, Y., et al., Downregulated VISTA enhances Thl7 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure. Hepatol Int, 2023. 17(4): p. 1000-1015.

[0765] 54. Yang, W ., et al., Interf er on-gamma negatively regulates Thl7- mediated immunopathology during mouse hepatitis virus infection. J Mol Med (Berl), 2011. 89(4): p. 399-409.

[0766] 55. Milosavljevic, N., et al., Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells. Liver Transpl, 2017. 23(8): p. 1040-1050.

[0767] 56. Zhang, H., et al., Adenovirus-mediated knockdown of activin A receptor type 2A attenuates immune-induced hepatic fibrosis in mice and inhibits interleukin- 17 -induced activation of primary hepatic stellate cells. Int J Mol Med, 2018. 42(1): p. 279-289.

[0768] 57. Lee, H. C . , et al . , IL-17 deficiency attenuates acetaminopheninduced hepatotoxicity in mice. Toxicol Lett, 2018. 292: p. 20-30.

[0769] 58. Liu, Y., et al., Fecal transplantation alleviates acute liver injury in mice through regulating Treg / Thl7 cytokines balance. Sci Rep, 2021. 11(1): p. 1611.

[0770] 59. Mohn, N., et al., Synthetic retinoid AM80 inhibits IL-17 production of gamma delta T cells and ameliorates biliary atresia in mice. Liver Int, 2020. 40(12): p. 3031-3041.

[0771] 60. Shi, Q., et al., Detoxification II Prescription Suppresses the Th-17 / IL-l 7 Inflammatory Axis to Improve the Liver Function of ACLF -Rats via Inactivating the P38MAPK Pathway. J Healthc Eng, 2021. 2021: p. 7563383.

[0772] 61. Park, S.W., et al., Paneth cell-derived inter leukin-17 A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury. Hepatology, 2011. 53(5): p. 1662-75.

[0773] 62. Herbert, F., et al., Evidence of IL-17, IP-10, and IL-10 involvement in multiple -organ dysfunction and IL-17 pathway in acute renal failure associated to Plasmodium falciparum malaria. J Transl Med, 2015. 13: p. 369.

[0774] 63. Zhang, W ., B. Chen, and W. Chen, LncRNA GAS5 relates to Thl7 cells and serves as a potential biomarker for sepsis inflammation, organ dysfunctions and mortality risk. J Clin Lab Anal, 2022. 36(5): p. e24309.

[0775] 64. Sonderegger, I., et al., Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol, 2006. 36(11): p. 2849- 56.

[0776] 65. Su, Z., et al., HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Thl7-cell expansion. Eur J Immunol, 2011. 41(12): p. 3586-95.

[0777] 66. Feng, W ., et al., IL-17 induces myocardial fibrosis and enhancesRANKL / OPG and MP / TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol, 2009. 87(3): p. 212-8.

[0778] 67. Liu, Y., et al., IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCbeta / Erkl / 2 / NF-kappaB-dependent signaling pathway. Int Immunol, 2012. 24(10): p. 605-12.

[0779] 68. Xue, G.L., et al., Interleukin- 17 upregulation participates in the pathogenesis of heart failure in mice via NF-kappaB-dependent suppression of SERCA2a and Cavl.2 expression. Acta Pharmacol Sin, 2021. 42(11): p. 1780-1789.

[0780] 69. Milovanovic, M., et al., Vitamin D deficiency is associated with increased IL- 17 and TNFalpha levels in patients with chronic heart failure. Arq Bras Cardiol, 2012. 98(3): p. 259-65.

[0781] 70. Yan, X., et al., Deleterious effect of the IL-23 / IL-17A axis and gammadeltaT cells on left ventricular remodeling after myocardial infarction. J Am Heart Assoc, 2012. 1(5): p. e004408.

[0782] 71. Wu, L., et al., Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med, 2014. 211(7): p. 1449-64.

[0783] 72. Zhou, S.F., et al., IL-17A promotes ventricular remodeling after myocardial infarction. J Mol Med (Berl), 2014. 92(10): p. 1105-16.

[0784] 73. Li, X.F., et al., Association ofNT-proBNP and interleukin- 17 levels with heart failure in elderly patients. Genet Mol Res, 2016. 15(2).

[0785] 74. Sandip, C., et al., Common variants in IL-17A / IL-17RA axis contribute to predisposition to and progression of congestive heart failure. Medicine (Baltimore), 2016. 95(27): p. e4105.

[0786] 75. Chang, S.L., et al., Interleukin- 17 enhances cardiac ventricular remodeling via activating MAP K pathway in ischemic heart failure. J Mol Cell Cardiol, 2018. 122: p. 69-79.

[0787] 76. Rahmati, Z., et al., Association of levels of interleukin 17 and T- helper 17 count with symptom severity and etiology of chronic heart failure: a casecontrol study. Croat Med J, 2018. 59(4): p. 139-148.

[0788] 77. Baumhove, L., et al., Clinical characteristics and prognosis of patients with heart failure and high concentrations of interleukin-17D. Int J Cardiol, 2024. 396: p. 131384.

[0789] 78. Gergely, T.G., et al., Characterization of immune checkpoint inhibitor -induced cardiotoxicity reveals interleukin- 17 A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol, 2023. 180(6): p. 740-761.

[0790] 79. Liu, W ., et al., Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats. Exp Mol Pathol, 2011. 91(1): p. 362-7.

[0791] 80. de Latour, R.P., et al., Thl7 immune responses contribute to the pathophysiology of aplastic anemia. Blood, 2010. 116(20): p. 4175-84.

[0792] 81. Wang, J., et al., High-dimensional immune profding using mass cytometry reveals IL- 17 A-producing gammadelta T cells as biomarkers in patients with T-cell-activated idiopathic severe aplastic anemia. Int Immunopharmacol, 2023. 125(Pt B): p. 111163.

[0793] 82. Vaht, K., et al., Bone marrow expression of CD68 / CD163 macrophages, IL-17 and FOXP3 cells in aplastic anemia and their relation to prognosis. Eur J Haematol, 2023. 110(3): p. 313-321.

[0794] 83. Gu, Y., et al., Interleukin (LL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol, 2008. 142(1): p. 109-14.

[0795] 84. Shen, M., et al., A novel senolytic drug for pulmonary fibrosis:BTSA1 targets apoptosis of senescent myofibroblasts by activating BAX. Aging Cell, 2024: p. el4229.

[0796] 85. Sun, W ., et al., Identification of vilazodone as a novel plasminogen activator inhibitor to overcome Alzheimer's disease through virtual screening, molecular dynamics simulation, and biological evaluation. Arch Pharm (Weinheim), 2024: p. e2400263.

[0797] 86. Jiang, J., et al., CD4(+)CD57(+) senescent T cells as promoters of systemic lupus erythematosus pathogenesis and the therapeutic potential of senolytic BCL-2 inhibitor. Eur J Immunol, 2024: p. e2350603.

[0798] 87. Katsuumi, G., et al., SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nat Aging, 2024.

[0799] 88. Zhang, J., et al., Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24-deficient mice. Cell Death Dis, 2024. 15(5): p. 380.

[0800] 89. Neuwahl, J., et al., Combined inhibition of class l-PI3K-alpha and delta isoforms causes senolysis by inducing p21(WAFl / CIPl) proteasomal degradation in senescent cells. Cell Death Dis, 2024. 15(5): p. 373.

[0801] 90. Zhang, S., et al., Targeting senescent HDF with the USP7 inhibitorP5091 to enhance DFU wound healing through the p53 pathway. Biochem Biophys Res Commun, 2024. 722: p. 150149.

[0802] 91. Chang, J., et al., Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med, 2016. 22(1): p. 78-83.

[0803] 92. Zhu, Y., et al., Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell, 2016. 15(3): p. 428-35.

[0804] 93. Pan, J., et al., Inhibition ofBcl-2 / xl With ABT-263 Selectively KillsSenescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice. Int J Radiat Oncol Biol Phys, 2017. 99(2): p. 353-361.

[0805] 94. Grezella, C., et al., Effects of senolytic drugs on human mesenchymal stromal cells. Stem Cell Res Ther, 2018. 9(1): p. 108.

[0806] 95. Mikawa, R., et al., Elimination of p!9(ARF) -expressing cells protects against pulmonary emphysema in mice. Aging Cell, 2018. 17(5): p. el2827.

[0807] 96. Walaszczyk, A., et al., Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging Cell, 2019. 18(3): p. el2945.

[0808] 97. Aguayo-Mazzucato, C., et al., Acceleration of beta Cell AgingDetermines Diabetes and Senolysis Improves Disease Outcomes. Cell Metab, 2019. 30(1): p. 129-142 e4.

[0809] 98. Yabluchanskiy, A., et al., Pharmacological or genetic depletion of senescent astrocytes prevents whole brain irradiation-induced impairment of neurovascular coupling responses protecting cognitive function in mice. Geroscience, 2020. 42(2): p. 409-428.

[0810] 99. Gonzalez-Gualda, E., et al., Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell, 2020. 19(4): p. el3142.

[0811] 100. Chung, L., et al., Interleukin 17 and senescent cells regulate the foreign body response to synthetic material implants in mice and humans. Sci Transl Med, 2020. 12(539).

[0812] 101. Shahbandi, A., et al., BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP 53 wild-type breast cancer. Cell Death Differ, 2020. 27(11): p. 3097-3116.

[0813] 102. Sierra-Ramirez, A., et al., Transient metabolic improvement in obese mice treated with navitoclax or dasatinib / quer cetin. Aging (Albany NY), 2020. 12(12): p. 11337-11348.

[0814] 103. Yang, H., et al., Navitoclax (ABT263) reduces inflammation and promotes chondr ogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis. Aging (Albany NY), 2020. 12(13): p. 12750-12770.

[0815] 104. Yamane, M., et al., Senescence-associated secretory phenotype promotes chronic ocular graft-vs-host disease in mice and humans. FASEB J, 2020. 34(8): p. 10778-10800.

[0816] 105. Saleh, T., et al., Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X(L) -BAX interaction. Mol Oncol, 2020. 14(10): p. 2504-2519.

[0817] 106. Jia, K., et al., Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice. J Cardiovasc Pharmacol, 2020. 76(4): p. 452-460.

[0818] 107. Acklin, S., et al., Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice. Sci Rep, 2020. 10(1): p. 14170.

[0819] 108. Dookun, E., et al., Clearance of senescent cells during cardiac ischemia-reperfusion injury improves recovery. Aging Cell, 2020. 19(10): p. el3249.

[0820] 109. Peng, X., et al., Cellular senescence contributes to radiation- induced hyposalivation by affecting the stem / progenitor cell niche. Cell Death Dis, 2020. 11(10): p. 854.

[0821] 110. Zhang, Y., et al., ABT-263 enhanced bacterial phagocytosis of macrophages in aged mouse through Beclin-1 -dependent autophagy. BMC Geriatr, 2021. 21(1): p. 225.

[0822] 111. Barrera- Vazquez, O.S., J.C. Gomez-Verjan, and G.A. Magos-Guerrero, Chemoinformatic Screening for the Selection of Potential Senolytic Compounds from Natural Products. Biomolecules, 2021. 11(3).

[0823] 112. Mylonas, K.J., et al., Cellular senescence inhibits renal regeneration after injury in mice, with senolytic treatment promoting repair. Sci Transl Med, 2021. 13(594).

[0824] 113. Paramos-de-Carvalho, D., et al., Targeting senescent cells improves functional recovery after spinal cord injury. Cell Rep, 2021. 36(1): p. 109334.

[0825] 114. Tarantini, S., et al., Treatment with the BCL-2 / BCL-xL inhibitor senolytic drug ABT263 / Navitoclax improves functional hyperemia in aged mice. Geroscience, 2021. 43(5): p. 2427-2440.

[0826] 115. Lee, S., et al., Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature, 2021. 599(7884): p. 283-289.

[0827] 116. Carpenter, V., et al., Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Biochem Pharmacol, 2021. 193: p. 114765.

[0828] 117. Fletcher-Sananikone, E., et al., Elimination of Radiation-InducedSenescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence.Cancer Res, 2021. 81(23): p. 5935-5947.

[0829] 118. Yamamoto, M., et al., Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.Neurooncol Adv, 2021. 3(1): p. vdabl48.

[0830] 119. Lim, S., et al., Senolytic Therapy for Cerebral Ischemia-Reperfusion Injury. Int J Mol Sci, 2021. 22(21).

[0831] 120. Ahmadinejad, F., et al., Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin. Mol Pharmacol, 2022. 101(3): p. 168-180.

[0832] 121. Sato, K., S. Iwasaki, and H. Yoshino, Effects and RelatedMechanisms of the Senolytic Agent ABT-263 on the Survival of Irradiated A549 and Ca9- 22 Cancer Cells. Int J Mol Sci, 2021. 22(24).

[0833] 122. Russo, M., et al., Biochemical and Cellular Characterization ofNew Radio-Resistant Cell Lines Reveals a Role of Natural Flavonoids to Bypass Senescence. Int J Mol Sci, 2021. 23(1).

[0834] 123. Fatt, M.P., et al., Restoration of hippocampal neural precursor function by ablation of senescent cells in the aging stem cell niche. Stem Cell Reports, 2022. 17(2): p. 259-275.

[0835] 124. Negi, A. and A.S. Voisin-Chiret, Strategies to Reduce the On-Target Platelet Toxicity ofBcl-x(L) Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches. Chembiochem, 2022. 23(12): p. e202100689.

[0836] 125. Huart, C., et al., Taking Advantage of the Senescence-PromotingEffect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT- 263. Cancers (Basel), 2022. 14(6).

[0837] 126. Yamamoto, M., et al., Gemcitabine Cooperates with Everolimus toInhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. Cancers (Basel), 2022. 14(7).

[0838] 127. Suzuki, K., et al., Characterization of radiation-induced micronuclei associated with premature senescence, and their selective removal by senolytic drug, ABT-263. Mutat Res Genet Toxicol Environ Mutagen, 2022. 876-877: p. 503448.

[0839] 128. Kim, H., et al., Inhibition of matrix metalloproteinase expression by selective clearing of senescent dermal fibroblasts attenuates ultraviolet-induced photoaging. Biomed Pharmacother, 2022. 150: p. 113034.

[0840] 129. Furukawa, M., et al., Analysis of senescence in gingival tissues and gingival fibroblast cultures. Clin Exp Dent Res, 2022. 8(4): p. 939-949.

[0841] 130. Fielder, E., et al., Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice. Elife, 2022. 11.

[0842] 131. Hellmich, C., et al., p!6INK4A-dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors. Blood Adv, 2023. 7(2): p. 256-268.

[0843] 132. Miura, Y., et al., Clearance of senescent cells with ABT-263 improves biological functions of synovial mesenchymal stem cells from osteoarthritis patients. Stem Cell Res Ther, 2022. 13(1): p. 222.

[0844] 133. Abdelgawad, I.Y., et al., EA.hy926 Cells and HUVECs ShareSimilar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263. Cells, 2022. 11(13).

[0845] 134. Lerida-Viso, A., et al., Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice. Pharmacol Res, 2022. 183: p. 106356.

[0846] 135. He, A., et al., Renal inflamm-aging provokes intra-grafi inflammation following experimental kidney transplantation. Am J Transplant, 2022. 22(11): p. 2529-2547.

[0847] 136. Golan, H., et al., Anti-Tumorigenic Effect of a Novel Derivative of2 -Hydroxy oleic Acid and the Endocannabinoid Anandamide on Neuroblastoma Cells.Biomedicines, 2022. 10(7).

[0848] 137. Kuehnemann, C . , et al . , Extracellular NicotinamidePhosphoribosyltransferase Is a Component of the Senescence-Associated Secretory Phenotype. Front Endocrinol (Lausanne), 2022. 13: p. 935106.

[0849] 138. Torres, P., et al., A motor neuron disease mouse model reveals a non-canonical profile of senescence biomarkers. Dis Model Meeh, 2022. 15(8).

[0850] 139. Rysanek, D., et al., Synergism ofBCL-2 family inhibitors facilitates selective elimination of senescent cells. Aging (Albany NY), 2022. 14(16): p. 6381-6414.

[0851] 140. Garcia-Puga, M., et al., Senescence plays a role in myotonic dystrophy type 1. JCI Insight, 2022. 7(19).

[0852] 141. Estepa-Fernandez, A., et al., Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. Pharmacol Res, 2023. 187: p. 106628.

[0853] 142. Fournier, F., et al., Obesity triggers tumoral senescence and renders poorly immunogenic malignancies amenable to senolysis. Proc Natl Acad Sci U S A, 2023. 120(1): p. e2209973120.

[0854] 143. Su, W ., et al., Clearance of senescent cells by navitoclax (ABT263) rejuvenates UHMWPE-induced osteolysis. Int Immunopharmacol, 2023. 115: p. 109694.

[0855] 144. Xing, J., et al., Protein phosphatase 2 A activators reverse age- related behavioral changes by targeting neural cell senescence. Aging Cell, 2023. 22(3): p. el3780.

[0856] 145. Jaber, S., et al., Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy. Mol Biomed, 2023. 4(1): p. 4.

[0857] 146. Budamagunta, V., et al., Effect of peripheral cellular senescence on brain aging and cognitive decline. Aging Cell, 2023. 22(5): p. el3817.

[0858] 147. Redgrave, R., et al., Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction. Res Sq, 2023.

[0859] 148. Fan, Y., et al., Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria. Front Physiol, 2020. 11: p. 593630.

[0860] 149. Kim, H., et al., Attenuation of intrinsic ageing of the skin via elimination of senescent dermal fibroblasts with senolytic drugs. J Eur Acad Dermatol Venereol, 2022. 36(7): p. 1125-1135.

[0861] 150. Beltzig, L., M. Christmann, and B. Kaina, Abrogation of CellularSenescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.Cells, 2022. 11(16).

[0862] 151. Koyanagi, A., et al., Protective roles of cytoplasmic p21(Cipl)( Vafl) in senolysis and ferroptosis of lung cancer cells. Cell Prolif, 2022. 55(12): p. el3326.

[0863] 152. Wang, Y., et al., Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging (Albany NY), 2016. 8(11): p. 2915- 2926.

[0864] 153. Zhu, Y., et al., New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, Al 331852 and Al 155463. Aging (Albany NY), 2017. 9(3): p. 955-963.

[0865] 154. Yousefzadeh, M.J., et al., Fisetin is a senotherapeutic that extends health and life span. EBioMedicine, 2018. 36: p. 18-28.

[0866] 155. Li, W. , et al . , Emerging senolytic agents derived from natural products. Meeh Ageing Dev, 2019. 181: p. 1-6.

[0867] 156. Crespo-Garcia, S., et al., Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab, 2021. 33(4): p. 818-832 e7.

[0868] 157. Maher, P . , Preventing and Treating Neurological Disorders w ith the Flavonol Fisetin. Brain Plast, 2021. 6(2): p. 155-166.

[0869] 158. Camell, C.D., et al., Senolytics reduce coronavirus-related mortality in old mice. Science, 2021. 373(6552).

[0870] 159. Elsallabi, O., et al., Fisetin as a Senotherapeutic Agent:Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection. Molecules, 2022. 27(3).

[0871] 160. Barra, V., et al., Specific Irreversible Cell-Cycle Arrest andDepletion of Cancer Cells Obtained by Combining Curcumin and the Flavonoids Quercetin and Fisetin. Genes (Basel), 2022. 13(7).

[0872] 161. Liu, L., et al., Senolytic elimination of senescent macrophages restores muscle stem cell function in severely dystrophic muscle. Aging (Albany NY), 2022. 14(19): p. 7650-7661.

[0873] 162. Gao, Y., et al., Increased cellular senescence in doxorubicin- induced murine ovarian injury: effect of senolytics. Geroscience, 2023. 45(3): p. 1775- 1790.

[0874] 163. Hambright, W.S., et al., The Senolytic Drug Fisetin AttenuatesBone Degeneration in the Zmpste24 (- / -) Progeria Mouse Model. J Osteoporos, 2023. 2023: p. 5572754.

[0875] 164. Russo, M., et al., Senolytic Flavonoids Enhance Type-I and Type-IICell Death in Human Radioresistant Colon Cancer Cells through AMPK / MAPK Pathway. Cancers (Basel), 2023. 15(9).

[0876] 165. Mullen, M., et al., Fisetin Attenuates Cellular SenescenceAccumulation During Culture Expansion of Human Adipose-Derived Stem Cells. Stem Cells, 2023. 41(7): p. 698-710.

[0877] 166. Mahoney, S. A., et al., Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence. Aging Cell, 2024. 23(3): p. el4060.

[0878] 167. Zhao, R., et al., Exploring the anti-aging effects of fisetin in telomerase-deficient progeria mouse model. Peer J, 2023. 11: p. el 6463.

[0879] 168. Ashiqueali, S. A., et al., Fisetin modulates the gut microbiota alongside biomarkers of senescence and inflammation in a DSS-induced murine model of colitis. Geroscience, 2024. 46(3): p. 3085-3103.

[0880] 169. Sip, S., et al., A Fisetin Delivery System for Neuroprotection: ACo-Amorphous Dispersion Prepared in Supercritical Carbon Dioxide. Antioxidants (Basel), 2023. 13(1).

[0881] 170. Wang, X., et al., Fisetin suppresses chondrocyte senescence and attenuates osteoarthritis progression by targeting sirtuin 6. Chem Biol Interact, 2024. 390: p. 110890.

[0882] 171. Li, W., et al., The cur cumin analog EF24 is a novel senolytic agent. Aging (Albany NY), 2019. 11(2): p. 771-782.

[0883] 172. Cho, H. J., et al., Identification of SYK inhibitor, R406 as a novel senolytic agent. Aging (Albany NY), 2020. 12(9): p. 8221-8240.Ill

[0884] 173. Born, E. , et al . , Eliminating Senescent Cells Can PromotePulmonary Hypertension Development and Progression. Circulation, 2023. 147(8): p. 650-666.

[0885] 174. Bugide, S., et al., ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience, 2024. 27(5): p. 109800.

[0886] 175. Toth, F., et al., In Vitro Investigation of Therapy-InducedSenescence and Senescence Escape in Breast Cancer Cells Using Novel Flow Cytometry- Based Methods. Cells, 2024. 13(10).

[0887] 176. Han, J., et al., Adipose tissue is an extramedullary reservoir for functional hematopoietic stem and progenitor cells. Blood, 2009.

[0888] 177. Feuerer, M., et al., Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med, 2009. 15(8): p. 930-9.

[0889] 178. Pittenger, M.F., et al., Multilineage potential of adult human mesenchymal stem cells. Science, 1999. 284(5411): p. 143-7.

[0890] 179. Casteilla, L., et al., Adipose-derived stromal cells: Their identity and uses in clinical trials, an update. World J Stem Cells, 2011. 3(4): p. 25-33.

[0891] 180. Aust, L., et al., Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy, 2004. 6(1): p. 7-14.

[0892] 181. Faustini, M., et al., Nonexpanded mesenchymal stem cells for regenerative medicine: yield in stromal vascular fraction from adipose tissues. Tissue Eng Part C Methods, 2010. 16(6): p. 1515-21.

[0893] 182. da Silva Meirelles, L., A.I. Caplan, and N.B. Nardi, In search of the in vivo identity of mesenchymal stem cells. Stem Cells, 2008. 26(9): p. 2287-99.

[0894] 183. da Silva Meirelles, L., et al., MSC frequency correlates with blood vessel density in equine adipose tissue. Tissue Eng Part A, 2009. 15(2): p. 221-9.

[0895] 184. Najafipour, H., et al., The effect of sodium valproate on differentiation of human adipose-derived stem cells into cardiomyocyte-like cells in two- dimensional culture and fibrin scaffold conditions. Cell Tissue Res, 2019. 378(1): p. 127- 141.

[0896] 185. Fu, Y., et al., Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity. Int J Biochem Cell Biol, 2014. 54: p. 68-77.

[0897] 186. Cho, H.H., et al., Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem, 2005. 96(3): p. 533-42.

[0898] 187. Hodjat, M., et al., Histone Deacetylase Inhibitors Restore theOdontogenic Differentiation Potential of Dental Pulp Stem Cells under Hyperglycemic Conditions. Curr Stem Cell Res Ther, 2024.

[0899] 188. Paino, F., et al., Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells, 2014. 32(1): p. 279-89.

[0900] 189. Fila-Danilow, A., et al., The influence of TSA and VPA on the in vitro differentiation of bone marrow mesenchymal stem cells into neuronal lineage cells:Gene expression studies. Postepy Hig Med Dosw (Online), 2017. 71(0): p. 236-242.

[0901] 190. Mahlknecht, U. and C. Schonbein, Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica, 2008. 93(3): p. 443-6.

[0902] 191. Tsai, L.K., et al., Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke, 2011. 42(10): p. 2932-9.

[0903] 192. Iwatani, S., et al., Gestational Age-Dependent Increase of SurvivalMotor Neuron Protein in Umbilical Cord-Derived Mesenchymal Stem Cells. Front Pediatr, 2017. 5: p. 194.

[0904] 193. Blecker, D., et al., New Insights into the Neural DifferentiationPotential of Canine Adipose Tissue-Derived Mesenchymal Stem Cells. Anat Histol Embryol, 2017. 46(3): p. 304-315.

[0905] 194. Jang, S. and H.S. Jeong, Histone deacetylase inhibition-mediated neuronal differentiation via the Wnt signaling pathway in human adipose tissue-derived mesenchymal stem cells. Neurosci Lett, 2018. 668: p. 24-30.

[0906] 195. Heng, B.C., et al., Small molecules enhance neurogenic differentiation of dental-derived adult stem cells. Arch Oral Biol, 2019. 102: p. 26-38.

[0907] 196. Chen, L., et al., Transplantation of bone marrow mesenchymal stem cells pretreated with valproic acid in rats with an acute spinal cord injury. Biosci Trends, 2014. 8(2): p. 111-9.

[0908] 197. Fernandes, S., et al., Improved neural differentiation of normal and abnormal induced pluripotent stem cell lines in the presence of valproic acid. J Tissue Eng Regen Med, 2019. 13(8): p. 1482-1496.

[0909] 198. Ghorbani, S., T. Tiraihi, and M. Soleimani, Differentiation of mesenchymal stem cells into neuron-like cells using composite 3D scaffold combined with valproic acid induction. J Biomater Appl, 2018. 32(6): p. 702-715.

[0910] 199. Linares, G.R., et al., Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease. Exp Neurol, 2016. 281: p. 81-92.

[0911] 200. Talwadekar, M., et al., Valproic acid enhances the neural differentiation of human placenta derived-mesenchymal stem cells in vitro. J Tissue Eng Regen Med, 2017. 11(11): p. 3111-3123.

[0912] 201. Arulmozhivarman, G., et al., Zebrafish In-Vivo Screening forCompounds Amplifying Hematopoietic Stem and Progenitor Cells: - Preclinical Validation in Human CD34+ Stem and Progenitor Cells. Sci Rep, 2017. 7(1): p. 12084.

[0913] 202. Elizalde, C., et al., Histone deacetylase 3 modulates the expansion of human hematopoietic stem cells. Stem Cells Dev, 2012. 21(14): p. 2581-91.

[0914] 203. Ullah, I., et al., Transdifferentiation of alpha-1, 3- galactosyltransferase knockout pig bone marrow derived mesenchymal stem cells into pancreatic beta-like cells by microenvironment modulation. Asian-Australas J Anim Sci, 2020. 33(11): p. 1837-1847.

[0915] 204. Coskun, E., M. Ercin, and S. Gezginci -Oktay oglu, The Role ofEpigenetic Regulation and Pluripotency-Related MicroRNAs in Differentiation of Pancreatic Stem Cells to Beta Cells. J Cell Biochem, 2018. 119(1): p. 455-467.

[0916] 205. Lee, S., et al., Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif, 2009. 42(6): p. 711-20.

[0917] 206. Marquez-Curtis, L.A., et al., Migration, proliferation, and differentiation of cord blood mesenchymal stromal cells treated with histone deacetylase inhibitor valproic Acid. Stem Cells Int, 2014. 2014: p. 610495.

[0918] 207. Salami, EL, et al., Evaluating the Differential Effects of ValproicAcid on Wharton's Jelly Mesenchymal Stem Cells. Adv Pharm Bull, 2019. 9(3): p. 497- 504.

[0919] 208. Dong, X., et al., Modification of histone acetylation facilitates hepatic differentiation of human bone marrow mesenchymal stem cells. PLoS One, 2013. 8(5): p. e63405.

[0920] 209. Tarique, S., et al., The role of epigenetic modifiers in the hepatic differentiation of human umbilical cord derived mesenchymal stem cells. Biol Futur, 2022. 73(4): p. 495-502.

[0921] 210. An, S.Y., et al., Valproic acid promotes differentiation of hepatocyte-like cells from whole human umbilical cord-derived mesenchymal stem cells. Tissue Cell, 2014. 46(2): p. 127-35.

[0922] 211. Rashid, S., et al., Effect of valproic acid on the hepatic differentiation of mesenchymal stem cells in 2D and 3D microenvironments. Mol Cell Biochem, 2021. 476(2): p. 909-919.

[0923] 212. Omer, D., et al., Chromatin-modifying agents reactivate embryonic renal stem / progenitor genes in human adult kidney epithelial cells but abrogate dedifferentiation and sternness. Cell Reprogram, 2013. 15(4): p. 281-92.

[0924] 213. Shokeir, A. A., et al., Human Wharton's jelly-derived mesenchymal stromal stem cells preconditioned with valproic acid promote cell migration and reduce renal inflammation in ischemia / reperfusion injury by activating the AKT / P13K and SDF1 / CXCR4 pathways. Arch Biochem Biophys, 2024. 755: p. 109985.

[0925] 214. Riordan, N.H., et al., Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med, 2009. 7: p. 29.

[0926] 215. Banfi, A., et al., Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Exp Hematol, 2000. 28(6): p. 707-15.

[0927] 216. Baxter, M. A., et al., Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells, 2004. 22(5): p. 675-82.

[0928] 217. Bonab, M.M., et al., Aging of mesenchymal stem cell in vitro. BMCCell Biol, 2006. 7: p. 14.

[0929] 218. Wagner, W ., et al., Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One, 2008. 3(5): p. e2213.

[0930] 219. Colter, D.C., et al., Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci U S A, 2000. 97(7): p. 3213-8.

[0931] 220. Fehrer, C., et al., Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell, 2007. 6(6): p. 745-57.

[0932] 221. Stenderup, K. , et al . , Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone, 2003. 33(6): p. 919-26.

[0933] 222. Mareschi, K., et al., Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem, 2006. 97(4): p. 744-54.

[0934] 223. Kern, S., et al., Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 2006. 24(5): p. 1294-301.

[0935] 224. Rodier, F. and J. Campisi, Four faces of cellular senescence. J CellBiol, 2011. 192(4): p. 547-56.

[0936] 225. Garcia-Olmo, D., et al., Treatment of enterocutaneous fistula inCrohn's Disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis, 2009. 24(1): p. 27-30.

[0937] 226. Ben-Ami, E., S. Berrih-Aknin, and A. Miller, Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev, 2011. 10(7): p. 410-5.

[0938] 227. Le Blanc, K., et al., HI A expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 2003. 31(10): p. 890-6.

[0939] 228. Tse, W.T., et al., Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 2003. 75(3): p. 389-97.

[0940] 229. Majumdar, M.K., et al., Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci, 2003. 10(2): p. 228- 41.

[0941] 230. Meisel, R., et al., Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3 -dioxygenase -mediated tryptophan degradation. Blood, 2004. 103(12): p. 4619-21.

[0942] 231. Aggarwal, S. and M.F. Pittenger, Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2005. 105(4): p. 1815-22.

[0943] 232. Sato, K., et al., Nitric oxide plays a critical role in suppression ofT-cell proliferation by mesenchymal stem cells. Blood, 2007. 109(1): p. 228-34.

[0944] 233. Nasef, A., et al., Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol, 2008. 253(1-2): p. 16-22.

[0945] 234. Nauta, A. J., et al., Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol, 2006. 177(4): p. 2080-7.

[0946] 235. Asari, S., et al., Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol, 2009. 37(5): p. 604-15.

[0947] 236. Nemeth, K., et al., Bone marrow stromal cells attenuate sepsis via prostaglandin E(2) -dependent reprogramming of host macrophages to increase their interleukin- 10 production. Nat Med, 2009. 15(1): p. 42-9.

[0948] 237. Johann, P.D., et al., Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer, 2010. 10: p. 501.

[0949] 238. Waterman, R.S., et al., A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC 1 or an Immunosuppressive MSC 2 phenotype. PLoS One, 2010. 5(4): p. el0088.

[0950] 239. Kronsteiner, B., et al., Human Mesenchymal Stem Cells fromAdipose Tissue and Amnion Influence T-Cells Depending on Stimulation Method and Presence of Other Immune Cells. Stem Cells Dev, 2011.

Claims

Claims1. A method of generating personalized regenerative cells, said method comprising the steps of: a) extracting an aliquot of blood; b) separating mononuclear cells from said blood; c) isolating cells with proclivity towards retrodifferentiation; d) optionally expanding in vitro said cells with potential for retrodifferentiation; e) contacting said cells with potential for retrodifferentiation with one or more inducers of retrodifferentiation; f) assessing extent of retrodifferentiation; g) optionally performing another contact with said one or more retrodifferentiating agents; h) assessing pluripotency status of said cells; and i) optionally differentiating said cells into mesenchymal stem cells..

2. The method of claim 1, wherein personalized regenerative cells are pluripotent.

3. The method of claim 2, wherein said pluripotent stem cells are capable of proliferation for more than 100 passages without exhibiting characteristics of senescence.

4. The method of claim 2, wherein said pluripotent stem cells are capable of proliferation for more than 100 passages without exhibiting karyotypic abnormalities.

5. The method of claim 2, wherein said pluripotent stem cells are capable of proliferation for more than 100 passages without alteration of rate of proliferation.

6. The method of claim 1, wherein said mononuclear cells isolated from blood are purified by use of a density gradient.

7. The method of claim 6, wherein said density gradient is ficoll.

8. The method of claim 6, wherein said density gradient is percoll.

9. The method of claim 6, wherein said mononuclear cell is further purified for expression of CD 105.

10. The method of claim 9, wherein said expression of CD 105 is used to magnetically isolate cells from a heterogenous population of cells.

11. The method of claim 6, wherein said mononuclear cell is further purified for expression of CD34.

12. The method of claim 9, wherein said expression of CD34 is used to magnetically isolate cells from a heterogenous population of cells.

13. The method of claim 6, wherein said mononuclear cell is further purified for expression of VASA.

14. The method of claim 9, wherein said expression of VASA is used to magnetically isolate cells from a heterogenous population of cells.

15. The method of claim 10, wherein said CD 105 expressing cells are expanded in vitro.

16. The method of claim 15, wherein said CD 105 expressing cells are placed on mesenchymal stem cell feeder cells.

17. The method of claim 16, wherein said mesenchymal stem cell feeder cells are plastic adherent.

18. The method of claim 16, wherein said mesenchymal stem cell feeder cells express CD73.

19. The method of claim 16, wherein said mesenchymal stem cell feeder cells express CD39.

20. The method of claim 16, wherein said mesenchymal stem cell feeder cells express IL- 10 receptor.

21. The method of claim 16, wherein said mesenchymal stem cell feeder cells express TSGP.

22. The method of claim 16, wherein said mesenchymal stem cell feeder cells express c- met.

23. The method of claim 16, wherein said mesenchymal stem cell feeder cells are derived from bone marrow.

24. The method of claim 16, wherein said mesenchymal stem cell feeder cells are derived from Whatron’s Jelly.

25. The method of claim 16, wherein said mesenchymal stem cell feeder cells are derived from umbilical cord.

26. The method of claim 16, wherein said mesenchymal stem cell feeder cells are derived from umbilical cord blood.

27. The method of claim 16, wherein said mesenchymal stem cell feeder cells are derived from adipose tissue.

28. The method of claim 16, wherein said mesenchymal stem cell feeder cells are derived from amniotic membrane tissue.

29. The method of claim 16, wherein said mesenchymal stem cell feeder cells are derived from amniotic fluid.

30. The method of claim 16, wherein said mesenchymal stem cell feeder cells are treated with a histone deacetylase inhibitor prior to contact with said CD 105 expressing cells.

31. The method of claim 30, wherein said histone deacetylase inhibitor is valproic acid.

32. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 10 pg of HGF from 1 million mesenchymal stem cells.

33. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 20 pg of HGF from 1 million mesenchymal stem cells.

34. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of HGF from 1 million mesenchymal stem cells.

35. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of VEGF from 1 million mesenchymal stem cells.

36. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of VEGF from 1 million mesenchymal stem cells.

37. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of VEGF from 1 million mesenchymal stem cells.

38. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of IGF from 1 million mesenchymal stem cells.

39. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of IGF from 1 million mesenchymal stem cells.

40. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of IGF from 1 million mesenchymal stem cells.

41. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 1 ng of stem cell factor from 1 million mesenchymal stem cells.

42. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 2 ng of stem cell factor from 1 million mesenchymal stem cells.

43. The method of claim 31, wherein said valproic acid is added to said feeder cells at a concentration and duration sufficient to induce production of more than 5 ng of stem cell factor from 1 million mesenchymal stem cells.

44. The method of claim 30, wherein said histone deacetylase inhibitor is trichostatin A.

45. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 10 pg of HGF from 1 million mesenchymal stem cells.

46. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 20 pg of HGF from 1 million mesenchymal stem cells.

47. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of HGF from 1 million mesenchymal stem cells.

48. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of VEGF from 1 million mesenchymal stem cells.

49. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of VEGF from 1 million mesenchymal stem cells.

50. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of VEGF from 1 million mesenchymal stem cells.

51. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of IGF from 1 million mesenchymal stem cells.

52. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of IGF from 1 million mesenchymal stem cells.

53. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of IGF from 1 million mesenchymal stem cells.

54. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 1 ng of stem cell factor from 1 million mesenchymal stem cells.

55. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 2 ng of stem cell factor from 1 million mesenchymal stem cells.

56. The method of claim 44, wherein said trichostatin A is added to said feeder cells at a concentration and duration sufficient to induce production of more than 5 ng of stem cell factor from 1 million mesenchymal stem cells.

57. The method of claim 30, wherein said histone deacetylase inhibitor is phenylbutyrate.

58. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 10 pg of HGF from 1 million mesenchymal stem cells.

59. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 20 pg of HGF from 1 million mesenchymal stem cells.

60. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of HGF from 1 million mesenchymal stem cells.

61. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of VEGF from 1 million mesenchymal stem cells.

62. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of VEGF from 1 million mesenchymal stem cells.

63. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of VEGF from 1 million mesenchymal stem cells.

64. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 50 pg of IGF from 1 million mesenchymal stem cells.

65. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 100 pg of IGF from 1 million mesenchymal stem cells.

66. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 500 pg of IGF from 1 million mesenchymal stem cells.

67. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 1 ng of stem cell factor from 1 million mesenchymal stem cells.

68. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 2 ng of stem cell factor from 1 million mesenchymal stem cells.

69. The method of claim 44, wherein said phenylbutyrate is added to said feeder cells at a concentration and duration sufficient to induce production of more than 5 ng of stem cell factor from 1 million mesenchymal stem cells.

70. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing CD 105.

71. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing c-kit.

72. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing CD 105.

73. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing c-met.

74. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing leukemia inhibitory factor receptor.

75. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing IL-3 receptor.

76. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing G-CSF receptor.

77. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing GM-CSF receptor.

78. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing M-CSF receptor.

79. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing erythropoietin receptor.

80. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA.

81. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and GM-CSF receptor.

82. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and stem cell factor receptor.

83. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and M-CSF receptor.

84. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and oxytocin receptor.

85. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and IL-3 receptor.

86. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and CD200.

87. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and c-kit.

88. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA and DAZL receptor.

89. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and GM- CSF receptor.

90. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and IL-3 receptor.

91. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and IL-6 receptor.

92. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and IL-11 receptor.

93. The method of claim 1, wherein isolating cells with proclivity towards retrodifferentiation is performed by isolation of cells expressing VASA, DAZL and NANOG.

94. The method of claim 1, wherein cells with proclivity towards retrodifferentiation are treated with cytoplasmic extract from a pluripotent stem cell.

95. The method of claim 1, wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing microRNAs.

96. The method of claim 1, wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing small molecules.

97. The method of claim 1, wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing RNA interference stimulating molecules.

98. The method of claim 1, wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing genes.

99. The method of claim 1, wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing mRNAs.

100. The method of claim 1, wherein cells with proclivity towards retrodifferentiation are treated with retrodifferentiation inducing proteins.

101. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of superoxide dismutase as compared to a non-engineered mesenchymal stem cell.

102. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of manganese dependent superoxide dismutase as compared to a non-engineered mesenchymal stem cell.

103. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of bone morphogenic protein 2 as compared to a non-engineered mesenchymal stem cell.

104. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of bone morphogenic protein 4 as compared to a non-engineered mesenchymal stem cell.

105. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of VEGF as compared to a non-engineered mesenchymal stem cell.

106. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of VEGF-C as compared to a non-engineered mesenchymal stem cell.

107. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of CXCL12 as compared to a non-engineered mesenchymal stem cell.

108. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of TIMP-1 as compared to a non-engineered mesenchymal stem cell.

109. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of TIMP-3 as compared to a non-engineered mesenchymal stem cell.

110. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of TIMP-5 as compared to a non-engineered mesenchymal stem cell.

111. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of IL-10 as compared to a non-engineered mesenchymal stem cell.

112. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of Fas ligand as compared to a non-engineered mesenchymal stem cell.

113. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of HLA-G as compared to a non-engineered mesenchymal stem cell.

110. The mesenchymal stem cell of claim 1, wherein said cell is engineered to possess increased expression of TIMP-5 as compared to a non-engineered mesenchymal stem cell.

111. The mesenchymal stem cell of claim 1, wherein said cell is utilized to enhance engraftment of a chondrocytic progenitor.

112. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is autologous to the recipient.

113. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is allogeneic to the recipient.

114. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is xenogeneic to the recipient.

115. The mesenchymal stem cell of claim 111, wherein said mesenchymal stem cell is cultured with said chondrocytic progenitor before administration of said chondrocytic progenitor.

116. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is utilized to treat a defect of hyalin cartilage.

117. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is utilized to treat rheumatoid arthritis.

118. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is utilized to treat osteoarthritis.

119. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is utilized to treat disc degenerative disease.

120. The mesenchymal stem cell of claim 111, wherein said chondrocytic progenitor is administered together with FGF-5.

121. The mesenchymal stem cell of claim 1, wherein said cell is utilized to treat a nonunion bone fracture.

122. The mesenchymal stem cell of claim 121, wherein said mesenchymal stem cell is administered together with an anti-inflammatory agent.

123. The mesenchymal stem cell of claim 122, wherein said anti-inflammatory agent is capable of inhibiting activation of NF -kappa B.

124. The mesenchymal stem cell of claim 122, wherein said anti-inflammatory agent is capable of inhibiting degradation of i-kappa B.

125. The mesenchymal stem cell of claim 122, wherein said anti-inflammatory agent is n-acetylcysteine.

126. The mesenchymal stem cell of claim 125, wherein said n-acetylcysteine is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

127. The mesenchymal stem cell of claim 125, wherein said n-acetylcysteine is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

128. The mesenchymal stem cell of claim 125, wherein said n-acetylcysteine is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

129. The mesenchymal stem cell of claim 122, wherein said anti-inflammatory agent is quercetin.

130. The mesenchymal stem cell of claim 125, wherein said quercetin is administered at a concentration sufficient to increase production of IL-10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

131. The mesenchymal stem cell of claim 125, wherein said quercetin is administered at a concentration sufficient to increase production of IL-10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

132. The mesenchymal stem cell of claim 125, wherein said quercetin is administered at a concentration sufficient to increase production of IL-10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

133. The mesenchymal stem cell of claim 122, wherein said anti-inflammatory agent is indomethacin.

134. The mesenchymal stem cell of claim 125, wherein said indomethacin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

135. The mesenchymal stem cell of claim 125, wherein said indomethacin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

136. The mesenchymal stem cell of claim 125, wherein said indomethacin is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

137. The mesenchymal stem cell of claim 122, wherein said anti-inflammatory agent is ampiroxicam.

138. The mesenchymal stem cell of claim 125, wherein said ampiroxicam is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 25% as compared to baseline.

139. The mesenchymal stem cell of claim 125, wherein said ampiroxicam is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 50% as compared to baseline.

140. The mesenchymal stem cell of claim 125, wherein said ampiroxicam is administered at a concentration sufficient to increase production of IL- 10 from mesenchymal stem cells stimulated with HMGB1 by over 100% as compared to baseline.

141. The mesenchymal stem cell of claim 125, wherein said cell is maintained in an undifferentiated state.

142. The mesenchymal stem cell of claim 141, wherein said maintenance in said undifferentiated state is accomplished by culture in a media conditioned by dedifferentiated fibroblasts.

143. The mesenchymal stem cell of claim 142, wherein said dedifferentiated fibroblasts are fibroblasts transfected with OCT4.

144. The mesenchymal stem cell of claim 142, wherein said dedifferentiated fibroblasts are fibroblasts transfected with NANOG.

145. The mesenchymal stem cell of claim 142, wherein said dedifferentiated fibroblasts are fibroblasts transfected with lin28.

146. The mesenchymal stem cell of claim 142, wherein said dedifferentiated fibroblasts are fibroblasts transfected with one or more proteins selected from a group comprising of: a) PIM1; b) c-myc; c) k-ras; d) bcr-abl; e) KLF4; f) c-met; g) OCT4; h) NANOG; and i) AIRE.

147. The mesenchymal stem cell of claim 142, wherein said dedifferentiated fibroblasts are obtained from a tissue possessing immature properties.

148. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from testicular tissue.

149. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from ovarian tissue.

150. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from placental tissue.

151. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from amniotic membrane tissue.

152. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from amniotic fluid.

153. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from bone marrow.

154. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood.

155. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with G-CSF.

156. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with GM-CSF.

157. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with M-CSF.

158. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with an agonist of CXCR4.

159. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with mozibil.

160. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with flt3 ligand.

161. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with beta glucan.

162. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from peripheral blood of a patient treated with Poly IC.

163. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from fallopian tube tissue.

164. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from adipose tissue.

165. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from deciduous tooth tissue.

166. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from Wharton’s Jelly.

167. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from omental tissue.

168. The mesenchymal stem cell of claim 147, wherein said fibroblasts are obtained from adherent pluripotent stem cells.

169. The mesenchymal stem cell of claim 168, wherein said pluripotent stem cells are induced pluripotent stem cells.

170. The mesenchymal stem cell of claim 168, wherein said pluripotent stem cells are parthenogenic derived pluripotent stem cells.

171. The mesenchymal stem cell of claim 168, wherein said pluripotent stem cells are stress derived pluripotent stem cells.

172. The mesenchymal stem cell of claim 168, wherein said pluripotent stem cells are somatic nuclear transfer derived pluripotent stem cells.

173. The mesenchymal stem cell of claim 147, wherein said fibroblasts are dedifferentiated by treatment with a “dedifferentiating agent”.

174. The mesenchymal stem cell of claim 173, wherein said dedifferentiating agent is a histone deacetylase inhibitor.

175. The mesenchymal stem cell of claim 174, wherein said histone deacetylase inhibitor is valproic acid.

176. The mesenchymal stem cell fo claim 175, wherein said valproic acid is added together with lithium chloride.

177. The mesenchymal stem cell fo claim 175, wherein said valproic acid is added together with a ROCK inhibitor.

178. The mesenchymal stem cell fo claim 175, wherein said valproic acid is added together with GDF -15.

179. The mesenchymal stem cell fo claim 175, wherein said valproic acid is added together with a cyclooxygenase 2 inhibitor.

180. The mesenchymal stem cell of claim 174, wherein said histone deacetylase inhibitor is trichostatin A.

181. The mesenchymal stem cell of claim 180, wherein said trichostatin A is added together with lithium chloride.

182. The mesenchymal stem cell of claim 180, wherein said trichostatin A is added together with a ROCK inhibitor.

183. The mesenchymal stem cell of claim 180, wherein said trichostatin A is added together with GDF -15.

184. The mesenchymal stem cell of claim 180, wherein said trichostatin A is added together with a cyclooxygenase 2 inhibitor.

185. The mesenchymal stem cell of claim 174, wherein said histone deacetylase inhibitor is phenylbutyrate.

186. The mesenchymal stem cell of claim 185, wherein said phenylbutyrate is added together with lithium chloride.

187. The mesenchymal stem cell of claim 185, wherein said phenylbutyrate is added together with a ROCK inhibitor.

188. The mesenchymal stem cell of claim 185, wherein said phenylbutyrate is added together with GDF -15.

189. The mesenchymal stem cell of claim 185, wherein said phenylbutyrate is added together with a cyclooxygenase 2 inhibitor.

190. The mesenchymal stem cell of claim 174, wherein said histone deacetylase inhibitor is vorinostat.

191. The mesenchymal stem cell of claim 190, wherein said vorinostat is added together with lithium chloride.

192. The mesenchymal stem cell of claim 190, wherein said vorinostat is added together with a ROCK inhibitor.

193. The mesenchymal stem cell of claim 190, wherein said vorinostat is added together with GDF-15.

194. The mesenchymal stem cell of claim 190, wherein said vorinostat is added together with a cyclooxygenase 2 inhibitor.

195. A method of creating an autologous pluripotent stem cell derived from peripheral blood sources, said method comprising of: a) selecting a population of blood mononuclear cell; b) isolating from said blood mononuclear cells a population of cells expressing the marker DAZL; c) expanding said DAZL expressing cell population in vitro; and d) contacting said DAZL expressing cells with a dedifferentiation means.

196. The method of claim 195, wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing multipotency.

197. The method of claim 195, wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing pluripotency.

198. The method of claim 195, wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing ability to form a teratoma when said cells are administered into an immunodeficient animal.

199. The method of claim 195, wherein said dedifferentiating means are proteins, nucleic acids, or small molecules capable of endowing immortality in treated cells.

200. The method of claim 195, wherein said dedifferentiation means involves transfer of cytoplasm from an immature cell into a cell which is meant to be dedifferentiated.

201. The method of claim 200, wherein said cytoplasm transfer is facilitated by the use of cell fusion.

202. The method of claim 201, wherein said fusion is catalyzed by treatment with a membrane fusogenic agent.

203. The method of claim 202, wherein said fusogenic agent is polyethylene glycol.

204. The method of claim 195, wherein said dedifferentiation means is transfection with one or more genes selected from a group comprising of: a) OCT4; b) NANOG; c) SOX-2; d) KLF4; and e) PIM1.

205. The method of generating a pluripotent stem cell, wherein said cell-free means is extracted or obtained from a regenerative cell, wherein said regenerative cell has been treated with a “promoting agent”, wherein said promoting agent inhibits cellular differentiation while maintaining pluripotency.

206. The method of claim 205, wherein said promoting agent is GDF-11.

207. The method of claim 205, wherein said promoting agent is GDF-15.

208. The method of claim 205, wherein said promoting agent is amniotic fluid.

209. The method of claim 205, wherein said promoting agent is umbilical cord blood plasma.

210. The method of claim 205, wherein said promoting agent is BMP2.

211. The method of claim 205, wherein said promoting agent suppresses NF-kappa B activation.

212. The method of claim 205, wherein said promoting agent increases NRF2 activation.

213. The method of claim 205, wherein said promoting agent increases heme-oxygenase-1 activation.

214. The method of claim 205, wherein said promoting agent increases bcl-2 activation.

215. The method of claim 205, wherein said promoting agent increases bcl-2XL activation.

216. The method of claim 205, wherein said promoting agent increases survivin activation.

217. The method of claim 205, wherein said promoting agent increases livin activation.

218. The method of claim 205, wherein said promoting agent is an HDAC inhibitor.

219. The method of claim 218, wherein said HDAC inhibitor is valproic acid.

220. The method of claim 218, wherein said HDAC inhibitor is trichostatin A.

221. The method of claim 205, wherein said HDAC inhibitor is sodium phenylbutyrate.

222. The method of claim 218, wherein said HDAC inhibitor is butyrate.

223. The method of claim 205, wherein said promoting agent is a GSK-3 inhibitor.

224. The method of claim 223, wherein said GSK-3 inhibitor is lithium.

225. The method of claim 205, wherein said promoting agent causes a change in the genotype of the cell population.

226. The method of claim 205, wherein at least one promoting agent comprises or consists of an immortalizing oncogene.

227. The method of claim 205, wherein said promoting agent is PIM1.

228. The method of claim 226, wherein said promoting agent is SV40 large T antigen.

229. The method of claim 226, wherein said promoting agent is abll.

230. The method of claim 226, wherein said promoting agent is AFF4.

231. The method of claim 226, wherein said promoting agent is AKT2.

232. The method of claim 226, wherein said promoting agent is AKL.

233. The method of claim 226, wherein said promoting agent is AML1.

234. The method of claim 226, wherein said promoting agent is MTG8.

235. The method of claim 226, wherein said promoting agent is BCL6.

236. The method of claim 226, wherein said promoting agent is MCF2.

237. The method of claim 226, wherein said promoting agent is DCF3.

238. The method of claim 226, wherein said promoting agent is EGFR.

239. The method of claim 226, wherein said promoting agent is MLLT11.

240. The method of claim 226, wherein said promoting agent is ERBB2.

241. The method of claim 226, wherein said promoting agent is ETS1.

242. The method of claim 226, wherein said promoting agent is CSF1R.

243. The method of claim 226, wherein said promoting agent is FOS.

244. The method of claim 226, wherein said promoting agent is FES.

245. The method of claim 226, wherein said promoting agent is GNAS.

246. The method of claim 226, wherein said promoting agent is HER2.

247. The method of claim 226, wherein said promoting agent is FGF3.

248. The method of claim 226, wherein said promoting agent is FGF4.

249. The method of claim 226, wherein said promoting agent is JUN.

250. The method of claim 226, wherein said promoting agent is c-kit.

251. The method of claim 226, wherein said promoting agent is K-SAM.

252. The method of claim 226, wherein said promoting agent is AKAP13.

253. The method of claim 226, wherein said promoting agent is LCK.

254. The method of claim 226, wherein said promoting agent is LM01.

255. The method of claim 226, wherein said promoting agent is LYL1.

256. The method of claim 226, wherein said promoting agent is MASI.

257. The method of claim 226, wherein said promoting agent is MDM2.

258. The method of claim 226, wherein said promoting agent is MOS.

259. The method of claim 226, wherein said promoting agent is MYH11.

260. The method of claim 226, wherein said promoting agent is MYB.

261. The method of claim 226, wherein said promoting agent is MYCN.

262. The method of claim 226, wherein said promoting agent is PAX5.

263. The method of claim 226, wherein said promoting agent is RAF.

264. The method of claim 226, wherein said promoting agent is RAS.

265. The method of claim 226, wherein said promoting agent is REL.

266. The method of claim 226, wherein said promoting agent is ROS1.

267. The method of claim 226, wherein said promoting agent is SKI (PDGF-BB).

268. The method of claim 226, wherein said promoting agent is SET.

269. The method of claim 226, wherein said promoting agent is SRC.

270. The method of claim 226, wherein said promoting agent is TALI.

271. The method of claim 226, wherein said promoting agent is TAN1.

272. The method of claim 226, wherein said promoting agent is TIAN.

273. The method of claim 226, wherein said promoting agent is TSC2.

274. The method of claim 226, wherein said promoting agent is TRK.

275. The method of claims 227 to 274, wherein said promoting agent can be conditionally inactivated.

276. The method of claim 151, wherein said tissue specific progenitors are immortalized.

277. The method of claim 276, wherein said immortalization is performed by transfection with an immortalizing factor.

278. The method of claim 277, wherein said immortalizing factor is one or more oncogenes selected from a group comprising of: ABCB1, ABCG2, ABI1, ABL1, ABL2, ACKR3, ACSL3, ACSL6, ACVR1B, ACVR2A, AFF1, AFF3, AFF4, AKAP9, AKT1, AKT2, AKT3, ALDH1A1, ALDH2, ALK, AMER1, ANGPT1, ANGPT2, ANKRD23, APC, AR, ARAF, AREG, ARFRP1, ARHGAP26, ARHGEF12, ARID! A, ARID I B, ARID2, ARNT, ASPSCR1, ASXL1, ATF1, ATIC, ATM, ATP1A1, ATP2B3, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BBC3, BCL10, BCL11A, BCL1 IB, BCL2, BCL2L1, BCL2L11, BCL2L2, BCL3, BCL6, BCL7A, BCL9, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRINP3, BRIP1, BTG1, BTG2, BTK, BUB1B, Cl lorf30, C15orf65, C2orf44, CA6, CACNA1D, CALR, CAMTAI, CANT1, CARD11, CARS, CASC5, CASP8, CBFA2T3, CBFB, CBL, CBLB, CBLC, CCDC6, CCNB1IP1, CCND1, CCND2, CCND3, CCNE1, CD19, CD22, CD274, CD38, CD4, CD70, CD74, CD79A, CD79B, CD83, CDC73, CDH1, CDH11, CDK12, CDK4, CDK6, CDK7, CDK8, CDK9, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDX2, CEBPA, CHCHD7, CHD2, CHD4, CHEK1, CHEK2, CHIC2, CHN1, CHORDCI, CIC, CIITA, CLP1, CLTC, CLTCL1, CNBP, CNOT3, CNTRL, COL1A1, COPB1, COX6C, CRBN, CREB1, CREB3L1, CREB3L2, CREBBP, CRKL, CRLF2, CRTC1, CRTC3, CSF1R, CSF3R, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3, CXCR4, CYLD, CYP17A1, CYP2D6, DAXX, DDB2, DDIT3, DDR1, DDR2, DDX10, DDX3X, DDX5, DDX6, DEK, DICER1, DIS3, DLL4, DNM2, DNMT1, DNMT3A, DOT1L, DPYD, DUSP4, DUSP6, EBF1, ECT2L, EDNRB, EED, EGFR, EIF4A2, ELF4, ELK4, ELL, ELN, EML4, EP300, EPHA3, EPHA5, EPHA7, EPHA8, EPHB1, EPHB2, EPHB4, EPS15, ERBB2, ERBB3, ERBB4, ERC1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EREG, ERG, ERN1, ERRFI1, ESRI, ETV1, ETV4, ETV5, ETV6, EWSR1, EXT1, EXT2, EZH2, EZR, FAF1, FAIM3, FAM46C, FANCA,FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS, FAT1, FBX011, FBXW7, FCRL4, FEV, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR1OP, FGFR2, FGFR3, FGFR4, FH, FHIT, FIP1L1, FKBP1A, FLCN, FLU, FLT1, FLT3, FLT4, FNBP1, FOXA1, FOXL2, FOXO1, FOXO3, FOXO4, FOXP1, FRS2, FSTL3, FUBP1, FUS, GABRA6, GAS7, GATA1, GATA2, GATA3, GATA4, GATA6, GID4, GLI1, GMPS, GNA11, GNA12, GNA13, GNAQ, GNAS, GNRH1, GOLGA5, GOPC, GPC3, GPHN, GPR124, GRIN2A, GRM3, GSK3B, GUCY2C, H3F3A, H3F3B, HCK, HDAC1, HERPUD1, HEY1, HGF, HIP1, HIST1H1E, HIST1H3B, HIST1H4I, HLF, HMGA1, HMGA2, HMGN2P46, HNF1A, HNMT, HNRNPA2B1, HNRNPK, H00K3, H0XA11, H0XA13, H0XA9, HOXC11, HOXC13, H0XD11, H0XD13, HRAS, HSD3B1, HSP90AA1, HSP90AB1, IAPP, ID3, IDH1, IDH2, IGF1R, IGF2, IKBKE, IKZF1, IL2, IL21R, IL3RA, IL6, IL6ST, IL7R, INHBA, INPP4B, IRF2, IRF4, IRS2, ITGAV, ITGB1, ITK, ITPKB, JAK1, JAK2, JAK3, JAZF1, JUN, KAT6A, KAT6B, KCNJ5, KDM1A, KDM5A, KDM5C, KDM6A, KDR, KDSR, KEAP1, KEL, KIAA1549, KIF5B, KIR3DL1, KIT, KLF4, KLHL6, KLK2, KMT2A, KMT2C, KMT2D, KRAS, KTN1, LASPI, LCK, LCP1, LGALS3, LGR5, LHFP, LIFR, LM01, LM02, LOXL2, LPP, LRIG3, LRP1B, LUC7L2, LYL1, LYN, LZTR1, MAF, MAFB, MAGED1, MAGI2, MALT1, MAML2, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAPK1, MAPK11, MAX, MCL1, MDM2, MDM4, MDS2, MECOM, MED12, MEF2B, MEN1, MET, MITF, MKI67, MKL1, MLF1, MLH1, MLLT1, MLLT10, MLLT11, MLLT3, MLLT4, MLLT6, MMP9, MN1, MNX1, MPL, MRE11 A, MS4A1, MSH2, MSH6, MSI2, MSN, MST1R, MTCP1, MTF2, MTOR, MUC1, MUC16, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, MYH11, MYH9, NACA, NAE1, NBN, NCKIPSD, NCOA1, NCOA2, NCOA4, NDRG1, NF1, NF2, NFE2L2, NFIB, NFKB2, NFKBIA, NIN, NKX2-1, NONO, NOTCH1, NOTCH2, NOTCH3, NPM1, NR4A3, NRAS, NSD1, NT5C2, NTRK1, NTRK2, NTRK3, NUMA1, NUP214, NUP93, NUP98, NUTM1, NUTM2B, OLIG2, OMD, P2RY8, PAFAH1B2, PAK3, PALB2, PARK2, PARP1, PATZ1, PAX3, PAX5, PAX7, PAX8, PBRM1, PBX1, PCM1, PCSK7, PDCD1, PDCD1LG2, PDE4DIP, PDGFB, PDGFRA, PDGFRB, PDK1, PEC AMI, PERI, PHF6, PHOX2B, PICALM, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIM1, PLAG1, PLCG2, PML, PMS1, PMS2, POLDI, POLE, POTI, POU2AF1, POU5F1, PPARG, PPP2R1A, PRCC, PRDM1, PRDM16, PREX2, PRF1, PRKAR1A, PRKCI, PRKDC, PRLR, PRPF40B, PRRT2, PRRX1, PRSS8, PSIP1, PSMD4, PTBP1, PTCHI, PTEN, PTK2, PTPN11, PTPRC, PTPRD, QKI,RABEP1, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAFI, RALGDS, RANBP17, RANBP2, RAP1GDS1, RARA, R131, RBM10, RBM15, RCOR1, RECQL4, REL, RELN, RET, RHOA, RHOH, RICTOR, RIPK1, RMI2, RNF213, RNF43, ROS1, RPL10, RPL22, RPL5, RPN1, RPS6KB1, RPTOR, RUNX1, RUNX1T1, S1PR2, SAMHD1, SBDS, SDC4, SDHA, SDHAF2, SDHB, SDHC, SDHD, SEPT5, SEPT6, SEPT9, SET, SETBP1, SETD2, SF1, SF3A1, SF3B1, SF3B2, SFPQ, SGK1, SH2B3, SH3GL1, SLAMF7, SLC34A2, SLC45A3, SLIT2, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCE1, SMC1A, SMC3, SMO, SNCAIP, SNX29, SOCS1, SOXIO, SOX11, SOX2, SOX9, SPECC1, SPEN, SPOP, SPTA1, SRC, SRGAP3, SRSF2, SRSF3, SS18, SS18L1, SSX1, STAG2, STAT3, STAT4, STAT5B, STEAP1, STIL, STK11, SUFU, SUZ12, SYK, TAF1, TAF15, TALI, TAL2, TBL1XR1, TBX3, TCEA1, TCF12, TCF3, TCF7L2, TCL1A, TEK, TERC, TERT, TET1, TET2, TFE3, TFEB, TFG, TFPT, TFRC, TGFB1, TGFBR2, THRAP3, TIMP1, TJP1, TLX1, TLX3, TM7SF2, TMPRSS2, TNFAIP3, TNFRSF14, TNFRSF17, TNFRSF18, TNFRSF9, TNFSF11, TOPI, TOP2A, TP53, TP63, TPBG, TPM3, TPM4, TPR, TRAF2, TRAF3, TRAF3IP3, TRAF7, TRIM26, TRIM27, TRIM33, TRIP11, TRRAP, TSC1, TSC2, TSHR, TTK, TTL, TYMS, U2AF1, U2AF2, UBA1, UBR5, USP6, VEGFA, VEGFB, VHL, VPS51, VTI1A, WAS, WEE1, WHSCI, WHSC1L1, WIFI, WISP3, WNT11, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT6, WNT7B, WRN, WT1, WWTR1, XBP1, XPA, XPC, XPO1, YWHAE, YWHAZ, ZAK, ZBTB16, ZBTB2, ZMYM2, ZMYM3, ZNF217, ZNF331, ZNF384, ZNF521, ZNF703 and ZRSR2279. A method for treated age associated degeneration and / or stimulation of regeneration in an organism comprising administration of one or more regenerative cells, together with one or more senolytic agents, while concurrently inducing dedifferentiation, wherein said dedifferentiation is induced by using retroviral expression means of dedifferentiation factors.

280. The method of claim 279, wherein said retroviral expression vector is a pMXs vector.

281. The method of claim 279, wherein said retroviral expression vector is a lentiviral vector.

282. The method of claim 279, wherein said retroviral expression vector is an adenoviral vector.

283. The method of claim 279, wherein said retroviral expression vector is a pMXs adeno-associated vector.

284. The method of claim 279, wherein said retroviral expression vector is a herpesvirus vector.

285. The method of claim 279, wherein said dedifferentiation genes are delivered by means of a plasmid based vector.

286. The method of claim 279, wherein said dedifferentiation genes are delivered by means of an RNA based vector.

287. The method of claim 279, wherein said dedifferentiation genes are delivered by means of an mRNA based vector.

288. The method of claim 279, wherein said dedifferentiation genes are delivered by means of an microRNA based vector.

289. The method of claim 279, wherein said dedifferentiation factors are administered together with ascorbic acid.

290. The method of claim 279, wherein said dedifferentiation factors are administered together with ascorbic acid.

291. The method of claim 279, wherein said dedifferentiation factors are administered together with a stimulator of the RAS pathway.

292. The method of claim 279, wherein said dedifferentiation factors are administered together with a stimulator of the myc pathway.

293. The method of claim 279, wherein said dedifferentiation factors are administered together with a stimulator of the PIM-1 pathway.

294. The method of claim 279, wherein said dedifferentiation factors are administered together with a stimulator of the j anus activated kinase pathway.

295. A method of reducing age associated fibrosis in a patient comprising administration of T regulatory cells, and / or T regulatory cell derived cell-free means together with one or more senolytic agents.

296. The method of claim 295, wherein said T regulatory cells generated subsequent to administration of mesenchymal stem cells or cell free mesenchymal stem cell derived means.

297. The method of claim 296, wherein said mesenchymal stem cells are selected for release of brain derived neurotrophic factor upon stimulation with molecular signals associated with tissue injury.

298. The method of claim 297, wherein mesenchymal stem cells are selected for expression of CD56.

299. The method of claim 297, wherein mesenchymal stem cells produce at least 10 pg of brain derived neurotrophic factor per milliliter subsequent to stimulation with Poly IC.

300. The method of claim 297, wherein mesenchymal stem cells produce at least 25 pg of brain derived neurotrophic factor per milliliter subsequent to stimulation with Poly IC.

301. The method of claim 297, wherein mesenchymal stem cells produce at least 100 pg of brain derived neurotrophic factor per milliliter subsequent to stimulation with Poly IC.

302. The method of claim 296, wherein said mesenchymal stem cells are selected for release of ciliary neurotrophic growth factor upon stimulation with molecular signals associated with tissue injury.

303. The method of claim 302, wherein mesenchymal stem cells are selected for expression of CD73.

304. The method of claim 302, wherein mesenchymal stem cells produce at least 4 pg of ciliary neurotrophic growth factor per milliliter subsequent to stimulation with Poly IC.

305. The method of claim 302, wherein mesenchymal stem cells produce at least 8 pg of ciliary neurotrophic growth factor per milliliter subsequent to stimulation with Poly IC.

306. The method of claim 302, wherein mesenchymal stem cells produce at least 12 pg of ciliary neurotrophic growth factor per milliliter subsequent to stimulation with Poly IC.

307. The method of claim 296, wherein said mesenchymal stem cells are selected for release of basic fibroblast growth factor upon stimulation with molecular signals associated with tissue injury.

308. The method of claim 302, wherein mesenchymal stem cells are selected for expression of CD 105.

309. The method of claim 302, wherein mesenchymal stem cells produce at least 50 pg of basic fibroblast growth factor per milliliter subsequent to stimulation with Poly IC.

310. The method of claim 302, wherein mesenchymal stem cells produce at least 100 pg of basic fibroblast growth factor per milliliter subsequent to stimulation with Poly IC.

311. The method of claim 302, wherein mesenchymal stem cells produce at least 100 pg of basic fibroblast growth factor per milliliter subsequent to stimulation with Poly IC.

312. The method of claim 295, wherein said T regulatory cells and / or cell free means secreted by said T regulatory cells are administered subsequent to administration of a fibrinolytic enzyme.

313. The method of claim 312, wherein said enzyme is a matrix metalloprotease.

314. The method of claim 313, wherein said matrix metalloprotease is MMP-3.

315. The method of claim 313, wherein said matrix metalloprotease is MMP-5.

316. The method of claim 313, wherein said matrix metalloprotease is MMP-6.

317. The method of claim 313, wherein said matrix metalloprotease is MMP-9.

318. The method of claim 313, wherein said matrix metalloprotease is MMP-12.

319. The method of claim 295, wherein said T regulatory cells and / or cell free means generated by said T regulatory cells are administered subsequent to administration of an inhibitor of NOGO.

320. The method of claim 319, wherein said inhibitor of NOGO is an antisense oligonucleotide.

321. The method of claim 319, wherein said inhibitor of NOGO is a one or more molecules capable of inducing RNA interference.

322. The method of claim 321, wherein said molecule capable of inducing RNA interference is a short interfering RNA.

323. The method of claim 321, wherein said molecule capable of inducing RNA interference is a short hairpin RNA.

324. The method of claim 319, wherein said inhibitor of NOGO is a small molecule inhibitor.

325. The method of claim 319, wherein said inhibitor of NOGO is an antibody.

326. The method of claim 319, wherein said inhibitor of NOGO is an aptamer.

327. The method of claim 319, wherein said inhibitor of NOGO is a somamer.

328. The method of claim 319, wherein said inhibitor of NOGO is bispecific antibody.

329. The method of claim 319, wherein said inhibitor of NOGO is a ribozyme.

330. The method of claim 319, wherein said inhibitor of NOGO is an antibody.

331. The method of claim 319, wherein said inhibitor of NOGO is a microantibody.

332. The method of claim 319, wherein said inhibitor of NOGO is a hammerhead ribozyme.

333. The method of claim 319, wherein said inhibitor of NOGO is a soluble receptor.

334. The method of claim 295, wherein said T regulatory cells are administered subsequent to administration of a myeloid lineage cell.

335. The method of claim 334, wherein said myeloid lineage cell is a myeloid derived dendritic cell.

336. The method of claim 334, wherein said myeloid dendritic cell is immature.

337. The method of claim 336, wherein said myeloid dendritic cell generated from a monocytic progenitor.

338. The method of claim 337, wherein said monocyte is isolated from peripheral blood.

339. The method of claim 337, wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with G-CSF.

340. The method of claim 337, wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with GM-CSF.

341. The method of claim 337, wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with M-CSF.

342. The method of claim 337, wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with interleukin-3.

343. The method of claim 337, wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with interleukin-10.

344. The method of claim 337, wherein said monocyte is isolated from peripheral blood that is mobilized by treatment with beta glucan.

345. The method of claim 337, wherein said monocyte is isolated from peripheral blood that is mobilized by treatm6ent with interferon gamma.

346. The method of claim 337, wherein said monocyte is isolated from menstrual blood.

347. The method of claim 337, wherein said monocyte is isolated from umbilical cord blood.

348. The method of claim 337, wherein said monocyte is isolated from Wharton’s Jelly.

349. The method of claim 337, wherein said monocyte is isolated from bone marrow.

350. The method of claim 337, wherein said monocyte is isolated from adipose tissue.

351. The method of claim 337, wherein said monocyte is isolated from omental tissue.

352. The method of claim 337, wherein said monocyte is pretreated with one or more agents to induce a tolerogenic phenotype prior to differentiation into a myeloid dendritic cells with immature phenotype and exosomes are derived from said myeloid dendritic cells.

353. The method of claim 352, wherein said monocyte is pretreated with PGE2 at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

354. The method of claim 352, wherein said monocyte is pretreated with PGE2 at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

355. The method of claim 352, wherein said monocyte is pretreated with PGE2 at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

356. The method of claim 352, wherein said monocyte is pretreated with genistein at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

357. The method of claim 352, wherein said monocyte is pretreated with genistein at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

358. The method of claim 352, wherein said monocyte is pretreated with genistein at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

359. The method of claim 352, wherein said monocyte is pretreated with quercetin at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

360. The method of claim 352, wherein said monocyte is pretreated with quercetin at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

361. The method of claim 352, wherein said monocyte is pretreated with quercetin at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

362. The method of claim 352, wherein said monocyte is pretreated with hypertonic saline at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

363. The method of claim 352, wherein said monocyte is pretreated with hypertonic saline at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

364. The method of claim 352, wherein said monocyte is pretreated with hypertonic saline at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

365. The method of claim 352, wherein said monocyte is pretreated with VEGF at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

366. The method of claim 352, wherein said monocyte is pretreated with VEGF at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

367. The method of claim 352, wherein said monocyte is pretreated with VEGF at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

368. The method of claim 352, wherein said monocyte is pretreated with PDGF-BB at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

369. The method of claim 352, wherein said monocyte is pretreated with PDGF-BB at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

370. The method of claim 352, wherein said monocyte is pretreated with PDGF-BB at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

371. The method of claim 352, wherein said monocyte is pretreated with IGF-1 at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

372. The method of claim 352, wherein said monocyte is pretreated with IGF-1 at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

373. The method of claim 352, wherein said monocyte is pretreated with IGF-1 at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

374. The method of claim 352, wherein said monocyte is pretreated with salinomycin at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

375. The method of claim 352, wherein said monocyte is pretreated with salinomycin at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

376. The method of claim 352, wherein said monocyte is pretreated with salinomycin at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

377. The method of claim 352, wherein said monocyte is pretreated with erythropoietin at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

378. The method of claim 352, wherein said monocyte is pretreated with erythropoietin at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

379. The method of claim 352, wherein said monocyte is pretreated with erythropoietin at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

380. The method of claim 352, wherein said monocyte is pretreated with NF-kappa B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

381. The method of claim 352, wherein said monocyte is pretreated with NF-kappa B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

382. The method of claim 352, wherein said monocyte is pretreated with NF-kappa B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

383. The method of claim 352, wherein said monocyte is pretreated with Ikk-B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

384. The method of claim 352, wherein said monocyte is pretreated with Ikk-B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

385. The method of claim 352, wherein said monocyte is pretreated with Ikk-B decoy oligonucleotides at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

386. The method of claim 352, wherein said monocyte is pretreated with interleukin-35 at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

387. The method of claim 352, wherein said monocyte is pretreated with interleukin-35 at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

388. The method of claim 352, wherein said monocyte is pretreated with interleukin-35 at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

386. The method of claim 352, wherein said monocyte is pretreated with TGF-beta at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

387. The method of claim 352, wherein said monocyte is pretreated with TGF-beta at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

388. The method of claim 352, wherein said monocyte is pretreated with TGF-beta at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

389. The method of claim 352, wherein said monocyte is pretreated with ascorbic acid at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

390. The method of claim 352, wherein said monocyte is pretreated with ascorbic acid at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

391. The method of claim 352, wherein said monocyte is pretreated with ascorbic acid at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

392. The method of claim 352, wherein said monocyte is pretreated with n-acetylcysteine at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

393. The method of claim 352, wherein said monocyte is pretreated with n-acetylcysteine at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

394. The method of claim 352, wherein said monocyte is pretreated with n-acetylcysteine at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

392. The method of claim 352, wherein said monocyte is pretreated with alpha lipoic acid at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

393. The method of claim 352, wherein said monocyte is pretreated with alpha lipoic acid at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

394. The method of claim 352, wherein said monocyte is pretreated with alpha lipoic acid at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

395. The method of claim 352, wherein said monocyte is pretreated with methylene blue at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

396. The method of claim 352, wherein said monocyte is pretreated with methylene blue at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

397. The method of claim 352, wherein said monocyte is pretreated with methylene blue at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

398. The method of claim 352, wherein said monocyte is pretreated with valproic acid at a sufficient concentration and for a time period to stimulate production of at least 10 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

399. The method of claim 352, wherein said monocyte is pretreated with valproic acid at a sufficient concentration and for a time period to stimulate production of at least 20 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

400. The method of claim 352, wherein said monocyte is pretreated with valproic acid at a sufficient concentration and for a time period to stimulate production of at least 40 pg / ml of interleukin- 10 from a culture of 1 million monocytes.

401. The method of claim 352, wherein said immature dendritic cell expresses interleukin-10.

402. The method of claim 352, wherein said immature dendritic cell expresses interleukin-4.

403. The method of claim 352, wherein said immature dendritic cell expresses interleukin-13.

404. The method of claim 352, wherein said immature dendritic cell expresses interleukin-20.

405. The method of claim 352, wherein said immature dendritic cell expresses TGF-beta.

406. The method of claim 352, wherein said immature dendritic cell expresses interleukin-20.

407. The method of claim 352, wherein said immature dendritic cell expresses interleukin-22.

408. The method of claim 352, wherein said immature dendritic cell expresses interleukin-35.

409. The method of claim 352, wherein said immature dendritic cell expresses interleukin-37.

410. The method of claim 352, wherein said immature dendritic cell expresses interleukin-38.

411. The method of claim 352, wherein said immature dendritic cell expresses TGF-beta.

412. The method of claim 352, wherein said immature dendritic cell expresses endoglin.

413. The method of claim 352, wherein said immature dendritic cell expresses VEGF.

414. The method of claim 352, wherein said immature dendritic cell expresses HLA-G.

415. The method of claim 352, wherein said immature dendritic cell expresses interleukin- 12 p40 homodimer.

416. The method of claim 352, wherein said immature dendritic cell possesses increased phagocytic activity as compared to a mature dendritic cell.

417. The method of claim 352, wherein said immature dendritic cell possesses increased migratory activity towards chemotactic gradients as compared to a mature dendritic cell.

418. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine IL-8.

419. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine MIP-1 alpha.

420. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine MIP-1 beta.

421. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine CXCL12.

422. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine MCP-1.

423. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine TNF-alpha.

424. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine lymphotoxin.

425. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine hyaluronic acid degradation products.

426. The method of claim 417, wherein said chemotactic gradient is comprised of the chemokine HMGB 1.

427. The method of claim 352, wherein said immature dendritic cell possesses decreased HLA II compared to a mature dendritic cell.

428. The method of claim 352, wherein said immature dendritic cell possesses decreased HLA I compared to a mature dendritic cell.

429. The method of claim 352, wherein said immature dendritic cell possesses decreased CD la compared to a mature dendritic cell.

430. The method of claim 352, wherein said immature dendritic cell possesses decreased CD40 compared to a mature dendritic cell.

431. The method of claim 352, wherein said immature dendritic cell possesses decreased CD80 compared to a mature dendritic cell.

432. The method of claim 352, wherein said immature dendritic cell possesses decreased CD86 compared to a mature dendritic cell.

433. The method of claim 352, wherein said immature dendritic cell possesses decreased interleukin- 15 receptor compared to a mature dendritic cell.

434. The method of claim 352, wherein said immature dendritic cell possesses decreased interferon gamma compared to a mature dendritic cell.

435. The method of claim 352, wherein said immature dendritic cell possesses decreased interleukin- 18 receptor compared to a mature dendritic cell.

436. The method of claim 352, wherein said immature dendritic cell possesses decreased progesterone receptor compared to a mature dendritic cell.

437. The method of claim 352, wherein said immature dendritic cell possesses decreased c-kit compared to a mature dendritic cell.

438. The method of claim 352, wherein said immature dendritic cell is capable of inducing generation of T regulatory cells upon culture with allogeneic naive T cells.

439. The method of claim 438, wherein said immature dendritic cells upregulate expression of AIRE upon contact with said allogeneic naive T cells.

440. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in an interleukin- 10 dependent manner.

441. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in a TGF-beta dependent manner.

442. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in a soluble HLA-G dependent manner.

443. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in an endoglin dependent manner.

444. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in an FGF-1 dependent manner.

445. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in an FGF-2 dependent manner.

446. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in an FGF-5 dependent manner.

447. The method of claim 439, wherein said dendritic cells upregulate expression of AIRE in a NOTCH dependent manner.

448. The method of claim 334, wherein said myeloid lineage cell is an immature neutrophil.

449. The method of claim 448, wherein said immature neutrophil is a neutrophil progenitor.

450. The method of claim 448, wherein said immature neutrophil is capable of differentiating along the neutrophilic lineage or the monocytic lineage.

451. The method of claim 448, wherein said immature neutrophil expresses PU 1.1.

452. The method of claim 448, wherein said immature neutrophil expresses G-CSF receptor.

453. The method of claim 448, wherein said immature neutrophil expresses stem cell factor receptor.

454. The method of claim 448, wherein said immature neutrophil expresses c-met.

455. The method of claim 448, wherein said immature neutrophil expresses M-CSF receptor.

456. The method of claim 448, wherein said immature neutrophil expresses GM-CSF receptor.

457. The method of claim 448, wherein said immature neutrophil produces interleukin- 10 upon stimulation with a TLR-4 agonist.

458. The method of claim 457, wherein said TLR-4 agonist is beta glucan.

459. The method of claim 457, wherein said TLR-4 agonist is hyaluronic acid degradation products.

460. The method of claim 457, wherein said TLR-4 agonist is HMGB1.

461. The method of claim 457, wherein said TLR-4 agonist is histones.

462. The method of claim 334, wherein said myeloid lineage cell is a myeloid suppressor cell.

463. The method of claim 462, wherein said myeloid suppressor cell is capable of producing Reptimed.

464. The method of claim 462, wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with All Trans Retinoic Acid.

465. The method of claim 462, wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with vitamin D3.

466. The method of claim 462, wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with M-CSF.

467. The method of claim 462, wherein said myeloid suppressor cell is capable of differentiating into monocytes when treated with GM-CSF.

468. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of nitric oxide.

469. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of reactive oxygen species.

470. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of superoxide.

471. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of hydrogen peroxide.

472. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of arginase.

473. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of interleukin- 10.

474. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of soluble PD-L1.

475. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of soluble VISTA.

476. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of LAG-3.

477. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of TIM3.

478. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of PGE2.

479. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of secreted vimentin.

480. The method of claim 462, wherein said myeloid suppressor cell inhibit T cell proliferation by production of secreted calreticulin.

481. The method of claim 295, wherein said T regulatory cell is administered together with a mesenchymal cell differentiated to the oligodendrocyte linage.

482. The method of claim 295, wherein said T regulatory cell is administered together with a pluripotent stem cell differentiated to the oligodendrocyte linage.

483. The method of claim 482, wherein said pluripotent stem cell is generated by transfecting a somatic cell with cytoplasm from an oocyte.

484. The method of claim 483, wherein said cytoplasm is transfected by use of electroporation.

485. The method of claim 483, wherein said cytoplasm is transfected by use of cell fusion.

486. The method of claim 483, wherein said cytoplasm is transfected by use of streptolysin O to generate transient holes in the cytoplasm of said recipient cell.

487. The method of claim 483, wherein said cytoplasm is transfected by use of cell penetrating peptides to generate transient holes in the cytoplasm of said recipient cell.

488. The method of claim 482, wherein said pluripotent stem cell is an induced pluripotent stem cell.

489. The method of claim 488, wherein said induced pluripotent stem cell is created by transfection of cells with pluripotency inducing factors.

490. The method of claim 489, wherein said pluripotency inducing factor is OCT4.

491. The method of claim 489, wherein said pluripotency inducing factor is PIM-1.

492. The method of claim 489, wherein said pluripotency inducing factor is NANOG.

493. The method of claim 489, wherein said pluripotency inducing factor is c-met.

494. The method of claim 489, wherein said pluripotency inducing factor is hTERT.

495. The method of claim 489, wherein said pluripotency inducing factor is OCT4.

496. The method of claim 489, wherein said pluripotency inducing factor is KLF4.

497. The method of claim 489, wherein said pluripotency inducing factor is RAS.

498. The method of claim 489, wherein said pluripotency inducing factor is NOTCH.

499. The method of claim 489, wherein said pluripotency inducing factor is BMP2.

500. The method of claim 489, wherein said pluripotency inducing factor is BMP4.

501. The method of claim 489, wherein said pluripotency inducing factor is AIRE.

502. A method of regenerating aged tissue comprising administration of T regulatory cell derived cell-free means, wherein said T regulatory cells are optionally treated with one or more histone deactylase inhibitors.

503. The method of claim 502, wherein said cell free means are exosomes.

504. The method of claim 503, wherein said cell free means are exosomes expressing CD8.

505. The method of claim 503, wherein said cell free means are exosomes expressing phosphatidylserine.

506. The method of claim 503, wherein said cell free means are apoptotic bodies507. The method of claim 503, wherein said cell free means are ferroptotic bodies.

508. The method of claim 503, wherein said cell free means is conditioned media.

509. The method of claim 503, wherein said cell free means is conditioned media from stressed cells.

510. The method of claim 509, wherein said cellular stress is exposure to inflammatory stimuli.

511. The method of claim 510, wherein said inflammatory stimuli is activation of one or more danger associated receptors.

512. The method of claim 511, wherein said danger associated receptor is a toll like receptor.

513. The method of claim 512, wherein said toll like receptor is activated by treatment with beta glucan.

514. The method of claim 512, wherein said toll like receptor is activated by treatment with poly IC.

515. The method of claim 512, wherein said toll like receptor is activated by treatment with poly LC.

516. The method of claim 512, wherein said toll like receptor is activated by treatment with CpG DNA.

517. The method of claim 512, wherein said toll like receptor is activated by treatment with BCG.

518. The methods of claim 512, wherein said toll like receptor is activated by treatment with flaggelin.

519. The method of claim 512, wherein said toll like receptor is activated by treatment with lipopolysaccharide.

520. The method of claim 512, wherein said toll like receptor is activated by treatment with low molecular weight hyaluronic acid.

521. The method of claim 512, wherein said toll like receptor is activated by treatment with free histone.

522. The methods of claim 512, wherein said toll like receptor is activated by treatment with a Isoxazolo[5,4 -d]pyrimidine.

523. The method of claim 512, wherein said toll like receptor is activated by treatment with imiquimod.

524. The method of claim 512, wherein said toll like receptor is activated by treatment with Poly A:U.

525. The method of claim 512, wherein said toll like receptor is activated by treatment with MPL.

526. The methods of claim 512, wherein said toll like receptor is activated by treatment with Poly G3.

527. The method of claim 512, wherein said toll like receptor is activated by treatment with Poly GIO.

528. The method of claim 512, wherein said toll like receptor is activated by treatment with hyperthermia exposed cells.

529. The method of claim 528, wherein said hyperthermia exposed cells possess an upregulation of hsp90 of more than 50% as compared to untreated cells of the same type.

530. The method of claim 502, wherein a histone deacetylase inhibitor is administered locally and / or systemically to enhance reparative activity of said T regulatory cell.

531. The method of claim 530, wherein said histone deacetylase inhibitor is CXD101.

532. The method of claim 530, wherein said histone deacetylase inhibitor is HDAC10-IN- 1.

533. The method of claim 530, wherein said histone deacetylase inhibitor is Tubastatin A TFA.

534. The method of claim 530, wherein said histone deacetylase inhibitor is ACY-775.

535. The method of claim 530, wherein said histone deacetylase inhibitor is Panobinostat.

536. The method of claim 530, wherein said histone deacetylase inhibitor is Trichostatin A.

537. The method of claim 530, wherein said histone deacetylase inhibitor is Vorinostat.

538. The method of claim 530, wherein said histone deacetylase inhibitor is Entinostat.

539. The method of claim 530, wherein said histone deacetylase inhibitor is BML-210.

540. The method of claim 530, wherein said histone deacetylase inhibitor is Abexinostat.

541. The method of claim 530, wherein said histone deacetylase inhibitor is Dacinostat.

542. The method of claim 530, wherein said histone deacetylase inhibitor is Quisinostat.

543. The method of claim 530, wherein said histone deacetylase inhibitor is Mocetinostat.

544. The method of claim 530, wherein said histone deacetylase inhibitor is Valproic Acid.

545. The method of claim 530, wherein said histone deacetylase inhibitor is CUDC-101546. The method of claim 530, wherein said histone deacetylase inhibitor isGSK3117391.

547. The method of claim 530, wherein said histone deacetylase inhibitor is Droxinostat.

548. The method of claim 530, wherein said histone deacetylase inhibitor is MC1568.

549. The method of claim 530, wherein said histone deacetylase inhibitor is Pracinostat.

550. The method of claim 530, wherein said histone deacetylase inhibitor is Divalproex Sodium.

551. The method of claim 530, wherein said histone deacetylase inhibitor is Diferuloylmethane.

552. The method of claim 530, wherein said histone deacetylase inhibitor is Sodium butyrate.

553. The method of claim 530, wherein said histone deacetylase inhibitor is PCI-34051.

554. The method of claim 530, wherein said histone deacetylase inhibitor is SR-4370.

555. The method of claim 530, wherein said histone deacetylase inhibitor is Givinostat.

556. The method of claim 530, wherein said histone deacetylase inhibitor is Tubacin.

557. The method of claim 530, wherein said histone deacetylase inhibitor is AR-42.

558. The method of claim 530, wherein said histone deacetylase inhibitor is (-)- Parthenolide.

559. The method of claim 530, wherein said histone deacetylase inhibitor is Tubastatin A HC1.

560. The method of claim 530, wherein said histone deacetylase inhibitor is Resminostat.

561. The method of claim 530, wherein said histone deacetylase inhibitor is CUDC-907.

562. The method of claim 530, wherein said histone deacetylase inhibitor is M344.

563. The method of claim 530, wherein said histone deacetylase inhibitor is Tacedinaline.

564. The method of claim 530, wherein said histone deacetylase inhibitor is Romidepsin.

565. The method of claim 530, wherein said histone deacetylase inhibitor is 4- Phenylbutyric acid.

566. The method of claim 530, wherein said histone deacetylase inhibitor is Sinapinic acid.

567. The method of claim 530, wherein said histone deacetylase inhibitor is Sulforaphane.

568. The method of claim 530, wherein said histone deacetylase inhibitor is UF010.

569. The method of claim 530, wherein said histone deacetylase inhibitor isSuberohydroxamic acid.

570. The method of claim 530, wherein said histone deacetylase inhibitor is NKL 22.

571. The method of claim 530, wherein said histone deacetylase inhibitor is ITSA-1.

572. The method of claim 530, wherein said histone deacetylase inhibitor is KA2507.

573. The method of claim 530, wherein said histone deacetylase inhibitor is Isoguanosine.

574. The method of claim 530, wherein said histone deacetylase inhibitor is Raddeanin A.

575. The method of claim 530, wherein said histone deacetylase inhibitor is BRD3308.

576. The method of claim 530, wherein said histone deacetylase inhibitor is TH34.

577. The method of claim 530, wherein said histone deacetylase inhibitor isTinostamustine.

578. The method of claim 502, wherein exosomes from a pluripotent stem cell derived mesenchymal stem cell population are administered systemically from either a culture vessel or through the use of a bioreactor.

579. The method of claim 578, wherein said mesenchymal stem cell is transfected with a growth factor.

580. The method of claim 579, wherein said growth factor is HGF-1.

581. The method of claim 579, wherein said growth factor is FGF-1.

582. The method of claim 579, wherein said growth factor is EGF-1.

583. The method of claim 579, wherein said growth factor is angiopoietin.

584. The method of claim 579, wherein said growth factor is placental growth factor.

585. The method of claim 579, wherein said growth factor is adiponectin.

586. The method of claim 579, wherein said growth factor is vasoactive intestinal peptide precursor.

587. The method of claim 579, wherein said growth factor is endoglin.

588. The method of claim 579, wherein said growth factor is myostatin.

589. The method of claim 579, wherein said growth factor is TGF-beta.

590. The method of claim 579, wherein said growth factor is vascular endothelial growth factor.

591. The method of claim 579, wherein said growth factor is GDF-11.

592. The method of claim 579, wherein said growth factor is GDF-15.

593. The method of claim 579, wherein said growth factor is hyaluronic acid synthease.

594. The method of claim 579, wherein said growth factor is interleukin-33.

595. The method of claim 579, wherein said growth factor is osteosarcoma-derived growth factor.

596. The method of claim 579, wherein said growth factor is midkine.

597. The method of claim 579, wherein said growth factor is PDGF-BB.

598. The method of claim 579, wherein said growth factor is IGF-1.

599. The method of claim 579, wherein said growth factor is nerve growth factor.

Images